INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTA..

ISTH 2015 Congress

 

20-25 June 2015 Toronto
Close
N. Poster
Poster title
Applicant name
Status
  1-TUE-PO POLYPHOSPHATE AS A NOVEL THERAPEUTIC FOR AGE-RELATED MACULAR DEGENERATION Linnette Ocariza Received Received
  1-WED-PO ACQUIRED HEMOSTATIC DISORDERS BY ORTHOTOPIC LIVER TRANSPLANATION Dorit Blickstein Received Received
  2-MON-PO AN UNBALANCE BETWEEN VON WILLEBRAND FACTOR AND ADAMTS13 FOLLOWING A MAJOR PARTIAL HEPATECTOMY Dafna Groeneveld Received Received
  2-TUE-PO ANTI-OXIDANT TREATMENT IMPROVES CARDIAC DYSFUNCTION IN BMAL1 DEFICIENT MICE Bianca Hemmeryckx Received Received
  3-MON-PO THE NOVEL C.774_775 INS CCGCGCC MUTATION COMBINED WITH C.4085 TA IN THE ADAMTS13 GENE CONTRIBUTES TO THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) Juvenal Paiva Received Received
  3-WED-PO PERSISTENT INTERNATIONAL NORMALIZED RATIO (INR) ELEVATION ASSOCIATED WITH OLMESARTAN-INDUCED ENTEROPATHY IN A PATIENT RECEIVING WARFARIN Jennifer Lowerison Received Received
  4-MON-PO THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A MEMBER OF A FAMILY WITH ADAMTS13 GENE ABNORMALITIES Juvenal Paiva Received Received
  5-MON-PO CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) CAUSED BY COMPOUND HETEROZYGOSITY OF C.1225CT AND A NOVEL C.2321DELG ADAMTS13 GENE MUTATIONS Juvenal Paiva Received Received
  5-WED-PO HEMOSTATIC EFFECTS OF REGENERATIVE THERAPY IN PATIENTS WITH ALCOHOLIC CIRRHOSIS-A DEVELOPING COUNTRY EXPERIENCE. Priyanka Saxena Received Received
  6-MON-PO QUALITY ASSESSMENT FOR ADAMTS-13 TESTING: A CANADIAN EXPERIENCE Arnaud Bonnefoy Received Received
  6-TUE-PO FAMILIAL FELINE HYPERTROPHIC CARDIOMYOPATHY: A MODEL FOR EVALUATING PLATELET ACTIVATION AND CLOPIDOGREL THERAPY Ronald Li Received Received
  7-TUE-PO PLATELET EFFECTS OF EPISODIC OZONE AND PM EXPOSURE DURING POSTNATAL DEVELOPMENT Fern Tablin Received Received
  7-WED-PO TREATMENT OF AQUIRED FACTOR V INHIBITORS RESULTING IN DISSEMINATED INTRAVASCULAR COAGULATION Julie Tarrant Received Received
  7-MON-PO PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS: THE ROLE OF ADAMTS13 Raimondo De Cristofaro Received Received
  8-WED-PO LUPUS ANTICOAGULANT - HYPOPROTHROMBINEMIA SYNDROME IN A 7-YEAR OLD GIRL: A CASE REPORT PATIROGLU PATIROGLU Received Received
  8-TUE-PO EVALUATION OF FACTOR XIA PHARMACOKINETICS IN MICE WITH A THROMBIN GENERATION ASSAY Mikhail Ovanesov Received Received
  9-MON-PO PAR1-STIMULATED PLATELETS ENHANCE ANGIOGENIC ACTIVITIES OF ENDOTHELIAL PROGENITOR CELLS MORE POTENTLY THAN PAR4-STIMULATED PLATELETS Nailin Li Received Received
  9-WED-PO ACHIEVING HAEMOSTATIC CONTROL IN ACQUIRED HAEMOPHILIA A WITH PLASMA DERIVED FVIII INFUSIONS Pu-Lin Luo Received Received
  9-TUE-PO RESISTANCE TO ANTI-PLATELET AGENTS IN PATIENTS WITH ISCHEMIC STROKE Anil Pathare Received Received
  10-WED-PO ACQUIRED VON WILLEBRAND SYNDROME (AVWS) IN PATIENTS WITH CARDIOVASCULAR DISORDERS: A SINGLE CENTRE COHORT STUDY Maria Joana Costa Pinto Prego de Faria Received Received
  10-MON-PO DEVELOPMENT OF AN EX OVO CHICKEN EMBRYO MODEL FOR MEASURING TRACTION FORCES DURING IN VIVO ANGIOGENESIS Sandra Baker-Groberg Received Received
  10-TUE-PO MECHANISM OF ANTIPLATELET ACTION INDUCED BY GUANOSINE VIA INCREASE IN CAMP LEVELS AND ITS ANTITHROMBOTIC ACTIVITY Eduardo Fuentes Received Received
  11-TUE-PO IMPACT OF NON-INHIBITED PLATELET SUPPLEMENTATION ON PLATELET REACTIVITY IN PATIENTS TREATED WITH PRASUGREL OR TICAGRELOR FOR AN ACUTE CORONARY SYNDROME: AN EX-VIVO STUDY Pierre Fontana Received Received
  11-MON-PO MICRORNA-126 REDUCES BLOOD-RETINAL BARRIER BREAKDOWN IN OXYGEN-INDUCED RETINOPATHY MOUSE MODEL Yanyan Bai Received Received
  11-WED-PO ACQUIRED HAEMOPHILIA A IN POLAND A REPORT FROM AHA-POL REGISTRY Jerzy Windyga Received Received
  12-TUE-PO THE EFFECTS OF TWO COMMONLY USED HERBAL PRODUCTS ON HAEMOSTATIC SYSTEM AND THEIR INTERACTIONS WITH ASPIRIN Wan Hui Wong Received Received
  12-WED-PO SUCCESSFUL THERAPY WITH BORTEZOMIB FOR ERRADICATION OF INHIBITOR IN A PATIENT WITH MULTIPLE MYELOMA AND ACQUIRED HEMOPHILIA A Susana Nobre Fernandes Received Received
  12-MON-PO STIMULATION OF PAR-1 OR PAR-4 PROMOTES A SIMILAR PATTERN OF PLATELET-MEDIATED ANGIOGENESIS Mirta Schattner Received Received
  13-TUE-PO EFFICACY OF PLATELET INHIBITION WITH PRASUGREL IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING THERAPEUTIC HYPOTHERMIA AFTER CARDIOPULMONARY RESUSCITATION Andreas Schaefer Received Received
  13-MON-PO PLATELET MEMBRANE GLYCOPROTEIN CD151 PROMOTES ENDOTHELIAL PROGENITOR CELL ANGIOGENESIS Zhangsen Huang Received Received
  14-WED-PO CLINICAL UTILITY OF HEAT INACTIVATED NIJMEGEN MODIFIED BETHESDA ASSAYS IN FVIII DEFICIENCY A 4 YEAR SINGLE CENTRE EXPERIENCE Tejas Gandhi Received Received
  14-TUE-PO ANTIBODY TARGETED, THROMBIN-SENSITIVE POLYMER CAPSULES FOR UROKINASE DELIVERY Christoph Hagemeyer Received Received
  14-MON-PO PROANGIOGENIC PROPERTIES OF FUCOIDAN IS ASSOCIATED WITH RECRUITMENT AND MODULATION OF MACROPHAGE POLARIZATION Elene Sapharikas Received Received
  15-WED-PO COMPARISON OF DIFFERENT COAGULATION ASSAYS FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA Elizabeth Donnachie Received Received
  15-MON-PO UNALTERED ANGIOGENESIS-REGULATORY ACTIVITIES OF PLATELETS FROM MILD TYPE 2 DM PATIENTS DESPITE A MARKED PLATELET HYPERREACTIVITY Nailin Li Received Received
  16-TUE-PO TICAGRELOR REVERSAL: IN VITRO ASSESSMENT OF VARIOUS HEMOSTATIC AGENTS Anne Godier Received Received
  16-MON-PO HUMAN PLATELET LYSATE GEL (HPLG) SUPPORTS AND STIMULATES ENDOTHELIAL PROGENITOR CELL-DRIVEN VASCULOGENESIS Giordano Pula Received Received
  17-TUE-PO TWO DISINTEGRINS, TFV-1 AND TFV-3, PURIFIED FROM TRIMERESURUS FLAVOVIRIDIS SNAKE VENOM, EXHIBIT DISTINCT EFFECTS ON PLATELET ACTIVATION Tzu Yu Pan Received Received
  17-WED-PO ASSESSMENT OF PROTHROMBIN TIME PROLONGATION BY THROMBOELASTOMETRY AND THROMBELASTOGRAPHY DURING LIVER TRANSPLANTATION Kenichi Tanaka Received Received
  18-TUE-PO PLATELET INHIBITION MONITORING WITH THROMBOELASTOGRAPHY (TEG) PLATELET MAPPING IN PEDIATRIC PATIENTS WITH VENTRICULAR ASSIST DEVICE tiphaine belleville Received Received
  19-TUE-PO THE PROGNOSTIC UTILITY OF PLATELET FUNCTION TESTING FOR THE DETECTION OF ASPIRIN RESISTANCE IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE Marie Lordkipanidze Received Received
  20-WED-PO USEFULNESS OF VARIOUS SCORING METHODS WITH CROSS-MIXING TEST FOR DETECTION OF LUPUS ANTICOAGULANT Sumiyoshi Naito Received Received
  20-TUE-PO A TIME COURSE STUDY OF HIGH ON TREATMENT PLATELET REACTIVITY IN ACS PATIENTS ON DUAL ANTIPLATELET THERAPY Gori Anna Maria Received Received
  21-MON-PO PLASMIN, NOT THROMBIN, ACTIVATES COMPLEMENT IN ARTERIAL AND VENOUS THROMBOSIS Jonathan Foley Received Received
  21-WED-PO DEFINING COAGULATION DYSFUNCTION IN PATIENTS WITH LEPTOSPIROSIS lallindra gooneratne Received Received
  21-TUE-PO INHIBITION OF PLATELET AGGREGATION BY GLS-409, AN ANTAGONIST OF BOTH P2Y1 AND P2Y12, IS DISTINCT FROM INHIBITION BY SELECTIVE P2Y1 AND P2Y12 ANTAGONISTS Thomas Gremmel Received Received
  22-WED-PO ACQUIRED VON WILLEBRAND SYNDROME DIAGNOSIS AND MANAGEMENT. Angelika Batorova Received Received
  22-MON-PO ESTABLISHMENT OF A VASCULAR INJURY MODEL DEMONSTRATING DIFFERENT EFFICACIES OF ANTITHROMBOTIC AGENTS ON THROMBUS FORMATION IN MICE Chaojun TANG Received Received
  23-WED-PO ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN ELDERLY PEOPLE WITH AND WITHOUT COGNITIVE IMPAIRMENT Maria das Graas Carvalho Received Received
  23-MON-PO FERRIC CHLORIDE-INDUCED VENOUS THROMBOSIS MODEL IN RATS: FINDING THE OPTIMAL CONCENTRATION OF FERRIC CHLORIDE Polina Alekseeva Received Received
  25-TUE-PO INCREASED MEAN PLATELET VOLUME (MPV) OF ACUTE CORONARY SYNDROMES (ACS) PATIENTS WITH CHEST PAIN AT THE EMERGENCY ROOM (ER) AL-ZAMZAM ABUBAKAR Received Received
  26-TUE-PO RESIDUAL PLATELET FUNCTION IN ACS PATIENTS TREATED WITH PRASUGREL IS LOWER THAN IN PATIENTS TREATED WITH CLOPIDOGREL BUT NOT IN PATIENTS WITH HYPERTENSION Stanj Heptinstall Received Received
  27-WED-PO ACQUIRED INHIBITORS TO FACTOR VIII AND IX, A CASE REPORT Sasa Anzej Doma Received Received
  28-TUE-PO EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON THE RISK OF MORTALITY, THROMBOSIS AND BLEEDING IN PATIENTS WITH SECONDARY HYPERALDOSTERONISM: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Laura Elbers Received Received
  28-MON-PO RABBIT MODEL OF FERRIC CHLORIDE-INDUCED CAROTID ARTERIAL THROMBOSIS OPTIMIZED FOR TRANSLATIONAL DRUG DISCOVERY Xinkang Wang Received Received
  29-MON-PO DISSECTION OF THE THERAPEUTIC EFFICACY OF FIX-TRIPLE FOR REDUCING HAEMOPHILIC ARTHROPATHY IN HEMOPHILIA B USING A BLOOD-INDUCED JOINT INJURY MURINE MODEL Guan-Ying Zheng Received Received
  29-TUE-PO URINARY 11-DEHYDRO-THROMBOXANE B2 IS ASSOCIATED WITH CARDIOVASCULAR EVENTS AND MORTALITY IN ATRIAL FIBRILLATION PATIENTS. pasquale pignatelli Received Received
  29-WED-PO EFFICACY OF FVIII IN THE TREATMENT OF PATIENTS WITH ACQUIRED HAEMOPHILIA A AND VASCULAR DISEASES Samantha Pasca Received Received
  31-TUE-PO VASCULAR SMOOTH MUSCLE CELLS ARE RESPONSIBLE FOR A PROTHROMBOTIC PHENOTYPE OF SPONTANEOUSLY HYPERTENSIVE RAT ARTERIES MOHAMADI AMEL Received Received
  31-WED-PO NEUTRALIZING AUTOANTIBODY AGAINST FACTOR XIII A SUBUNIT WITH MULTIPLE INHIBITORY EFFECT ON FACTOR XIII ACTIVATION/ACTIVITY RESULTED IN SEVERE BLEEDING WITH FATAL OUTCOME Krisztina Pénzes-Daku Received Received
  31-MON-PO GENERATION OF HEMOPHILIA B MICE IN NSG BACKGROUND USING CRISPR/CAS9 TECHNOLOGY Meng-Ni Fan Received Received
  33-WED-PO PREDICTION OF BLEEDING COMPLICATIONS AFTER RENAL BIOPSY IN POST-RENAL TRANSPLANT PATIENTS WITH UREMIA Gerhardus Kuiper Received Received
  33-TUE-PO ELEVATED ARTERIAL STIFFNESS AND THROMBIN GENERATION IN PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING HEMODIALYSIS Veronique REGNAULT Received Received
  34-MON-PO GENOME-WIDE KNOCKDOWNS IN ZEBRAFISH TO STUDY THROMBOCYTE FUNCTION Pudur Jagadeeswaran Received Received
  34-TUE-PO THROMBOGENIC STATE AFTER VASCULAR SURGERY AND PERIOPERATIVE CARDIOVASCULAR EVENTS Daniela CALDERARO Received Received
  34-WED-PO ANALYSIS OF THE PROFILE OF IMMUNE CELLS, CYTOKINES AND CHEMOKINES IN PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA Leticia Jardim Received Received
  35-WED-PO PROSPECTIVE VALIDATION OF CLINI-BIOLOGICAL PARAMETERS INCLUDING INITIAL HEMOSTASIS, WHICH IMPROVE THE PREDICTION OF DEATH AT 1 MONTH AMONG PATIENTS WITH SEPTIC SHOCK: SEPSICOAG STUDY Géraldine LAVIGNE-LISSALDE Received Received
  35-MON-PO BRAIN WHITE MATTER MICROSCRUTURE IS ALTERED IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EVIDENCES FROM DIFFUSION-TENSOR MRI IN ASYMPTOMATIC NEUROLOGICAL PATIENTS Jean-Christophe GRIS Received Received
  36-WED-PO Conformational Activation of ADAMTS13 and Control of VWF Dependent Platelet Deposition Under Flow kieron south Received Received
  36-TUE-PO SIMULTANEOUS OBSERVATION OF PERIPHERAL MONONUCLEAR CELL AND PLASMA TFS EXPRESSION FOR PREVENTION AND TREATMENT OF ISCHEMIC CARDIOCEREBROVASCULAR DISEASES Rui Wang Received Received
  36-MON-PO THROMBOTIC RISK OF REDUCED ADAMTS13 ACTIVITY IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES Hyun Kyung Kim Received Received
  37-MON-PO MIXING TEST SPECIFIC CUT-OFF IS MORE SENSITIVE AT DETECTING IN VITRO LUPUS ANTICOAGULANT INHIBITION THAN THE INDEX OF CIRCULATING ANTICOAGULANT Gary Moore Received Received
  37-TUE-PO TOTAL CHEMICAL SYNTHESIS OF COVALENT RANTES-PF4 HETERODIMERS TO STUDY INITIATION AND PROGRESSION OF ATHEROSCLEROSIS Stijn Agten Received Received
  38-TUE-PO ENDOTHELIAL DELETION OF THIOREDOXIN-INTERACTING PROTEIN PRESERVES MOUSE ARTERIES FROM AGING INDUCED BY METABOLIC DISORDERS Elise Dreano Received Received
  38-WED-PO ADAMTS13: VON WILLEBRAND FACTOR CLEAVING PROTEASE. GROWTH FACTOR? Justin Keener Received Received
  39-MON-PO PERSISTENT LUPUS ANTICOAGULANT IN CLINICAL SETTINGS OTHER THAN ANTIPHOSPHOLIPID SYNDROME Lucia Remotti Received Received
  39-TUE-PO HIGH LIPOPROTEIN(A) LEVELS ARE ASSOCIATED WITH CORONARY CALCIUM SCORE IN THE MONTIGNOSO STUDY POPULATION Anna Maria Gori Received Received
  40-TUE-PO ASSOCIATION OF GAMMA-GLUTAMYL TRANSFERASE TO THE PREMATURE CORONARY ARTERY DISEASE IN YOUNG ASIAN INDIANS Rajani kanth Vangala Received Received
  40-MON-PO HOW APPROPRIATE IS THE ANTIPHOSPHOLIPID ANTIBODIES TESTING AT SIRIRAJ HOSPITAL? Yingyong Chinthammitr Received Received
  40-WED-PO CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UPSHAW-SCHULMAN SYNDROME RECEIVING MAINTENANCE HEMODIALYSIS DUE TO CHRONIC RENAL FAILURE Masanori Matsumoto Received Received
  41-TUE-PO CORONARY ARTERY DISEASE SEVERITY IS A MARKER OF THE ANTI-INFLAMMATORY RESPONSE TO STATIN THERAPY Udaya Tantry Received Received
  41-MON-PO THROMBOMODULIN DOWN-REGULATION IS RELATED TO THE THROMBOSIS RISK IN ANTIPHOSPHOLIPID SYNDROME PATIENTS Osamu Kumano Received Received
  42-WED-PO ANTI-ADAMTS13 ANTIBODY FEATURES (IG ISOTYPE TITERS, FUNCTIONAL ADAMTS13 INHIBITOR AND CIRCULATING IMMUNE COMPLEXES (CIC)) IN PATIENTS WITH ACQUIRED THROMBOSIS THROMBOCITOPENIC PURPURA (ATTP) AT FIRST CONSULTATION IN OUR INSTITUTION. Juvenal Paiva Received Received
  42-MON-PO USE OF D DIMER IN BIOLOGICAL CONTROL OF PREGNANCY Ana Lena Received Received
  43-TUE-PO ATHEROSCLEROTIC CARDIOVASCULAR MORTALITY IN GOUTY ARTHRITIS AND RHEUMATOID ARTHRITIS: IS IT ASSOCIATED WITH MEAN PLATELET VOLUME AND NEUTROPHIL/LYMPHOCYTE RATIO GULSUM EMEL PAMUK Received Received
  43-MON-PO ANTI-ANNEXIN V ANTIBODIES IN PATIENTS WITH OBSTETRIC MORBILITY Susana Ouviña Received Received
  45-WED-PO DETECTION OF PLASMA ADAMTS13 ACTIVITY USING E. COLI DERIVED VWF-A2 SUBSTRATES AND MICROSPHERE-CYTOMETRY ASSAYS Sriram Neelamegham Received Received
  45-TUE-PO EFFECTS OF LOW AND HIGH LEVELS OF NON VKA ORAL ANTICOAGULANTS ON A COMPREHENSIVE PANEL OF ROUTINE AND SPECIALTY COAGULATION TESTS Franois Depasse Received Received
  45-MON-PO PROPOSED TRIAL: HYPATIA - A PROSPECTIVE RANDOMISED CONTROLLED TRIAL OF HYDROXYCHOROQUINE VERSUS PLACEBO DURING PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID ANTIBODIES Karen Schreiber Received Received
  47-TUE-PO DIFFERENT CENTRIFUGATION CONDITIONS DO NOT INTERFERE WITH D-DIMER RESULTS Carlos Aguilar Received Received
  48-TUE-PO THROMBIN GENERATION IN THE NORMAL POPULATION FLATTENED THROMBIN GENERATION CURVES ASSOCIATED WITH POOR LIPID PROFILE AND MALE SEX. Prahlad Ho Received Received
  48-MON-PO ANALYTICAL AND CLINICAL PERFORMANCE OF A NEW AUTOMATED CHEMILUMINESCENT ASSAY (CIA) Teresa Iwaniec Received Received
  48-WED-PO ASSESSMENT OF MOD-5014, A LONG ACTING FVIIA, PHARMACOKINETIC, PHARMACODYNAMICS AND CORRECTION OF HEMOPHILIC COAGULOPATHY IN DOGS WITH HEMOPHILIA A AS PART OF THE PREPARATION FOR FIRST IN HUMAN STUDY Lior Binder Received Received
  49-TUE-PO THE RIVAROXABAN-CALIBRATED ANTI-FXA ASSAY CAN RELIABLY IDENTIFY PRESENCE OF RIVAROXABAN IN PLASMA Jerzy Windyga Received Received
  50-MON-PO FREQUENCY OF CLINICALLY SIGNIFICANT ANTIPHOSPHOLIPID ANTIBODIES PROFILE IN PATIENTS WITH VENOUS THROMBOEMBOLISM, STROKE , MYOCARDIAL INFARCTION, PERIPHERAL ARTERIAL DISEASE AND PREGANCY MORBIDITY Benilde Cosmi Received Received
  50-WED-PO AN ANTIBODY PRETREATMENT STRATEGY FOR IMPROVING CELL-BASED THERAPY IN A MOUSE MODEL OF HEMOPHILIA B Meng-Ni Fan Received Received
  50-TUE-PO A FULLY AUTOMATED AID FOR THE IMPROVEMENT OF HIL INTERFERENCE MANAGEMENT IN THE HEMOSTASIS LABORATORY: TEST ASSAY-SPECIFIC FLAGGING OF LABORATORY RESULTS FOR HEMOLYSIS, ICTERUS AND LIPEMIA/TURBIDITY Janos Polgar Received Received
  51-TUE-PO HANDLING OF THE HEMOCLOT THROMBIN INHIBITOR ASSAY REAGENTS ON SYSMEX CS-2100I WHEN MONITORING DABIGATRAN IN ACUTE CLINICAL SITUATIONS Louise Faaborg Received Received
  51-MON-PO CLINICAL ASSESSMENT OF ANTIPHOSPHOLIPID ANTIBODIES AGAINST 2-GLYCOPROTEIN DOMAIN I IN ANTIPHOSPHOLIPID SYNDROME. PASCUAL MARCO Received Received
  52-WED-PO ASSESSMENT OF KNEE JOINT BLEEDING IN HEMOPHILIA B MICE BY FLUORESCENCE MOLECULAR TOMOGRAPHY Elizabeth Chappell Received Received
  53-TUE-PO USEFULNESS OF DILUTE RUSSELLS VIPER VENOM CLOTTING TIME (DRVVT) FOR THE ROUTINE MONITORING OF NEW ORAL ANTICOAGULANTS Debra Hoppensteadt Received Received
  53-WED-PO SERUM ENDOCAN LEVELS AS A POTENTIAL NON-INVASIVE BIOMARKER FOR DIAGNOSING DIFFERENT HEPATIC DISEASES Rachel Palumbo Received Received
  54-TUE-PO PERFORMANCE OF HEMOSIL DIRECT THROMIN INHIBITOR (DTI) ASSAY ON THE ACL TOP FAMILY INSTRUMENTS Judith Hammelburger Received Received
  54-WED-PO EFFECT OF A RECOMBINANT PLANT ELASTASE INHIBITOR WITH ANTI-INFLAMMATORY ACTION - RBBCI (BAUHINIA BAUHINIOIDES CRUZAIN/CRUZIPAIN INHIBITOR) ON A RAT MODEL OF VENOUS THROMBOSIS Francisco H.A. Maffei Received Received
  54-MON-PO IMPACT OF PREANALYTICAL DELAY ON RESULTS OF LIGHT TRANSMITTANCE AGGREGOMETRY IN STEMI PATIENTS Anna Vybivantseva Received Received
  55-TUE-PO IN VITRO CORRECTION OF IMPAIRED BLOOD COAGULATION IN A MODEL OF SEVERE THROMBOCYTOPENIA Boris Shenkman Received Received
  55-WED-PO EVALUATION OF THE IMPORTANCE OF MIXING PATIENT PLASMA WITH A POOL OF NORMAL PLASMAS WHEN DIAGNOSING LUPUS ANTICOAGULANT Ana Lena Received Received
  55-MON-PO ASSOCIATION OF PLATELET RESPONSE TO CILOSTAZOL WITH CLINICAL OUTCOME AND CYP GENOTYPES IN PATIENTS WITH CEREBRAL INFARCTION JUN YAMANOUCHI Received Received
  56-MON-PO Platelet reactivity based risk assessment for frail patients with coronary artery disease on P2Y12 inhibitors Minka Vries Received Received
  56-TUE-PO NEW IMMUNODEPLETED PLASMA FOR DETERMINATION OF FACTOR XI ACTIVITY Vicente Cortina Received Received
  57-WED-PO NEW MIXING TEST INDEX TO DISCRIMINATE BETWEEN LUPUS ANTICOAGULANT AND COAGULATION INHIBITOR Osamu Kumano Received Received
  57-MON-PO PLATELET FUNCTION TESTING IN ACS PATIENTS USING MEASUREMENT OF PLATELET P-SELECTIN: COMPARISON WITH OTHER COMMERCIAL TESTS Stan Heptinstall Received Received
  58-MON-PO EFFICACY OF PRASUGREL ADMINISTRATION IMMEDIATELY AFTER PERCUTANEOUS CORONARY INTERVENTION IN ACUTE MYOCARDIAL INFARCTION Andreas Schaefer Received Received
  58-TUE-PO EVALUATION OF A NEW ASSAY FOR THE MEASUREMENT OF THE DIRECT FXA INHIBITOR RIVAROXABAN (DG-CHROM ANTI-XA) ON THE Q HEMOSTASIS ANALYZER (GRIFOLS) KIERON HICKEY Received Received
  59-TUE-PO HOW THE DIRECT ORAL ANTICOAGULANT APIXABAN AFFECTS THROMBIN GENERATION PARAMETERS erica scalambrino Received Received
  59-WED-PO DETECTION OF ANTIPHOSPHOLIPID ANTIBODIES IN NORMAL PREGNANT WOMEN AND IN PREGNANT WOMEN AT THE TIME OF PREECLAMPSIA ONSET beatriz grand Received Received
  60-TUE-PO THE CORRELATION OF ATYPICAL APTT CURVES WITH TYPE OF COAGULATION DEFECT Ludek Slavik Received Received
  60-MON-PO CORRELATION BETWEEN PLATELET MRP4 EXPRESSION AND PLATELET FUNCTION IN PATIENTS UNDER CHRONIC ASPIRIN TREATMENT Fabio Pulcinelli Received Received
  61-WED-PO PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID SYNDROME. Denisa Jankovicova Received Received
  61-TUE-PO EFFICACY OF NOVEL ORAL ANTICOAGULANTS (NOACS) USING DILUTED RUSSELLS VIPER VENOM TEST (DRVVT) Makoto Kaneko Received Received
  62-WED-PO ANTIPHOSPHOLIPID ANTIBODIES IN CEREBRAL VASCULAR EVENTS Héla Baccouche Received Received
  62-TUE-PO EX-VIVO AND IN-VITRO COMPARATIVE ASSESSMENT OF MOD-5014 (FACTOR VIIA-CTP), A NOVEL LONG-ACTING COAGULATION FACTORTO RECOMBINANT FVIIA Lior Binder Received Received
  62-MON-PO PLATELET REACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION CHRONICALLY TREATED WITH BETA-BLOCKERS BEFORE THE ONSET OF THE ACUTE EVENT. Antonio Moscardó Received Received
  63-MON-PO PROTEOMIC PROFILING OF PLATELET RESPONSE TO ANTIPLATELET AGENTS REVEALS A WIDE INTER-INDIVIDUAL VARIABILITY AND DISTINCT SIGNATURES OF DRUGS ALONE AND IN COMBINATION simone marcone Received Received
  63-TUE-PO IMPACT OF EDOXABAN ON HAEMOSTASIS DIAGNOSIS ASSAYS: PRACTICAL RECOMMENDATIONS Jonathan Douxfils Received Received
  64-TUE-PO INTRODUCTION OF A LIQUID ANTI-XA METHOD FOR QUANTIFICATION OF CURRENT THERAPEUTIC XA INHIBITORS Jane Needham Received Received
  65-MON-PO INHIBITION OF THIOREDOXIN INHIBITS GPVI-MEDIATED PLATELET ACTIVATION Carmen Coxon Received Received
  66-MON-PO PREDICTION OF HIGH ON-TREATMENT PLATELET REACTIVITY IN CLOPIDOGREL-TREATED PATIENTS WITH ACUTE CORONARY SYNDROMES, USING ADVANCED ARTIFICIAL NEURAL NETWORKS GianMarco Podda Received Received
  67-MON-PO ASPIRIN RESISTANCE IN MEDICAL INPATIENTS ON CHRONIC ASPIRIN TREATMENT Anna Maria Gori Received Received
  68-MON-PO TXA2-BINDING PROTEINS, DIPETALODIPIN AND TRIPLATIN, BLOCK PLATELET-MEDIATED NETS FORMATION IN VITRO AND INHIBIT THROMBOSIS IN VIVO WITHOUT IMPAIRING HEMOSTASIS Daniella Mizurini Received Received
  68-TUE-PO DO PT AND APTT SENSITIVITIES TO FACTORSDEFICIENCIES CALCULATED BY THE H47-A2 2008 CLSI GUIDELINE REFLECT THE DEFICIENCIES FOUND IN PLASMA FROM PATIENTS? Marta E Martinuzzo Received Received
  69-TUE-PO MARKERS OF HEMOSTASIS ACTIVATION AFTER EARLY DISCONTINUATION OF FONDAPARINUX IN LOW-RISK PATIENTS HOSPITALIZED WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME Igor Yavelov Received Received
  69-WED-PO EVALUATION OF ?2-GLYCOPROTEIN I LEVELS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME. Teresa Iwaniec Received Received
  70-WED-PO THE ASSOCIATION OF 3 STAT4 SINGLE NUCLEOTIDE POLYMORPHISMS AND ANTIPHOSPHOLIPID SYNDROME Magdalena Celi&324;ska-Lowenhoff Received Received
  71-MON-PO RETINAL VESSEL CALIBRES AND HAEMOSTASIS IN BLACK AND WHITE SOUTH AFRICANS: THE SABPA STUDY Leandi Lammertyn Received Received
  72-WED-PO PRODUCTION AND PURIFICATION OF VERSATILE ENZYMES FOR POTENTIAL ANTIPLATELET APPLICATIONS Bat-Erdene Jugder Received Received
  74-TUE-PO VARIABILITY IN NORMAL RANGES OF THROMBIN GENERATION BETWEEN LABORATORIES IS WIDE AND DEPENDENT ON TEST METHODOLOGY Hartirathpal Kaur Juspal Singh Received Received
  74-WED-PO PLATELET TRANSFUSION REVERSES BLEEDING EVOKED BY TRIPLE ANTI-PLATELET THERAPY INCLUDING VORAPAXAR, A NOVEL PLATELET THROMBIN RECEPTOR ANTAGONIST Tian-Quan Cai Received Received
  74-MON-PO CARDIOLOGICAL AND THROMBOPHILIC RISK PROFILE IN PATIENTS WITH OCULAR ARTERIAL OCCLUSION Jerzy Dropinski Received Received
  75-TUE-PO RESISTANCE TO THROMBOMODULIN BUT NOT TO ACTIVATED PROTEIN C IN CIRRHOTIC PATIENTS Thomas Sinegre Received Received
  75-MON-PO A NOVEL ASSAY DEMONSTRATES PROCOAGULANT PLATELETS ARE INCREASED IN PATIENT UNDERGOING CORONARY ANGIOGRAPHY WITH DIFFERENTIAL EFFECTS BY ANTI-PLATELET AND ANTI-COAGULANT THERAPY Leonardo Pasalic Received Received
  76-MON-PO RELATION BETWEEN INVASIVE CENTRAL PULSE PRESSURE AND THROMBOGENICITY Udaya Tantry Received Received
  76-WED-PO AN IN VITRO TRANSFUSION MODEL FOR THE ASSESSMENT OF PLATELET FUNCTION RECOVERY FOLLOWING EXPOSURE TO TRIPLE ANTI-PLATELET AGENTS Lisa Jennings Received Received
  77-TUE-PO EMERGENCY ASSESSEMENT OF PATIENTS IN DOACS: THE ROLE OF POINT-OF-CARE TESTING. Paolo Carraro Received Received
  78-WED-PO DEVELOPMENT OF A RECEPTOR OCCUPANCY ASSAY FOR ANFIBATIDE, A NOVEL GPIB ANTAGONIST Alysia Cox Received Received
  79-WED-PO PEGYLATED DISINTEGRIN EXHIBITS MORE POTENT ANTITHROMBOTIC ACTIVITY IN VIVO Chun-Chieh Hsu Received Received
  79-TUE-PO EFFECT OF THE RESIDUAL PLATELET COUNT ON DIFFERENT COAGULATION PARAMETERS IN FREEZE-THAW PLASMA SAMPLES AT -20C YOLANDA PATRICIA ADAMCZUK Received Received
  80-WED-PO RESISTANCE TO ASPIRIN IN MYELOPROLIFERATIVE NEOPLASMS. IS IT A REALITY ? ajzenberg nadine Received Received
  80-TUE-PO CORRELATION TO FVIII:C IN TWO THROMBIN GENERATION ASSAYS: TGA CAT AND INNOVANCE ETP Marcus Ljungkvist Received Received
  81-WED-PO PHARMACOKINETICS AND PHARMACODYNAMICS OF APAC, A DUAL NOVEL ANTICOAGULANT AND ANTIPLATELET HEPARIN COMPLEX Annukka Jouppila Received Received
  82-TUE-PO OVERALL HEMOSTATIC POTENTIAL ASSAY IS SENSITIVE TO DIFFERENT PLASMA FREEZING TECHNIQUES Mojca Bozic-Mijovski Received Received
  83-TUE-PO DEFINING THE REFERENCE RANGE FOR BLOOD CLOT GEL POINT AND FRACTAL DIMENSION Lindsay DSilva Received Received
  83-MON-PO CIRCULATING LYMPHOCYTES AND MONOCYTES AS RISK FACTORS FOR CORONARY ARTERY DISEASE IN INDIAN POPULATION Lakshmi Mundkur Received Received
  83-WED-PO HOW SHOULD WE MEASURE THE EFFECT OF PERSANTINE USING THROMBOELASTOGRAPHY? CORRELATION AND AGREEMENT BETWEEN PERCENT ADP INHIBITION AND ADP NET G patti massicotte Received Received
  84-WED-PO NSAIDS IN VIVO TREATMENT AND MRP4 EXPRESSION IN HUMAN PLATELETS Fabio Pulcinelli Received Received
  84-MON-PO TRANSLATIONAL INFORMATICS APPROACH LINKING RISK OF CORNARY ARTERY DISEASE, INFECTION AND INFLAMMATION Rajani kanth Vangala Received Received
  85-TUE-PO TEST SPECIFIC ASSESSMENT OF EFFECTS OF HAEMOLYSIS ON CITRATED BLOOD SAMPLES USING SYSMEX CS SERIES ANALYSERS Anita Woolley Received Received
  85-WED-PO THE EFFECTIVENESS OF P2Y12 RECEPTOR BLOCKADE IS STRONGLY DETERMINED BY THE PRESENCE OF ENDOTHELIAL MEDIATORS PROSTACYCLIN AND NITRIC OXIDE Rebecca Knowles Received Received
  86-WED-PO COMPARISON OF THE BIOCYTEX AND THE VASPFIX ASSAYS OF VASP PHOSPHORYLATION IN CORONARY-ARTERY DISEASE PATIENTS TREATED WITH CLOPIDOGREL PLUS ASPIRIN Marco Cattaneo Received Received
  86-TUE-PO PROVINCE WIDE IMPLEMENTATION OF THE THROMBIN TIME FOR QUALITATIVE ASSESSMENT OF DABIGATRAN CLEARANCE Artur Szkotak Received Received
  87-WED-PO LOCAL PARAMETERS OF HEMOSTASIS ACTIVATION IN THE FIBRILLATING ATRIUM Noemi Klara Toth Received Received
  87-TUE-PO EFFECTS OF RIVAROXABAN ON PT AND APTT AS DETERMINED WITH A FULL RANGE OF REAGENTS: RESULTS OF A UK NEQAS BLOOD COAGULATION EXERCISE Steve Kitchen Received Received
  88-MON-PO ACCURATE RECOVERY OF PEGYLATED AND NON-PEGYLATED THERAPEUTIC FVIII, USING A SPECIFIC APTT REAGENT, AND APPLICATION ON AN AUTOMATED COAGULATION ANALYZER MARY DOYLE Received Received
  88-WED-PO THE ASSESMENT OF ENDOTHELIAL PROGENITOR CELLS IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION UNDER FIBRINOLYTIC THERAPY OR PRIMARY PERCUTANEOUS CORONARY INTERVENTION Mehmet Sonmez Received Received
  89-WED-PO A single rhADAMTS13-treatment improves cardiac long-term functionality and remodeling after ischemia-reperfusion injury in mice Thilo Witsch Received Received
  90-MON-PO HAEMOSTASIS IN CARDIAC ARREST PATIENTS TREATED WITH THERAPEUTIC HYPOTHERMIA Anne Katrine Wulff Nielsen Received Received
  91-MON-PO IS TGA ABLE TO DISCRIMINATE A DIFFERENT COAGULATION PROFILE IN INHIBITOR PATIENTS WITH SEVERE HEMOPHILIA A AS COMPARED TO NON-INHIBITOR PATIENTS? Maria Elisa Mancuso Received Received
  91-WED-PO BLOCKING HETEROMERIZATION OF PLATELET CHEMOKINES CCL5 AND CXCL4 REDUCES INFLAMMATION AND PRESERVES HEART FUNCTION AFTER MYOCARDIAL INFARCTION Tanja Vajen Received Received
  92-MON-PO IMPACT OF EDOXABAN ON A LARGE PANEL OF ROUTINE OF MORE SPECIFIC COAGULATION ASSAYS Jonathan Douxfils Received Received
  92-TUE-PO EVALUATION OF AN AUTOMATED COAGULOMETER IN A NEW HAEMOPHILIA CARE CENTER Mirta Arias Received Received
  93-MON-PO MODIFICATION OF A THROMBIN GENERATION TEST TO IDENTIFY NEW COFACTORS OF THE PROTEIN C PATHWAY IN PLASMA Silvia Navarro Received Received
  94-WED-PO MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING CORONARY ANGIOPLASTY: ROLE OF NADPH OXIDASE P22PHOX GENE POLYMORPHISMS Betti Giusti Received Received
  95-MON-PO PROVISION OF EXTERNAL QUALITY ASSURANCE FOR THROMBOELASTOGRAPHY (TEG) AND THROMBOELASTOMETRY (ROTEM) Dianne Kitchen Received Received
  95-TUE-PO VTE RECURRENCE AND BLEEDING IN PATIENTS WITH CANCER. RESULTS OF THE OPTIMEV STUDY Sevestre Marie Received Received
  95-WED-PO THROMBOGENICITY ACCORDING TO THE VASCULAR SITE OF ATHEROSCLEROSIS DISEASE DANIELA CALDERARO Received Received
  96-MON-PO ANTICOAGULATION ASSESSMENT WITH PROTHROMBIN TIME AND ANTI-XA ASSAYS IN REAL-WORLD PATIENTS ON TREATMENT WITH RIVAROXABAN Oliver Knigsbrgge Received Received
  96-WED-PO THE ROLES OF TRANSGLUTAMINASE 2 AND FXIII-A IN ABDOMINAL AORTIC ANEURYSM DEVELOPMENT Kingsley Simpson Received Received
  98-WED-PO TWO PEPTIDE EPITOPES DERIVED FROM HUMAN AND MYCOBACTERIUM, RESPECTIVELY, REDUCE ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB(TM2SGY)/J MICE Xinjie Lu Received Received
  98-TUE-PO CANCER ASSOCIATED THROMBOSIS: DEVELOPING CONSENSUS GUIDANCE TO IMPROVE PATIENT CARE AND OUTCOMES Roopen Arya Received Received
  99-MON-PO MONITORING NEW ORAL ANTICOAGULANTS (NOACS) USING NEW-GENERATION THROMBELASTOGRAPHY TEG6S SYSTEM Udaya Tantry Received Received
  100-WED-PO THE ROLE OF CLOTTING FACTOR IX IN THE DEVELOPMENT OF ATHEROSCLEROSIS Laís Ívina Silva de Paula Laís Ívina Received Received
  100-TUE-PO AGE-ADJUSTED D-DIMER CUT-OFF LEVEL INCREASES THE NUMBER OF CANCER PATIENTS IN WHO PULMONARY EMBOLISM CAN BE SAFELY EXCLUDED WITHOUT CTPA IMAGING: THE ADJUST-PE CANCER SUBSTUDY Dorienke Wilts Received Received
  101-MON-PO FXII618, A NEW FACTOR XII INHIBITOR: VALIDATION FOR THROMBIN GENERATION ASSAY sara calzavarini Received Received
  101-WED-PO PHOSPHORYLATION OF PLATELET ACETYL-COA CARBOXYLASE IS INCREASED IN HUMAN AND MICE ATHEROSCLEROSIS AND COULD BE AN INDICATOR OF PERSISTENT THROMBIN GENERATION. Sophie Lepropre Received Received
  102-MON-PO PF4-R, A NOVEL HEPARIN NEUTRALIZING REAGENT SUITABLE FOR AUTOMATED COAGULOMETERS: COMPARISON WITH HEPARINASE IN ROUTINE COAGULATION TESTS Elaine Benoit Received Received
  104-WED-PO EFFECT OF DABIGATRAN ETEXILATE AND WARFARIN ON ATHEROSCLEROTIC PLAQUE CALCIFICATION IN APOE-/- MICE. Leon Schurgers Received Received
  104-MON-PO TESTING AN IN VITRO MODEL OF LAMINAR FLOW FOR USE IN LARGE-SCALE APTAMER SCREENING Laura Sommerville Received Received
  104-TUE-PO RISK OF CANCER AFTER VENOUS THROMBOEMBOLISM - THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) COHORT Hilde Jensvoll Received Received
  105-MON-PO POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH TYPE 2 DIABETES Jakub Siudut Received Received
  105-TUE-PO MANAGEMENT OF CANCER ASSOCIATED THROMBOSIS IN FRANCE : A NATIONAL SURVEY IN VASCULAR DISEASE AND SUPPORTIVE CARE SPECIALISTS Isabelle Mahé Received Received
  106-TUE-PO VENOUS THROMBOEMBOLISM AFTER SURGICAL TREATMENT OF SKELETAL METASTASES AN UNDERDIAGNOSED COMPLICATION Riitta Lassila Received Received
  106-MON-PO ACTIVATION OF COAGULATION BY ANTINEOPLASTIC DRUGS FOR LYMPHOID TUMORS Misae Tsunaka Received Received
  107-TUE-PO MAJOR AND NON-MAJOR CLINICALLY RELEVANT BLEEDING IN PATIENTS HOSPITALIZED IN PALLIATIVE CARE UNITS: RESULTS OF A FRENCH MULTICENTRE OBSERVATIONAL STUDY. Tardy Bernard Received Received
  107-MON-PO PROCOAGULANT TUMOR MICROENVIRONMENT AS TARGET FOR A TFPI-LIKE MOLECULE Kátia Luciano Pereira Morais Received Received
  109-MON-PO EFFECT OF HYPOXIA ON TISSUE FACTOR PATHWAY INHIBITOR EXPRESSION IN BREAST CANCER CELLS Xue Yan Cui Received Received
  110-WED-PO CAN COMPARING THE VALUE OF THE PROTHROMBIN TIME RATIO AND THE ACTIVATED PARTIAL THROMBOPLASTIN TIME RATIO HELP DIAGNOSE THE CAUSE OF COAGULOPATHY? Yingyong Chinthammitr Received Received
  110-MON-PO THE THROMBOTIC POTENTIAL OF CIRCULATING TUMOR MICROEMBOLI Annachiara Mitrugno Received Received
  111-MON-PO FIBRIN DEGRADATION BY RTPA IMPROVE NANOPARTICLE DRUG DELIVERY FOR TUMORS Bo Zhang Received Received
  111-TUE-PO AGE SHOULD NOT BE CONSIDERED A RISK FACTOR FOR CANCER-RELATED VENOUS THROMBOEMBOLISM: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER STUDY Kristine Blix Received Received
  112-TUE-PO CANCER-RELATED VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY Kristine Blix Received Received
  112-WED-PO EFFECT OF RECOMBINANT LUBRICIN ON COAGULATION PARAMETERS IN HUMAN BLOOD Jawed Fareed Received Received
  112-MON-PO HUMAN ANGIOSARCOMA CELLS EXPRESS TISSUE FACTOR AND GENERATE THROMBIN IN A TISSUE FACTOR-DEPENDENT MANNER Lauren Witter Received Received
  113-TUE-PO INCIDENCE, RISK FACTORS, AND OUTCOME OF EARLY HEMOSTATIC COMPLICATIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER STUDY OF 551 PATIENTS yue han Received Received
  114-WED-PO ABILITY OF THROMBOELASTOGRAPHY TO DISTINGUISH THE SEVERITY OF PHENOTYPE IN PATIENTS WITH SEVERE HEMOPHILIA Maria Elisa Mancuso Received Received
  114-TUE-PO DETECTION OF HYPERCOAGULABILITY IN HEPATOCELLULAR CARCINOMA (HCC). Spiezia Luca Received Received
  115-WED-PO ARE WHOLE BLOOD COAGULATION ANALYSES TEMPERATURE DEPENDENT? Anni Jeppesen Received Received
  116-TUE-PO FACTORS INFLUENCING THE USE OF THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS IN THE REAL WORLD CLINICAL PRACTICE Ramón Lecumberri Received Received
  117-MON-PO ACTIVATED PROTEIN C UP- REGULATES THE OVARIAN CANCER CELL MIGRATION AND PROMOTES UNCLOTTABILITY OF CANCER PERITONEAL FLUID Hamda Althawadi Received Received
  117-TUE-PO RESIDUAL VEIN THROMBOSIS TO ASSES THE DURATION OF LOW MOLECULAR WEIGHT HEPARIN (THE EXTENDED CANCER-DACUS) mariasanta Napolitano Received Received
  118-MON-PO ESTROGENS UPREGULATE TFPI-2 EXPRESSION IN MCF-7 CELLS PROBABLY BY PROMOTER DEMETHYLATION Grethe Skretting Received Received
  119-MON-PO ENDOTHELIAL PROTEIN C RECEPTOR IN BREAST CANCER CELLS, CO-EXPRESSED WITH MULTIDRUG RESISTANCE PROTEIN, INHIBITS FIBRIN FORMATION IN TUMOR MICRO ENVIRONMENT Halema AlFarsi Received Received
  119-WED-PO DOES ANTITHROMBOTIC THERAPY INFLUENCE RESULTS OBTAINED BY THROMBOELASTOMETRY? Mia Hammer Holck Received Received
  120-WED-PO SCREENING METHOD USING TWO DIFFERENT ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) REAGENTS FOR SPECIMENS WITH PROLONGED APTT Emi Takeo Received Received
  120-TUE-PO THROMBOEMBOLIC EVENTS IN CHILDREN WITH CANCER IN SRINAGARIND HOSPITAL Patcharee Komvilaisak Received Received
  120-MON-PO CHANGES IN COAGULATION IN ACUTE PROMYELOCYTIC LEUKAEMIA Richard Dillon Received Received
  121-MON-PO FIBRINOLYTIC ACTIVATION IN ACUTE PROMYELOCYTIC LEUKAEMIA Richard Dillon Received Received
  121-TUE-PO THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH LYMPHOMA Darko Antic Received Received
  121-WED-PO TROMBIN GENERATION; ESTABLISHMENT OF REFERENCE INTERVAL AND THE INFLUENCE OF ASPIRIN Vivi Bo Mogensen Received Received
  122-MON-PO CONDITIONAL INACTIVATION OF INTEGRIN ?V SUBUNIT IN VASCULAR SMOOTH MUSCLE CELLS DECREASES THROMBIN GENERATION IN VESSELS AND BLOOD. MOHAMADI AMEL Received Received
  122-WED-PO A NEW ASSAY FOR MEASUREMENT OF THE IN-VIVO THROMBIN ACTIVITY IN COMPARISON TO THE IN-VITRO THROMBIN GENERATION POTENTIAL IN PATIENTS WITH HYPER- AND HYPOCOAGULABLE STATE Silvia Koder Received Received
  123-MON-PO OESTROGENS REGULATE TFPI EXPRESSION THROUGH OESTROGEN RESPONSE ELEMENTS IN TFPI 5 FLANKING REGION Huda Omar Ali Received Received
  123-WED-PO INFLUENCE OF PRE-ANALYTICAL HEPARIN ON T-PA INDUCED FIBRINOLYSIS DETERMINED BY THROMBOELASTOGRAPHY. Floor Moenen Received Received
  124-WED-PO THE EFFECT OF FRESH FROZEN PLASMA IN CRITICALLY ILL PATIENTS Emil Vibede Received Received
  125-WED-PO A DRVVT-BASED ASSAY TO ESTIMATE THE INTENSITY OF ANTICOAGULATION IN PATIENTS TREATED WITH DIRECT ORAL ANTICOAGULANTS Anne-Laure Sennesael Received Received
  126-TUE-PO A NEW GENERIC RISK SCORE FOR PREDICTING VENOUS THROMBOEMBOLIC EVENTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY Andres Muñoz Received Received
  126-WED-PO PRE-ANALYTICAL SAMPLE CHECK IN HAEMOSTASIS: EVALUATION OF THE NEW COAGULOMETER ACL TOP 750 CTS SYSTEM Chiara Novelli Received Received
  127-MON-PO PROCOAGULANT EFFECTS OF LUNG CANCER CHEMOTHERAPY THROUGH RELEASE OF MICROPARTICLES AND CELL-FREE DNA. Zakhar Lysov Received Received
  127-TUE-PO THROMBOPROPHYLAXIS OF AMBULANT PANCREATIC CANCER PATIENTS: SINGLE CENTRE EXPERIENCE UTILIZING THE LESSONS FROM FRAGEM AND CONKO-04. Iqtedar Ahmed Received Received
  128-MON-PO THE REED STERNBERG CELL COAGULOME Gabriela Cesarman-Maus Received Received
  128-TUE-PO TREATMENT OF CANCER ASSOCIATED THROMBOSIS AFTER THE INITIAL 6 MONTH PERIOD. Petr Kessler Received Received
  129-MON-PO FACTOR VII DERIVED PROTEIN EGFP-EGF1 MEDIATE DRUG DELIVERY SYSTEM FOR HUMAN TUMOR Wei Shi Received Received
  130-WED-PO EVALUATION OF WAVEFORM ANALYSIS ON THE DESTINY MAX COAGULATION ANALYSER Jane Needham Received Received
  130-TUE-PO RIVAROXABAN ASSOCIATES WITH FACTOR XA FASTER THAN APIXABAN: A POTENTIAL EXPLANATION FOR THEIR DIFFERENT EFFECTS ON TESTS OF COAGULATION Calvin Yeh Received Received
  131-MON-PO HYPOXIA-INDEPENDENT TUMOR PROGRESSION: ACTIVATION OF TRANSCRIPTION FACTOR HIF 1 VIA PAR1 AND PAR2 RECEPTORS IN BREAST CANCER. Tainá Gomes Received Received
  131-WED-PO FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE SHOWS ANTICOAGULANT EFFECT WHEN USED FOR IN VITRO EXPERIMENTS Emilie Sandgaard Pedersen Received Received
  131-TUE-PO GENERATION OF A RECOMBINANT TRUNCATED ACTIVATED FACTOR X AS ANTI-HEMOPHILIC AGENT PLANTIER Jean-Luc Received Received
  133-MON-PO NEUTROPHIL EXTRACELLULAR TRAPS MEDIATE ARTERIAL AND VENOUS THROMBUS FORMATION IN A MURINE BREAST CANCER MODEL robson monteiro Received Received
  134-TUE-PO NOVEL F10: P. CYS57ARG MUTATION IN A PAKISTANI SEVERE FX-DEFICIENT PROBAND MUNIRA BORHANY Received Received
  134-WED-PO IMPACT OF SILVER NANOPARTICLES ON HEMOLYSIS, PLATELET FUNCTION, COMPLEMENT SYSTEM AND COAGULATION Julie Laloy Received Received
  135-MON-PO PROTEOLYTIC INACTIVATION OF COAGULATION FACTOR V BY OMPT FROM ENTEROHEMORRHAGIC ESCHERICHIA COLI. John Samis Received Received
  135-TUE-PO THE IL-10 POLARIZED CYTOKINE PATTERN IN INNATE AND ADAPTIVE IMMUNITY CELLS CONTRIBUTE TO THE DEVELOPMENT OF FVIII INHIBITORS Daniel Chaves Received Received
  136-WED-PO NEW LIQUID RECOMBINANT THROMBOPLASTIN (DG PT RECOMBILIQ, DIAGNOSTIC GRIFOLS) SUITABLE FOR ROUTINE USE Anita Woolley Received Received
  136-MON-PO COMBINED FV AND FVIII DEFICIENCY (F5F8D) IN A CHINESE FAMILY WITH A NOVEL MISSENSE MUTATION IN MCFD2 GENE anyou wang Received Received
  137-TUE-PO ASSOCIATION OF ARTERIAL AND VENOUS THROMBOSIS WITH CLOTTING FACTOR USED IN PATIENTS WITH HEMOPHILIA Jiaan-Der Wang Received Received
  137-MON-PO SUCCESSFUL ABDOMINAL OPERATION WITHOUT REPLACEMENT THERAPY IN A PATIENT WITH COMBINED FV AND FVIII DEFICIENCY DUE TO NOVEL HOMOZYGOUS MUTATION IN LMAN1 anyou wang Received Received
  138-WED-PO SILICA CLOTTING TIME (SCT) VS DILUTE RUSSELL VIPER VENOM TIME (dRVVT) AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) IN THE DIAGNOSIS OF ANTIPHOSPHOLIPID ANTIBODIES SYNDROME. Evelyn Cortina de la Rosa Received Received
  138-MON-PO ENGAGEMENT OF THE ACTIVE SITE OF THROMBIN BY DABIGATRAN OR ARGATROBAN MODULATES ITS EXOSITE-MEDIATED INTERACTIONS WITH FIBRIN AND FACTOR VA Calvin Yeh Received Received
  139-WED-PO DISCORDANCE BETWEEN ACTIVATED PARTIAL THROMBOPLASTIN TIME AND HEPARIN LEVEL MEASURED WITH ANTI-XA ASSAY IN ANTITHROMBIN-DEFICIENT PLASMA Alice Yi Received Received
  139-MON-PO FACTOR VA IN SYNERGY WITH PROTEIN S ENHANCES ACTIVATED PROTEIN C BINDING TO PHOSPHOLIPIDS Magdalena Gierula Received Received
  141-WED-PO EVALUATION OF THE NEW QSMART FROM GRIFOLS IN COMPARISON TO THE QHEMOSTASIS ANALYZER Anita Woolley Received Received
  141-MON-PO REFERENCE VALUE AND STABILITY OF FACTOR V Widhyastuti Reny Received Received
  142-WED-PO HEMOCOMPATIBILITY OF ESTETROL AND ESTRADIOL COUPLED TO CYCLODEXTRINES Julie Laloy Received Received
  142-TUE-PO THE TYPE OF REAGENTS DETERMINES THE ACCURACY OF CALIBRATION WITH A PRODUCT SPECIFIC STANDARD FOR THE MEASUREMENT OF THE B-DOMAIN DELETED RFVIII MOROCTOCOG ALFA-AF ACTIVITY. Jacquemin Marc Received Received
  143-WED-PO EVALUATION OF PROLONGED PT / APTT TESTS IN PRESURGICAL PLASMA SAMPLES ZHRE KAYA Received Received
  144-WED-PO VALIDATION OF NEW AUTOMATED LATEX-IMMUNOTURBIDIMETRIC ASSAY FOR MEASURING VWF ACTIVITY Desiree Coen Herak Received Received
  145-WED-PO LABORATORY EVALUATION OF PATIENTS WITH UNDIAGNOSED BLEEDING DISORDERS Fernanda Bassora Received Received
  146-WED-PO COMPARISON OF METHODS OF MEASUREMENT OF FACTOR VIII INHIBITORS IN A NEW HAEMOPHILIA CARE CENTER Mirta Arias Received Received
  147-WED-PO THE NORMAL RANGE OF THE THROMBODYNAMICS VALUES FOR APPARENTLY HEALTHY PREGNANT WOMEN Tatiana Vuimo Received Received
  148-MON-PO EARLY IMMUNOLOGICAL EVENTS IN AAV-F9 MEDIATED ITI FOR HEMOPHILIA B MICE WITH PATHOGENIC FIX INHIBITORS David Markusic Received Received
  149-TUE-PO DIFFERENT STRATEGIES FOR TREATMENT ON HEMOPHILIA PATIENTS WITH INHIBITOR, COSTS VERSUS BENEFITS Mohammadreza Baghaipour Received Received
  149-WED-PO CAN THE OVERALL HAEMOSTATIC POTENTIAL ASSAY PREDICT BLEEDING AND THROMBOSIS RISK IN WARFARINISED PATIENTS? Caroline Reddel Received Received
  150-MON-PO ASSESSMENT OF RECOMBINANT FACTOR IX-FC FUSION PROTEIN (RFIXFC) CLOTTING ACTIVITY IN PLASMA SAMPLES AT CANADIAN HAEMOPHILIA TREATMENT CENTRES Elaine Benoit Received Received
  151-MON-PO A CASE OF SEVERE HEMOPHILIA B ASSOCIATED WITH A LARGE INSERTION OF SVA RETROTRANSPOSON IN THE COAGULATION FACTOR IX GENE Naoki Mizutani Received Received
  151-WED-PO HEPARIN AND PROTAMINE CONFOUND FACTOR ACTIVITY AND INHIBITOR TESTING WHILE ON CARDIOPULMONARY BYPASS Michelle Sholzberg Received Received
  152-WED-PO HEMOSTASIS ALTERATIONS ASSOCIATED TO COMPLICATIONS IN SICKLE CELL SYNDROME HIGUERA DIEGO Received Received
  153-MON-PO THE EFFECTS OF A NOVEL LONG-ACTING FACTOR IX PRODUCT (N9-GP) ON WOUND HEALING Elizabeth Chappell Received Received
  154-WED-PO BLOOD COAGULATION TESTS: REVIEW OF VALIDATION REQUIREMENTS FOR FDA CLEARANCE Iwona Fijalkowska Received Received
  154-MON-PO INHERITED FACTOR VIII AND IX DEFICIENCY IN PATIENTS REPORTED TO A TERTIARY CARE UNIVERSITY HOSPITAL IN INDIA: A RETROSPECTIVE COHORT ANALYSIS Benson Babu Received Received
  155-MON-PO PROTEIN S, A NEW AGENT IN ADJUNCT THERAPY OF HEMOPHILIA B Rinku Majumder Received Received
  155-WED-PO SP-SELECTIN AS A MARKER OF PLATELET ACTIVATION IN AFRICANS WITH PROSTATE CANCER. HANNAH OMUNAKWE Received Received
  155-TUE-PO RATE-LIMITING ROLES OF TENASE COMPLEX OF FACTORS VIII AND IX IN PLATELET PROCOAGULANT ACTIVITY AND FORMATION OF PLATELET-FIBRIN THROMBI UNDER FLOW Johan Heemskerk Received Received
  156-MON-PO IN VIVO EFFICACY OF HUMAN RECOMBINANT FACTOR IX PRODUCED BY THE HUMAN HEPATOMA CELL LINE HUH-7 Nathalie ENJOLRAS Received Received
  156-WED-PO FRACTAL DIMENSION (DF) AS A MARKER OF HYPERCOAGULABILITY, CLOT STRUCTURE AND 12 MONTH SURVIVAL IN LUNG CANCER Nia Davies Received Received
  156-TUE-PO TREATMENT OF SEVERE BLEEDING AND PROPHYLAXIS WITH RFVIIA IN A CHILD WITH FVIII INHIBITOR adalet meral gunes Received Received
  157-MON-PO INCORPORATION OF MUTATIONS AT E410 OF FACTOR IX IMPROVES CLOTTING ACTIVITY IN VITRO AND IN VIVO Nathalie ENJOLRAS Received Received
  158-MON-PO THE SLEEPING-BEAUTY TRANSPOSON TECHNOLOGY FOR THE GENERATION OF CELLULAR AND ANIMAL MODELS OF HAEMOPHILIA B AND THE ASSESSMENT OF RNA-BASED THERAPEUTIC APPROACHES Elena Barbon Received Received
  159-MON-PO COMPARISON OF FACTOR IX GLYCOSYLATION IN DIFFERENT AGE GROUPS Helen Atkinson Received Received
  159-WED-PO FACTOR V LEIDEN MUTATION AND HIGH FVIII ARE ASSOCIATED WITH AN INCREASED RISK OF VTE IN WOMEN WITH BREAST CANCER DURING ADJUVANT TAMOXIFEN - RESULTS FROM A PROSPECTIVE, SINGLE CENTER, CASE CONTROL STUDY Mirjana Kovac Received Received
  159-TUE-PO INTRA-LABORATORY VARIATION IN FVIII :C INHIBITOR ASSAY :RESULTS OF A STUDY IN THREE FRENCH CENTERS Christophe NOUGIER Received Received
  160-MON-PO INVESTIGATIONS INTO ANTICOAGULANT RESISTANCE AND ENHANCED ACTIVATION AS PUTATIVE MOLECULAR MECHANISMS OF THE HYPERACTIVITY OF FACTOR IX PADUA Ben Samelson-Jones Received Received
  161-WED-PO INCREASING PLATELETS AND OTHER MEASURES ENHANCING HEMOSTASIS ARE BOTH IMPORTANT TO PREVENT BLEEDING EPISODES WHEN THROMBOCYTOPENIC PATIENTS REQUIRING ANTITHROMBOTIC THERAPY A REVIEW OF THE MEDICAL LITERATURE Howard Chan Received Received
  162-TUE-PO INVESTIGATING POTENTIAL DETERMINANTS OF ITI SUCCESS USING IMMUNE GENE EXPRESSION PROFILING: A PRELIMINARY STUDY Davide Matino Received Received
  162-WED-PO PANCREATIC CANCER PATIENTS EXPRESS ELEVATED FVIII LEVELS AND METASTASIS-ASSOCIATED FIBRIN TURNOVER PRIOR TO THEIR DIAGNOSIS Nora Varkila Received Received
  163-TUE-PO FACTOR VIII DEFICIENCY: INHIBITION OR ABNORMAL CONTACT? ANA AZEVEDO Received Received
  164-WED-PO PROTEIN C LEVELS ARE ASSOCIATED WITH MORTALITY IN PATIENTS WITH ADVANCED CANCER Dorienke Wilts Received Received
  165-MON-PO USING HPSEC TO QUANTIFY THE EFFECT OF GAMMA-CARBOXYLATION ON DIVALENT METAL-INDUCED COMPACTION OF VKD-PROTEINS AND BIOLOGICAL FUNCTION NIcholas Vanderslice Received Received
  165-WED-PO L-ASPARAGINASE LOWERS PLASMA ANTITHROMBIN AND MANNAN-BINDING-LECTIN LEVELS: IMPACT ON THROMBOTIC AND INFECTIOUS EVENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA Arnaud Bonnefoy Received Received
  166-WED-PO LONGITUDINAL ANALYSIS OF HEMOSTATIC BIOMARKERS IN CANCER PATIENTS DURING ANTI-TUMOR TREATMENT Eva-Maria Reitter Received Received
  167-WED-PO MICROVESICLES ARE A POTENTIAL BIOMARKER FOR THROMBOSIS AND DIC IN LEUKEMIC PATIENTS: A CROSS-SECTIONAL STUDY Damien Gheldof Received Received
  168-MON-PO EVALUATION OF HOST CELL PROTEIN IMMUNOGENICITY OF A POLISHED RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT, IB1001 IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B Bojan Drobic Received Received
  168-TUE-PO FACTOR XIA, FACTOR IXA AND TISSUE FACTOR ACTIVITY IN BLUNT TRAUMA PATIENTS Saulius Butenas Received Received
  169-WED-PO SIGNIFICANCE OF HAEMOSTATIC PARAMETERS IN PATIENTS WITH URINARY CANCER Paraskevi Kotsi Received Received
  169-MON-PO FACTOR IX IMMUNOGENICITY IN HEMOPHILIA B PATIENTS ON REPLACEMENT THERAPY WITH A RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT (IB1001) Bojan Drobic Received Received
  170-TUE-PO HISTIDINE-RICH GLYCOPROTEIN BINDS DNA AND RNA AND ATTENUATES THEIR CAPACITY TO ACTIVATE THE INTRINSIC PATHWAY OF COAGULATION Trang Vu Received Received
  171-TUE-PO LOCALIZATION OF FACTOR XI IN PLATELETS IS NOT RESTRICTED TO ALPHA GRANULES. Michal Zucker Received Received
  172-TUE-PO THE 2,5-DICHLOROPHENYL FRAGMENT AS STARTING POINT IN THE DESIGN OF NEW FXIIA INHIBITORS Charlotte Bouckaert Received Received
  174-MON-PO MOYAMOYA SYNDROME IN A HEMOPHILIA A PATIENT WITH A HIGH-TITRE FVIII INHIBITOR Wolf Hassenpflug Received Received
  174-TUE-PO EVALUATION OF THE EFFECTS OF A NOVEL CONTACT PATHWAY INHIBITOR, IR-CPI, ON IN VITRO PLATELET FUNCTION AND COAGULATION Jayaprakash Kotha Received Received
  175-MON-PO OPTIMIZING PROCOAGULANT ACTIVITY FOR MUTANT RECOMBINANT FACTOR IX WITH RESISTANCE TO HEPARIN- AND ANTITHROMBIN John Sheehan Received Received
  175-TUE-PO BLOOD GROUP, BLEEDING PHENOTYPE AND POST-PARTUM HAEMORRHAGE IN FACTOR XI-DEFICIENT WOMEN Bethan Myers Received Received
  175-WED-PO RIVAROXABAN IN PATIENTS WITH VTE AND CANCER: A SINGLE CENTER EXPERIENCE Samantha Pasca Received Received
  176-WED-PO D-DIMER PLASMA LEVELS AS A MARKER OF PULMONARY EMBOLISM IN PATIENTS UNDERGOING SURGERY FOR TUMORS OF THE CENTRAL NERVOUS SYSTEM Andrea Artoni Received Received
  176-MON-PO TO EVALUATE THE UTILITY OF ISTH SCORING SYSTEM, APTT AND SCHISTOCYTES AS MARKERS OF SEVERITY IN CASES OF DISSEMINATED INTRAVASCULAR COAGULATION. Anjali Kelkar Received Received
  176-TUE-PO IDENTIFICATION OF THREE NOVEL FACTOR XII MUTATIONS ASSOCIATED WITH CONGENITAL FACTOR XII DEFICIENCY Peipei Jin Received Received
  177-WED-PO TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IS A MARKER OF TUMOR PROGRESSION AND PROGNOSIS IN BREAST CANCER Mari Tinholt Received Received
  177-MON-PO ROLE OF PLASMA HIGH MOBILITY GROUP BOX 1 IN DISSEMINATED INTRAVASCULAR COAGULATION WITH LEUKEMIA. heng mei Received Received
  178-WED-PO INCREASED ACTIVATED PROTEIN C RESISTANCE AND D-DIMER IN BREAST CANCER: PHENOTYPIC AND GENOTYPIC DETERMINANTS AND ASSOCIATION WITH TUMOR CHARACTERISTICS Mari Tinholt Received Received
  179-WED-PO THROMBIN GENERATION (TG) IS DOWNREGULATED BY LOW MOLECULAR WEIGHT HEPARIN (LMWH) IN CANCER PATIENTS WITH VENOUS THROMBOEMBOLISM (VTE) Marina Marchetti Received Received
  179-MON-PO EVALUATION OF NEW CHINESE DIAGNOSTIC SCORING SYSTEM FOR DISSEMINATED INTRAVASCULAR COAGULATION. heng mei Received Received
  179-TUE-PO UNEXPECTED HEPATOCYTE GROWTH FACTOR ACTIVATOR (HGFA) ACTIVITY ALLOWS A POSSIBLE CROSSTALK BETWEEN ACTIVATED FACTOR XII AND THE HGF/C-MET PATHWAY IN HUMAN PLASMA Benedito Prezoto Received Received
  180-MON-PO A NOVEL MURINE MODEL OF DISSEMINATED INTRAVASCULAR COAGULATION (DIC) TO AID THE DEVELOPMENT OF NOVEL THERAPEUTICS TO TREAT DIC Majid Ali Received Received
  180-WED-PO HYPERCOAGULABILITY: AN ADDED SIDE EFFECT FOR ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER PATIENTS Harmanpreet Kaur Received Received
  180-TUE-PO FXI AND FXII ACTIVITY LEVELS IN YOUNG PATIENTS WITH CRYPTOGENIC ISCHEMIC STROKE Cristina Duboscq Received Received
  181-WED-PO IDENTIFICATION OF TWO NOVEL MISSENSE MUTATIONS CAUSING SEVERE FACTOR XIII DEFICIENCY MUNIRA BORHANY Received Received
  182-TUE-PO SURFACE PLASMON RESONANCE: SENSIQ PIONEER AS A MEANS TO SCREEN DRUG DISCOVERY FRAGMENTS FOR HITS Clare Wishart Received Received
  182-MON-PO BIOMARKER PROFILE OF SEPSIS-ASSOCIATED COAGULOPATHY USING BIOCHIP ASSAYS FOR INFLAMMATORY CYTOKINES Amanda Walborn Received Received
  182-WED-PO FIRST GROUNDING FOR COMPLETE STRUCTURAL CHARACTERIZATION OF FXIII HETEROTETRAMER: SUCCESSFUL DISULFIDES SNEHA GUPTA Received Received
  183-WED-PO REVISITING THE MECHANISM OF COAGULATION FACTOR XIII ACTIVATION; A STRUCTURE FUNCTIONAL PERSPECTIVE Sneha Gupta Received Received
  183-MON-PO HYPOXIA INDUCES DYSREGULATION OF MIR-126 AND AFFECTS VEGF AND MMP-9 EXPRESSION IN ENDOTHELIAL CELLS Satoshi Fujii Received Received
  184-WED-PO MUTATING CORE STRUCTURAL DISULFIDES OF THE FXIII B SUBUNIT AS A MEANS TO UNCOVER THE FUNCTIONAL ROLES OF INDIVIDUAL FXIIIB SUBUNIT SUSHI DOMAINS mohammad akhter Received Received
  184-TUE-PO EFFECT OF A PLANT INHIBITOR OF THE CONTACT SYSTEM ON A MOUSE THROMBOSIS MODEL Maria Luiza V. Oliva Received Received
  185-MON-PO ANTI-THROMBOTIC AND PRO-FIBRINOLYTIC EFFECTS OF LEVOSIMENDAN IN HUMAN ENDOTHELIAL CELLS IN VITRO Konstantin Krychtiuk Received Received
  185-TUE-PO ENDOTHELIAL CELL INCREASES ITS RIGIDITY DURING INFLAMMATION THROUGH MODIFICATION OF THE GAP JUNCTION Takayuki Okamoto Received Received
  185-WED-PO THE ACTIVATION PEPTIDE OF COAGULATION FACTOR XIII IS VITAL FOR ITS EXPRESSION AND STABILITY Verena Schroeder Received Received
  186-WED-PO THE B-SUBUNIT OF COAGULATION FACTOR XIII DOES NOT SPECIFICALLY INTERACT WITH COMPLEMENT FACTORS Verena Schroeder Received Received
  187-WED-PO THE EFFECT OF FACTOR XIII B SUBUNIT POLYMORPHISMS ON FACTOR XIII LEVELS AND ON THE RISK OF CORONARY ARTERY DISEASE; INTERACTION WITH FIBRINOGEN LEVEL AND FACTOR XIII A SUBUNIT P.VAL34LEU POLYMORPHISM László Muszbek Received Received
  187-MON-PO ENDOTHELIAL FIBRINOLYTIC RESPONSE ONTO AN EVOLVING MATRIX OF FIBRIN Marchi Rita Received Received
  188-MON-PO A MICROFLUIDIC VASCULAR INJURY MODEL USING HEAT-ACTIVATED ENDOTHELIAL CELLS Joanna Sylman Received Received
  188-WED-PO FXIII-A V34L AFFECTS THROMBUS CROSS-LINKING, BUT NOT SIZE, IN A MURINE THROMBOSIS MODEL Cedric Duval Received Received
  190-WED-PO RESIDENT TISSUE MACROPHAGES ARE THE PROBABLE SOURCE OF PLASMA CLOTTING FACTOR XIII-A Kingsley Simpson Received Received
  190-TUE-PO ACTIVATION OF THE ENDOTHELIUM MAY BE INVOLVED IN THE HEMOSTATIC ALTERATIONS INDUCED BY MICRURUS TENER TENER VENOM IN C57BL/6 MICE Emelyn Salazar Received Received
  190-MON-PO CIRCULATING ENDOTHELIAL CELLS ARE INCREASED IN POST-THROMBOTIC SYNDROME PATIENTS Mariane Flores-Nascimento Received Received
  191-TUE-PO INCREASED ENDOCAN LEVELS AND ITS ASSOCIATION WITH SEVERITY IN STEVENS JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS. Daneyal Syed Received Received
  191-WED-PO EFFECT OF STABLE GABARAP KNOCKOUT ON THE FVIII SECRETION Heike Singer Received Received
  192-MON-PO EFFECT OF MATERNAL ANTI-HPA-1A ANTIBODIES ON ENDOTHELIAL CELLS Rima Dardik Received Received
  192-WED-PO DIMERIC ORGANIZATION OF MEMBRANE-BOUND FACTOR VIII ON LIPID NANOTUBES Svetla Stoilova-McPhie Received Received
  193-MON-PO ENDOTHELIAL DYSFUNCTIONS IN CIRRHOSIS PATIENTS CLAUDIA MARIA RADU Received Received
  195-MON-PO EVALUATION OF DIFFERENT ASSAYS OF D-DIMER AND SOLUBLE FIBRIN IN EMERGENCY DEPARTMENT PATIENTS WITH SUSPECTED VENOUS THROMBOEMBOLISM Maria Farm Received Received
  196-WED-PO EXPRESSION, PURIFICATION AND CHARACTERIZATION OF CODON OPTIMIZED COAGULATION FACTOR VIII Andrey Sarafanov Received Received
  196-MON-PO PERFORMANCE OF AGE ADJUSTED D-DIMER CUT OFF VALUE: A STEP TOWARDS IMPROVING CLINICAL UTILITY IN DIAGNOSIS OF ASYMPTOMATIC VENOUS THROMBOEMBOLISM salma shawkat Received Received
  197-TUE-PO INTERNATIONAL STUDY TO ASSESS THE PERFORMANCES OF A NEW LIQUID ASSAY FOR DETERMINATION OF FIBRINOGEN Neil Harris Received Received
  198-WED-PO MINIGENE APPROACH TO CHARACTERIZE A NOVEL SPICE SITE MUTATION IN HUMAN F8 GENE CAUSING SEVERE HAEMOPHILIA A jourdy yohann Received Received
  200-TUE-PO A CASE OF THROMBOSIS IN CONGENITAL AFIBRINOGENEMIA PATIENT: A PHYSIOPATHOLOGIC AND MANAGEMENT DILEMMA Cristina Santoro Received Received
  201-TUE-PO CTEPH-ASSOCIATED DYSFIBRINOGENEMIA WITH ENHANCED ACCESSIBILITY ON FIBRIN OF LIGANDS FOR VE-CADHERIN Benjamin PLANQUETTE Received Received
  201-MON-PO AN EVALUATION OF THE TOSOH BIOSCIENCE ST AIA-PACK DDIMER PERFORMED WITH THE AIA-360 AUTOMATE Julie M Smith Received Received
  202-MON-PO EVALUATION OF DIAGNOSTIC ACCURACY OF TWO D-DIMER ASSAYS IN PULMONARY EMBOLISM Wallace Feese Received Received
  202-WED-PO MOLECULAR SIGNATURE OF LSECS: A F8 SECRETING ENDOTHELIAL CELLS Osman El-Maarri Received Received
  203-MON-PO DS-1040: A NOVEL SELECTIVE INHIBITOR OF ACTIVATED FORM OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR Kengo Noguchi Received Received
  203-WED-PO ANCESTRAL RECONSTRUCTION OF COAGULATION FACTOR VIII Philip Zakas Received Received
  204-TUE-PO HAEMOPHILIA PRESENTATIONS.LET ME COUNT THE WAYS. Vaughan WILLIAMS Received Received
  205-TUE-PO INTRACRANIAL HEMORRHAGE IN EARLY NEONATES WITH HEMOPHILIA IN JAPAN Masashi Taki Received Received
  205-WED-PO LONG-TERM PHENOTYPIC CORRECTION OF HEMOPHILIA A MICE BY NON-VIRAL PIGGYBAC TRANSPOSON VECTOR HIDETO MATSUI Received Received
  206-WED-PO DISCORDANT IN VITRO AND IN VIVO ACTIVITY OF FACTOR VIII MUTANTS Amine Bazaa Received Received
  207-MON-PO EXPERIMENTAL VALIDATION OF A STOCHASTIC MULTISCALE MODEL OF FIBRINOLYSIS Brittany Bannish Received Received
  207-TUE-PO NATIONAL INHIBITOR SURVEY IN HAEMOPHILIA PATIENTS (NISH) FROM INDIA Shrimati Shetty Received Received
  209-TUE-PO A STUDY OF DEPRESSION IN FAMILY MEMBERS OF HEMOPHILIAC PATIENTS Mikyung Kim Received Received
  209-MON-PO THE ANTIFIBRINOLYTIC EFFECT OF FACTOR XIII STRONGLY DEPENDS ON CLOT COMPACTION/RETRACTION Dick Rijken Received Received
  210-MON-PO THE ASSOCIATION OF PAI-1 AND CLOT LYSIS TIME WITH BODY COMPOSITION IN AFRICANS IS SEX DEPENDENT Zelda De Lange Received Received
  210-WED-PO RARE ALTERNATE PRESENTATIONS OF THE F8 INTRON 22 INVERSION MUTATION COMPLICATE DETECTION AND MAY LEAD TO MISDIAGNOSIS. Jacky Cutler Received Received
  210-TUE-PO HAEMTRACK: UK PATIENT HOME THERAPY REPORTING SYSTEM Rob Hollingsworth Received Received
  212-TUE-PO ENDOVASCULAR ABDOMINAL AORTIC ANEURYSM REPAIR IN A PATIENT WITH MILD HEMOPHILIA A ON DABIGATRAN FOR ATRIAL FIBRILLATION Beatriz Delgado Received Received
  213-TUE-PO ANALYSIS OF MODERATE PHENOTYPE OF HEMOPHILIA A WITH NOVEL MISSENSE MUTATION, W2229R IN C2 DOMAIN, OF WHICH FVIII HAS NO RESPONSIVENESS WITH DDAVP. Takashi Suzuki Received Received
  214-TUE-PO RUSSIAN NATIONAL REGISTRY OF INHIBITOR HEMOPHILIA PATIENTS: FIRST CUT-OFF ANALYSIS Nadezhda Zozulya Received Received
  214-MON-PO THE INFLUENCE OF RESIDUAL PLATELETS ON PLASMA PAI-1 ASSAYS Sunelle Barnard Received Received
  215-MON-PO CLOT LYSIS PARAMETERS ARE HIGHER IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH A HISTORY OF THROMBOEMBOLISM Lize Bollen Received Received
  215-TUE-PO SEPTIC ARTHRITIS IN HEMOPHILIC TARGET JOINTS A NOT UNCOMMON COMPLICATION AWARENESS IS THE MAIN DIAGNOSTIC FEATURE Peter Staritz Received Received
  216-WED-PO INTERNATIONAL STUDY TO ASSESS THE PERFORMANCE OF IMMUNODEPLETED PLASMAS FOR DETERMINATION OF FACTORS VIII AND IX ACTIVITY Chris Watson Received Received
  216-MON-PO TISSUE PLASMINOGEN ACTIVATOR (T-PA) RELEASED FROM HUMAN CELLS BY SOFT RUSH JUNCUS EFFUSUS L. VAR. DECIPENS Hiroyuki Sumi Received Received
  216-TUE-PO MANAGING MODERN MAJOR ORTHOPAEDIC SURGERY WITH PLASMA DERIVED FVIII CONCENTRATE (FANHDI) IN SEVERE HAEMOPHILIA A PATIENTS WITH ADVANCED ARTHROPATHY Pu-Lin Luo Received Received
  217-MON-PO GLOBAL FIBRINOLYTIC PROFILE IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION Aurélien Lebreton Received Received
  217-WED-PO GENETIC DETERMINANTS FOR FACTOR VIII LEVELS: GENOME-WIDE LINKAGE AND ASSOCIATION ANALYSES FROM THE GAIT PROJECT Sonia López Received Received
  217-TUE-PO Intra-operative monitoring of Hemophilia patients during coronary artery bypass graft surgery using Thromboelastogram Mudi Misgav Received Received
  218-TUE-PO FACTORS INFLUENCING RISK OF BLEEDING AFTER DENTAL EXTRACTION IN HEMOPHILIA PATIENTS Predrag Miljic Received Received
  220-MON-PO CELL-FREE DNA MODULATES CLOT STRUCTURE AND IMPAIRS FIBRINOLYSIS IN SEPSIS. Travis Gould Received Received
  220-TUE-PO INDIVIDUALISED TREATMENT IN HAEMOPHILIA A VARIABILITY IN FACTOR VIII ACTIVITY MEASUREMENT FOR PHARMACOKINETIC DOSING Jane Needham Received Received
  221-WED-PO LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 EXPRESSION IN LIVER IS ASSOCIATED WITH PLASMA FACTOR VIII LEVELS Luis Fernando Bittar Received Received
  221-TUE-PO CYCLOPHOSPHAMIDE EFFICACY AND TOXICITIES IN THE FIRST LINE TREATMENT OF ACQUIRED HEMOPHILIA John Chapin Received Received
  222-MON-PO IN-VITRO IMAGING OF PLATELET/FIBRIN CLOT FORMATION AND LYSIS IN FLOW CONDITION stéphane LOYAU Received Received
  222-TUE-PO TWO YEAR USE OF SHARED GUIDELINES AND A DEDICATED WEB SITE TO IMPROVE MANAGEMENT OF INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT Annarita Tagliaferri Received Received
  223-TUE-PO EVIDENCE OF APCC MODE OF ACTION IN A CLINICAL STUDY TREATING HEMOPHILIA A INHIBITOR PATIENTS WITH PROPHYLAXIS THERAPY Srilatha Tangada Received Received
  224-MON-PO THE EFFECT OF ALPHA-2 PLASMIN INHIBITOR ARG6TRP POLYMORPHISM ON THE RISK OF CORONARY ARTERY DISEASE Éva Katona Received Received
  225-TUE-PO LONG TERM FOLLOW-UP IN THE USE OF DIFFERENT TYPES OF CENTRAL VENOUS CATHETERS IN CHILDREN WITH HEMOPHILIA ON PROPHYLAXIS OR IMMUNE-TOLERANCE REGIMEN Marta Milan Received Received
  225-WED-PO HEMOPHILIA A CAUSED BY RETROTRANSPOSITION OF LONG INTERSPERSED ELEMENT-1 (LINE-1) INTO THE FVIII GENE Rima Dardik Received Received
  226-MON-PO IMPAIRED FIBRINOLYSIS IN BEHET SYNDROME Domenico Prisco Received Received
  226-TUE-PO SUCCESSFUL MULTI-VESSEL PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME IN A SEVERE TAIWANESE HEMOPHILIAC WITH HIV INFECTION UNDER HARRT:THE FIRST REPORTED CASE IN CHINESE POPULATION Chia-Yau Chang Received Received
  227-TUE-PO RELATIONSHIP BETWEEN QUALITY OF LIFE AND COAGULATION FACTOR LEVEL IN HEMOPHILIA CARRIERS: PRELIMINARY RESULTS Jane Young Received Received
  227-WED-PO SURFACE BOUND VON WILLEBRAND FACTOR MODULATES FACTOR VIII PEPTIDE PRESENTATION BY DENDRITIC CELLS Robin Hartholt Received Received
  227-MON-PO VARIABLE RESISTANCE TO PLASMINOGEN ACTIVATOR INITIATED FIBRINOLYSIS FOR INTERMEDIATE-RISK PULMONARY EMBOLISM William Stubblefield Received Received
  228-TUE-PO DOES THE QUALITY OF TREATMENT AND NOT ONLY FACTOR VIII LEVELS INFLUENCE GLOBAL HEMOSTASIS IN PATIENTS WITH HEMOPHILIA A? Maria Berndtsson Received Received
  228-MON-PO CARRIER AND PRENATAL DIAGNOSIS OF CHINESE HAEMOPHILIA A FAMILIES IN ONE CENTER FROM 2007 TO 2014 Yeling Lu Received Received
  229-WED-PO FVIII ACTIVITY ASSAY VARIABILITY OF THE PEGLYLATED FORM OF RFVIII ADVATE (BAX 855) IN CLINICAL HEMOSTASIS LABORATORIES: INTERIM RESULTS FROM A WORLD-WIDE FIELD STUDY Jane Mannion Received Received
  229-MON-PO GENETIC ALTERATIONS IN HEMOPHILIAC PATIENTS WITH INHIBITOR IN THE REGION OF MURCIA. SPAIN. FAUSTINO GARCÍA-CANDEL Received Received
  230-TUE-PO DEFINING ADHERENCE TO PROPHYLAXIS IN HAEMOPHILIA: RESULTS OF A DELPHI CONSENSUS PROCEDURE Liesbeth Schrijvers Received Received
  231-WED-PO COMPARISON OF METHODS FOR THE DOSAGE OF FVIII IN A NEW HAEMOPHILIA CENTER CARE Emanuel Sueldo Received Received
  231-MON-PO ANTIBODIES OF HIGH AVIDITY IS THE HALLMARK OF SEVERE HEMOPHILIA A PATIENTS WITH FVIII INHIBITORS Daniel Chaves Received Received
  232-MON-PO THE ROLE OF LARGE POPULATION-BASED DATABASES IN THE EVALUATION OF SAFETY OF BYPASSING AGENTS IN HEMOPHILIA PATIENTS WITH INHIBITORS Katsiaryna Bykov Received Received
  233-MON-PO EFFICACY OF SECONDARY PROPHYLAXIS ON ANNUAL BLEEDING RATIO (ABR) IN ADULT PATIENTS WITH HEMOPHILIA: A SINGLE CENTER OBSERVATION STUDY IN JAPAN. Teruhisa Fujii Received Received
  234-TUE-PO CONTINUOUS INFUSION OF FVIII IN OBESE PATIENTS WITH SEVERE HAEMOPHILIA A: IS WEIGHT-BASED DOSE-ADJUSTMENT REQUIRED? Boban Ana Received Received
  234-MON-PO IMPACT OF THE INTRINSIC PATHWAY IN INDIVIDUAL THROMBIN GENERATION AMONG HEMOPHILIA B PATIENTS Vuokko Jokela Received Received
  235-TUE-PO USE OF APCC IN COMBINATION WITH TRANEXAMIC ACID: A SINGLE CENTRE EXPERIENCE Jerzy Windyga Received Received
  236-MON-PO NEW ANTIVIRAL TREATMENT OF HCV INFECTED YOUNG HAEMOPHILIACS EXPECTATIONS TO CURE HEPATITIS C Katalin Koehler-Vajta Received Received
  236-WED-PO CHANGES OF COAGULATION PARAMETERS DURING HIGH ALTITUDE EXPEDITION. Susana Der Parsehian Received Received
  236-TUE-PO NON-NEUTRALIZING ANTIBODIES MODULATE FACTOR VIII PHARMACOKINETIC IN PATIENTS WITH HEMOPHILIA A WITHOUT FVIII INHIBITORS Christoph Hofbauer Received Received
  237-TUE-PO IPAQ SCORING AND CAROTID INTIMA MEDIA THICKNESS IN PATIENTS WITH HAEMOPHILIA Fahri Sahin Received Received
  237-WED-PO RELATIONSHIP BETWEEN OXIDATIVE STRESS AND BLOOD COAGULATION IN PAEDIATRIC CHRONIC KIDNEY DISEASE (CKD) Luci Maria SantAna Dusse Received Received
  238-TUE-PO LEFT VENTRICLE DIASTOLIC FUNCTIONS AND PHYSICAL ACTIVITY SCORE IN ADULT HEMOPHILIA PATIENTS: AEGEAN HAEMOPHILIA CENTER EXPERIENCE Fahri Sahin Received Received
  238-MON-PO BURDEN OF ILLNESS AMONG PERSONS WITH HEMOPHILIA B: DIRECT AND INDIRECT COSTS Christina Chen Received Received
  239-WED-PO CD44 LOCATED IN THE SURFACE OF SICKLE RED BLOOD CELL (SRBC) CORRELATES WITH REDUCED BLOOD HBF LEVELS AND INCREASED SRBC ADHESION TO FIBRIN Luciana Wermelinger Serro Received Received
  239-TUE-PO REGIONAL DATA SUPPORTS NEED FOR UNIFORM APPROACH TO EXTENDED HALF-LIFE (EHL) PRODUCT TRANSITION Stacy Croteau Received Received
  240-MON-PO ACUTE EFFECTS OF EXERCISE ON SPECIFIC AND GLOBAL COAGULATION PARAMETERS IN SEVERE HEMOPHILIA A Eva Zetterberg Received Received
  240-WED-PO FREE FATTY ACIDS MODULATE THROMBIN ACTIVITY ON FIBRINOGEN AND DESTABILISE FIBRIN CLOTS Anna Tanka-Salamon Received Received
  241-TUE-PO POPULATION PHARMACOKINETIC MODEL OF RECOMBINANT SINGLE-CHAIN FACTOR VIII (RVIII SINGLECHAIN) IN PATIENTS WITH HEMOPHILIA A Ying Zhang Received Received
  241-MON-PO FIRST PROSPECTIVE RESULTS OF JOINT DISTRACTION IN HAEMOPHILIC ANKLE ARTHROPATHY Lize van Vulpen Received Received
  243-MON-PO EVALUATION OF JOINT DAMAGE IN BOYS WITH HEMOPHILIC ARTHROPATHTY BY ULTRASONOGRAPHY AND BIOMARKER OF CARTILAGE TURNOVER URINARY C TERMINAL TELOPEPTIDE OF TYPE II COLLAGEN (U-CTX-II) Hoda Hassab Received Received
  244-WED-PO IMPACT OF MATERNAL D-DIMER LEVELS IN NEWBORN OF PREECLAMPTIC MOTHERS Melina de Barros Pinheiro Received Received
  245-WED-PO FIBRIN CLOT STRUCTURE IS AFFECTED BY LEVELS OF PARTICULATE AIR POLLUTION EXPOSURE IN PATIENTS WITH VENOUS THROMBOSIS Xiaoxi Pan Received Received
  245-TUE-PO A CORE SET OF OUTCOME MEASUREMENT TOOLS IN PATIENTS WITH HEMOPHILIA: A SYSTEMATIC REVIEW OF THE MEASUREMENT PROPERTIES Samantha Gouw Received Received
  245-MON-PO SYMPTOMATIC FEMALE HEMOPHILIA SEEN IN TAIWAN Ming-Ching Shen Received Received
  246-MON-PO NO RELATION BETWEEN PLATELET ACTIVITY AND HEMOPHILIA B PHENOTYPE Roger Schutgens Received Received
  246-WED-PO INCREASED PLASMA CLOT PERMEABILITY AND SUSCEPTIBILITY TO LYSIS ARE ASSOCIATED WITH HEAVY MENSTRUAL BLEEDING OF UNKNOWN CAUSE Anetta Undas Received Received
  246-TUE-PO CLINICAL SIGNIFICANCE OF TYPE 1, TYPE 2 T CELLS, TH17 AND TREG IN THE DEVELOPMENT OF FVIII INHIBITOR IN PEDIATRIC HEMOPHILIA A PATIENTS. Zhenping Chen Received Received
  247-MON-PO OUTCOME OF LONG TERM PLASMA DERIVED FVIII CONCENTRATE FANHDI USE IN THE MATURE HAEMOPHILIA POPULATION. Pu-Lin Luo Received Received
  247-WED-PO SEVERE THROMBOSIS IN PREGNANCY IN A PATIENT WITH CONGENITAL DYSFIBRINOGENEMIA Vera Geierova Received Received
  248-TUE-PO RESULTS OF ANKLE PROSTHESIS IN PATIENTS WITH SEVERE HAEMOPHILIC ARTHROPATHY FOLLOW UP Daniele Pillitteri Received Received
  248-WED-PO ARTERIOVENOUS FISTULAS FOR REPLACEMENT THERAPY IN ADULTS WITH HEMOPHILIA Jerome Teitel Received Received
  248-MON-PO RACE AND THE IMMUNE RESPONSE TO FACTOR VIII REPLACEMENT THERAPY Saulius Butenas Received Received
  249-TUE-PO IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A AND B WITH INHIBITOR. SINGLE CENTRE EXPERIENCE. Angelika Batorova Received Received
  249-MON-PO ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEALTHY SUBJECTS MYTH OR REALITY? Christian Lubich Received Received
  251-TUE-PO POPULATION PHARMACOKINETICS IN HEMOPHILIA A: TOWARDS INDIVIDUALIZATION OF PERIOPERATIVE REPLACEMENT THERAPY Hendrika Hazendonk Received Received
  251-MON-PO EXPRESSION OF PLATELET PROTEIN DISULFIDE ISOMERASE (PDI) IS INCREASED IN PATIENTS WITH HEMOPHILIA AND VON WILLEBRAND DISEASE Minna Voigtlaender Received Received
  252-MON-PO ALTERNATIONS OF OXIDATIVE STRESS MARKERS IN PATIENTS WITH SEVERE HAEMOPHILIA TREATED BY DIFFERENT PROPHYLAXIS REGIMENS Irena Djunic Received Received
  252-WED-PO VALIDATION OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS BLEEDING ASSESSMENT TOOL (ISTH-BAT) IN HEMOPHILIA CARRIERS Paula James Received Received
  253-TUE-PO BLEEDING AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEOPLE WITH HAEMOPHILIA PATIENTS (PWH) EVEN A SINGLE BLEED MATTERS Sylvia von Mackensen Received Received
  253-MON-PO HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOFILIA A AND B IN BRAZIL Daniel Chaves Received Received
  254-MON-PO COMPARISON OF PROPHYLAXIS AND EPISODIC TREATMENT IN CHILDREN WITH MODERATE TO SEVERE HEMOPHILIA A Darintr Sosothikul Received Received
  254-TUE-PO INTRACRANIAL HEMORRHAGE AND MANAGEMENT IN HEREDITARY BLEEDING DISORDERS: THE EXPERIENCE OF CUKUROVA UNIVERSITY , ADANA, TURKEY Ilgen Sasmaz Received Received
  255-TUE-PO EXPLORING COST EFFECTIVENESS OF VARIOUS PROPHYLACTIC TREATMENT STRATEGIES FOR SEVERE HAEMOPHILIA USING A COMPUTER SIMULATION MODEL Kathelijn Fischer Received Received
  255-MON-PO USING MINUTE DOSES OF APTT REAGENT AND TISSUE FACTOR AS THE COAGULATION TRIGGER TO QUANTIFY THE COAGULATION PROFILE IN HEMOPHILIA A Shu He Received Received
  256-TUE-PO ULTRASOUND EVALUATION OF HAEMOPHILIC JOINTS BY HAEMOPHILIA PHYSICIANS: A RELIABILITY STUDY Kathelijn Fischer Received Received
  257-MON-PO ONCE WEEKLY NONACOG ALFA IN HEMOPHILIA B (HEMB): A TIME COURSE PROFILE OF SPONTANEOUS BLEEDS IN PATIENTS FROM A PIVOTAL TRIAL Bartholomew Tortella Received Received
  259-TUE-PO INHIBITORS IN HEMOPHILIA (HA): EXPERIENCE OF A SINGLE CENTER IN THE LAST 22 YEARS. Cristina Santoro Received Received
  259-WED-PO A NOVEL MISSENSE MUTATION, P.PHE360CYS, IN F9 GENE RESULTS IN HEMOPHILIA B IN FEMALE PATIENT Ziqiang Yu Received Received
  260-WED-PO INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HEMOPHILIA A: A FOLLOW-UP COHORT STUDY. Maria Elisa Mancuso Received Received
  261-MON-PO BAYESIAN APPROACH TO THE ASSESSMENT OF THE POPULATION SPECIFIC RISK OF INHIBITORS Alfonso Iorio Received Received
  261-WED-PO SATISFACTION PATIENT SURVEY: A KEY TOOL TO IMPROVE PATIENT DELIVERY OF CARE AT A PORTUGUESE COMPREHENSIVE HEMOPHILIA CENTRE Manuela Carvalho Received Received
  262-MON-PO PHARMACOKINETIC CHARACTERISTICS OF FACTOR VIII AND IX CONCENTRATES A SYSTEMATIC REVIEW Alfonso Iorio Received Received
  263-TUE-PO ARGATROBAN IN THE MANAGEMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II: AN OPEN-LABEL, MULTICENTER CLINICAL TRIAL IN FRANCE Brigitte TARDY Received Received
  263-WED-PO THE EFFECT OF NORDIC WALKING ON JOINT STATUS, QUALITY OF LIFE, PHYSICAL ABILITY, EXERCISE CAPACITY AND PAIN IN OLDER MEN WITH HEMOPHILIA Maryem Salim Received Received
  264-MON-PO 2003-2014 TWELVE YEAR RESULTS OF INHERITED BLEEDING DISORDERS REGISTRY OF THE EMILIA ROMAGNA REGION IN ITALY Gianna Franca Rivolta Received Received
  264-WED-PO PERIOPERATIVE MANAGEMENT AND OUTCOME OF URGENT APPENDECTOMY IN A PATIENT WITH SEVERE HEMOPHILIA Murat Sker Received Received
  264-TUE-PO CASE REPORT: DABIGATRAN USE IN A POSTOPERATIVE ORTHOPEDIC PATIENT WITH HEPARIN INDUCED THROMBOCYTOPENIA Luciana Goncalves Received Received
  265-WED-PO PREVALENCE, SEVERITY AND CORRELATION FACTORS OF HEMOPHILIC ARTHROPATHY AMONG TAIWANESE HEMOPHILIACS Chia-Yau Chang Received Received
  265-MON-PO CONGENITAL FACTOR DEFICIENCIES: TWENTY-FIVE-YEAR FOLLOW-UP zafer salcioglu Received Received
  266-MON-PO THERE IS A DIRECT RELATIONSHIP BETWEEN THE PHYSICAL ACTIVITY SCORE AND HDL CHOLESTEROL LEVEL IN HEMOPHILIA PATIENTS Fahri Sahin Received Received
  266-TUE-PO THE INCIDENCE OF HEPARIN-INDUCED THROMBOCYTOPENIA IN CRITICALLY ILL MEDICAL PATIENTS Noppacharn Uaprasert Received Received
  267-MON-PO MEASUREMENT OF GAIT VARIABILITY IN PATIENTS WITH AND WITHOUT HEMOPHILIC ARTHROPATHY: MOVE-STUDY (NTR 4561) Sara Stoof Received Received
  267-TUE-PO EVALUATING EFFICACY, SAFETY AND COMPLIANCE OF ARGATROBAN DOSING NOMOGRAM AT CANADIAN TEACHING HOSPITAL Harsimran Saini Received Received
  268-MON-PO THE EFFECTIVENESS OF EXERCISE PROGRAMME AND RADIOISOTOPE SYNOVECTOMYIN HEMOPHILIC PATIENTS melike sezginevim Received Received
  268-WED-PO QUALITY OF LIFE AMONG HAEMOPHILIA IN THAILAND Yingyong Chinthammitr Received Received
  268-TUE-PO RAPID FUNCTIONAL ASSAY FOR HEPARIN-INDUCED THROMBOCYTOPENIA USING A PRACTICAL FLOW CYTOMETRY APPROACH Michal Cipok Received Received
  269-WED-PO IMPACT OF TRANSITION ON CLINICAL OUTCOMES IN HEMOPHILIA: 10 YEARS OF EXPERIENCE AT A MAJOR CANADIAN TREATMENT CENTER Celina Woo Received Received
  269-TUE-PO HEPARIN-INDUCED THROMBOCYTOPENIA AND CALIBRATED THROMBIN GENERATION ASSAY. Valentine Minet Received Received
  269-MON-PO ADHERENCE TO TREATMENT IN PATIENTS WITH HAEMOPHILIA IN GERMANY Wolfgang Miesbach Received Received
  270-WED-PO PRO- AND ANTICOAGULANT FACTORS BALANCE THROMBIN GENERATION INDUCED BY APCC Peter Turecek Received Received
  270-TUE-PO THE ROLE OF CELLULAR IMMUNITY IN CHILDREN WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA erol erduran Received Received
  271-TUE-PO DIAGNOSIS OF VENOUS THROMBOEMBOLISM DURING ELTROMBOPAG THERAPY FOR IMMUNE THROMBOCYTOPENIA AND SUCCESSFUL REPLACEMENT WITH ROMIPLOSTIM. Odelia Amit Received Received
  271-WED-PO MUSCLE STRENGTH IN LOAD-BEARING JOINTS IN HAEMOPHILIC PATIENTS: COMPARATIVE VALUES WITH THE GENERAL POPULATION. Santiago Bonanad-Boix Received Received
  272-MON-PO COMPARING THROMBIN GENERATION IN PATIENTS WITH HAEMOPHILIA A AND PATIENTS ON VITAMIN K ANTAGONISTS Marie-Sophie de Koning Received Received
  273-MON-PO COATED PLATELET LEVELS IN SEVERE HEMOPHILIA DO NOT CORRELATE TO BLEEDING PHENOTYPE Kelly Lastrapes Received Received
  274-TUE-PO EXTENDED PLATELET PARAMETERS AS A MEANS TO DIFFERENTIATE IMMUNE THROMBOCYTOPENIA FROM HYPOPROLIFERATIVE THROMBOCYTOPENIAS Hrvoje Melinscak Received Received
  274-MON-PO SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN AN ADULT WITH HEMOPHILIA A AND CHRONIC INHIBITOR A CASE STUDY Michelle Sholzberg Received Received
  275-MON-PO PROPHYLACTIC APPROACH TO RECCURRENT BLEEDING IN HEMOPHILIA WITH INHIBITORS Bulent Zulfikar Received Received
  275-TUE-PO TREATMENT OF ATRAUMATIC SPLENIC RUPTURE IN AN ADOLESCENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND AUTOIMMUNE CYTOPENIAS: A CASE REPORT Rungrote Natesirinilkul Received Received
  276-TUE-PO CD70 MOLECULE INVOLVED IN THE DENDRITIC CELLS DYSFUNTIONIN PATIENTS WITH IMMUNE THROMBOCYTOPENIA Xian Zhang Received Received
  276-MON-PO UTILIZATION OF ANTI-INHIBITORS PRODUCTS AND INHIBITORS STATUS OF SEVERE HEMOPHILIA PATIENTS: 5 YEARS NATIONAL DATA FROM THE CANADIAN HEMOPHILIA ASSESSMENT AND RESOURCE MANAGEMENT SYSTEM Aicha N. TRAORE Received Received
  278-WED-PO A CASE OF ACUTE CEREBRAL INFARCTION IN A PATIENT WITH HEMOPHILIA B Sunah Lee Received Received
  278-TUE-PO THE INVOLVEMENT OF NEUROPILIN-1 IN PRIMARY IMMUNE THROMBOCYTOPENIA Hu Zhou Received Received
  279-MON-PO RESULTS OF RADIOSYNOVECTOMY IN CHILDREN WITH SEVERE HEMOPHILIAAND FACTOR VIII OR IX INHIBITOR Pawel Laguna Received Received
  279-TUE-PO SUCCESSFUL TREATMENT OF REFRACTORY ITP WITH CYCLOSPORINE A, TWO CASE REPORTS Antonin Hlusi Received Received
  279-WED-PO THE USE OF SECONDARY PROPHYLAXIS IN THE HAEMOPHILIA A PATIENTS Gonul Aydogan Received Received
  280-TUE-PO EFFICACY AND PROGNOSIS OF SHORT TERM AND VERY LOW-DOSE IVIG THERAPY (200 MG/KG/D) FOR NEWLY DIAGNOSED ACUTE IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN Kun Soo Lee Received Received
  280-MON-PO F8 MUTATION AND INHIBITOR DEVELOPMENT IN SEVERE FACTOR VIII DEFICIENCY: RESULTS FROM THE IRISH NATIONAL DATABASE Vince Jenkins Received Received
  280-WED-PO COMPARATIVE STUDY OF THE PREVALENCE OF CLOTTING FACTOR DEFICIENCY IN CARRIERS OF HEMOPHILIA A AND B Boban Ana Received Received
  281-TUE-PO A SYNTHETIC PEPTIDE, CORRESPONDING TO THE NONCANONICAL PAR1- TETHERED LIGAND, MIMICS THE APC-INDUCED STIMULATION OF WOUND HEALING IN VITRO. Ekaterina Kiseleva Received Received
  281-WED-PO PREVALENCE AND INCIDENCE OF HEMOPHILIA IN THE NORTH OF TUNISIA mariem melliti Received Received
  282-WED-PO EFFECTS OF MODERATE-INTENSITY PHYSICAL EXERCISE ON PHARMACOKINETICS OF FACTOR VIII AND VON WILLEBRAND FACTOR IN YOUNG ADULTS WITH SEVERE HAEMOPHILIA A. Nichan zourikian Received Received
  282-MON-PO RECURRENT HEMATURIA IN HEMOPHILIA PATIENTS IS NOT INDICATIVE OF THE PRESENCE OF AN UNDERLYING CAUSE Greta Mulders Received Received
  282-TUE-PO DIFFERENTIAL IN VIVO ACTIVATION OF MONOCYTE SUBSETS DURING EXPERIMENTAL ENDOTOXEMIA IN HUMANS Barbara Thaler Received Received
  283-MON-PO SPONTANEOUS INTRACRANIAL BLEEDING IS A MAJOR CAUSE OF DEATH IN NONSEVERE HEMOPHILIA A PATIENTS Janneke Loomans Received Received
  283-TUE-PO REGULATION OF IL-10 AND HIGH MOBILITY GROUP BOX 1 (HMGB1) EXPRESSION IN HUMAN MONOCYTES BY PLATELETS AND NEUTROPHILS Bjarne sterud Received Received
  285-TUE-PO DOES THE COAGULATION CASCADE PLAY A ROLE IN RETINAL PATHOLOGIES? tami livnat Received Received
  286-TUE-PO CLINICAL PRESENTATION OF THROMBOEMBOLIC EVENTS IN INFLAMMATORY BOWEL DISEASE Lize Bollen Received Received
  286-MON-PO ASSESSMENT OF INHIBITOR RISK AFTER SWITCHING FROM PLASMA-DERIVED FACTOR VIII CONCENTRATE TO RECOMBINANT FACTOR VIII (BRASIL-RFVIII: BRAZILIAN STUDY OF INHIBITOR LINKED TO RECOMBINANT FACTOR VIII) Alessandra Prezotti Received Received
  287-MON-PO PHENOTYPIC PROFILE OF A CHILD WITH SEVERE HEMOPHILLIA B AND INHIBITORS WITH NOVEL MUTATION IN THE FIX (F9) GENE Zorica Trajkova Antevska Received Received
  287-TUE-PO LOSS OF PAR-4 RECEPTOR AFFECTS RENAL ISCHEMIA REPERFUSION IN MICE Marcel Jansen Received Received
  288-TUE-PO TIPE2 IS INDUCED BY SIMULATED MICROGRAVITY IN MONOCYTES Shilong Xiong Received Received
  288-MON-PO MILD HEMOPHILIA A COMPLICATED BY INHIBITOR AFTER SURGERY AND FACTOR REPLACEMENT THERAPY Miguel Escobar Received Received
  288-WED-PO IMPROVEMENT OF THE QUALITY OF HEALTH CARE FOR CHILDREN WITH SEVERE HAEMOPHILIA A USING PROPHYLAXIS AND TREATMENT OF BLEEDING EPISODES WITH RECOMBINANT FACTOR VIII Sofijanka Glamocanin Received Received
  289-TUE-PO MOUSE MACROPHAGES UPREGULATE PODOPLANIN UNDER INFLAMMATORY AND APOPTOTIC CONDITIONS Julie Rayes Received Received
  289-WED-PO INHIBITOR DEVELOPMENT AS SWITCHING FULL-LENGTH RECOMBINANT FVIII TO B-DOMAIN DELETED RECOMBINANT FVIII IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A:TAIWANS EXPERIENCE Chia-Yau Chang Received Received
  290-WED-PO ULTRASONOGRAPHY OF JOINTS AND CORRELATION WITH FUNCTION IN HAEMOPHILIC ARTHROPATHY - RESULTS OF A CLINICAL PILOT TRIAL (HAMARTHROSONOPILOT)AND POTENTIAL IMPORTANCE OF JOINT-ULTRASOUND FOR AN INDIVIDUALIZED PROPHYLAXIS Michael Sigl-Kraetzig Received Received
  291-TUE-PO HIGH-FAT DIET IS ASSOCIATED WITH INCREASED VON WILLEBRAND FACTOR-RELATED PROCOAGULANT ACTIVITY IN HUMAN AND MURINE MODELS. Alison Michels Received Received
  291-MON-PO BOVINE AND PORCINE MUCOSAL HEPARINS EXHIBIT SIMILAR BIOLOGIC PROFILES Jawed Fareed Received Received
  292-TUE-PO INFLAMMATORY AND ENDOTHELIAL MARKERS AND THEIR RELATIONS TO THE HAEMOSTATIC POTENTIAL DURING THE MENSTRUAL CYCLE. Roza Chaireti Received Received
  293-MON-PO COMPARATIVE STUDIES ON THE MOLECULAR AND FUNCTIONAL PROFILE OF SHEEP MUCOSAL DERIVED ENOXAPARIN WITH VARYING ANHYDRO-MANNO GROUPS Schuharazad Abro Received Received
  294-MON-PO SEVUPARIN; MINOR EFFECTS ON HEMOSTASIS OF A NOVEL POLYSACCHARIDE DRUG DERIVED FROM HEPARIN Maria Lindgren Received Received
  295-WED-PO EFFECTIVE RADYOACTIVE SYNOVECTOMY IN HEMOPHILIA WITH INHIBITORS Bulent Zulfikar Received Received
  295-MON-PO REVERSAL OF THE HEPARINOID EFFECT WITH PROTHROMBIN COMPLEX CONCENTRATE AN IN VITRO STUDY USING THE THROMBIN GENERATION ASSAY Emma Fosbury Received Received
  295-TUE-PO THE ROLE OF INFLAMMATION IN PREGNANCY-RELATED VENOUS THROMBOSIS Hilde Skuterud Wik Received Received
  296-WED-PO IMPROVING HEMOPHILIA CARE IN BRAZIL: AVAILABILITY OF FACTOR CONCENTRATES AND BEYOND RESULTS OF LEVANTH SURVEY Samuel Medina Received Received
  297-TUE-PO CRITICAL BEHAVIOR OF SUBCELLULAR DENSITY ORGANIZATION DURING NEUTROPHIL ACTIVATION AND MIGRATION Sandra Baker-Groberg Received Received
  297-MON-PO STRATEGIES AND OUTCOMES OF PERIPROCEDURAL BRIDGING THERAPY WITH LOW-MOLECULAR-WEIGHT- HEPARIN IN PATIENTS WITH MECHANICAL HEART VALVES Jacqueline Schulman Received Received
  299-TUE-PO C. CANIMORSUS AFFECTS COAGULATION BY PROTEOLYTIC CLEAVAGE OF FACTOR X Katrin Hack Received Received
  299-MON-PO MEASUREMENT OF HEPARANASE ACTIVITY IN PLASMA REQUIRES THE USE OF SAMPLE ANTITHROMBIN-DEPLETION Shahsoltan MIRSHAHI Received Received
  300-WED-PO IMMUNE TOLERANCE INDUCTION IN PATIENTS WITH SEVERE HEMOPHILIA A WITH INHIBITORS IN KOREA Young Shil Park Received Received
  300-MON-PO NOVEL SYNTHETIC COPOLYMERS ABLE TO BIND UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS. Andrzej Mogielnicki Received Received
  301-WED-PO THE USAGE OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) DURING MAJOR AND MINOR SURGERIES IN SEVERE HEMOPHILIA PATIENTS WITH INHIBITOR Bulent Antmen Received Received
  301-TUE-PO HUMAN MONOCYTE SUBSETS DIFFERENTLY EXPRESS TISSUE FACTOR Konstantin Krychtiuk Received Received
  301-MON-PO DIFFERENCES BETWEEN NORMAL AND CANCER CELLS IN THE BIO-RESPONSE TO HEPARIN Yunliang Chen Received Received
  302-MON-PO MONITORING UNFRACTIONATED HEPARIN IN CHILDREN APTT, ANTI-XA AND ACT IN A RANDOMIZED CONTROLLED TRIAL OF COMPARING TWO DOSE PROTOCOLS Katharina Thom Received Received
  303-WED-PO A PROSPECTIVE ITALIAN SURVEY ON INTRACRANIAL HEMORRHAGE IN HEMOPHILIA PATIENTS: CHANGES OVER TIME Ezio Zanon Received Received
  303-TUE-PO PROTHROMBIN MUTANTS REVEAL A NEW MECHANISM OF MASP-1 MEDIATED CLOTTING Lorenz Jenny Received Received
  304-WED-PO COMBINATION OF BIOMARKERS FOR ASSESSMENT OF HEMOPHILIC ARTHROPATHY Yeu-Chin Chen Received Received
  304-TUE-PO COMPLEMENT AND TISSUE-FACTOR INDUCED THROMBIN GENERATION IN THE PATHOGENESIS OF VENOUS THROMBOEMBOLISM Ina Hiland Received Received
  304-MON-PO THE EFFICACY AND SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN THROMBOPROPHYLAXIS IN CRITICALLY ILL ADULT PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS Annukka Ylnen Received Received
  305-WED-PO HOW HAEMOPHILIA PATIENTS IN GERMANY PERCEIVE THEIR ACTUAL TREATMENT AND WHAT THEY EXPECT FOR FUTURE TREATMENT WITH NEW LONG-LASTING PRODUCTS Sylvia von Mackensen Received Received
  307-WED-PO FACTOR XI DEFICIENCY AND BLEEDING RISK ON ANTICOAGULATION John Chapin Received Received
  307-TUE-PO TOLL-LIKE RECEPTOR LIGANDS INDUCE THE FORMATION OF PLATELET-NEUTROPHIL AND PLATELET-MONOCYTE COMPLEXES IN HUMAN WHOLE BLOOD Julia Seyfert Received Received
  307-MON-PO ARGATROBAN VS FONDAPARINUX IN HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS: A RESPONSE COMPARATIVE STUDY Fahad Aleidan Received Received
  308-TUE-PO COMPLEMENT ACTIVATION AND THROMBIN GENERATION IN HEALTHY INDIVIDUALS SUBJECTED TO MILD ISOBARIC HYPOXIA AND VENOUS STASIS Ina Hiland Received Received
  308-WED-PO THE EFFECT OF ADVANCING AGE ON THE RESPONSE TO DDAVP IN RE-EXPOSED NONSEVERE HEMOPHILIA A PATIENTS Janneke Loomans Received Received
  309-TUE-PO RETROSPECTIVE EVALUATION OF THE USE OF RECOMBINANT FACTOR VIIA BEFORE AND AFTER THE IMPLEMENTATION OF A PHARMACIST-LED FACTOR STEWARDSHIP PROGRAM Taylor White Received Received
  310-TUE-PO USE OF A 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE IN A UNITED STATES COMMUNITY HOSPITAL SYSTEM Linda R Kelly Received Received
  311-WED-PO EFFICACY ASSESSMENT OF FONDAPARINUX TREATMENT OF PATIENTS WITH HITHEPARIN INDUCED THROMBOCYTOPENIA (HIT) Franciszek Grzegorczyk Received Received
  311-MON-PO THROMBOPOIETIN RECEPTOR AGONISTS DO NO NOT CAUSE COAGULATION ACTIVATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA Lamya Garabet Received Received
  311-TUE-PO IN VITRO OPTIMIZATION OF AN INNOVATIVE BIOLOGICAL GLUE COMPOSITION PLANTIER Jean-Luc Received Received
  312-WED-PO SAFETY AND EFFICACY OF STARTING WARFARIN AFTER TWO CONSECUTIVE PLATELET RISES IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA Lydia Chen Received Received
  313-TUE-PO EVALUATION OF THE PERFORMANCE OF EIGHT SCORES FOR PREDICTION OF BLEEDING RISK IN BRAZILIAN HEART DISEASE OUTPATIENTS TREATED WITH WARFARIN Joao Oliveira Received Received
  313-WED-PO RAPID FUNCTIONAL HEPARIN INDUCED THROMBOCYTOPENIA (HIT) ASSAY USING MULTIPLATE: COMPARISON WITH HEPARIN INDUCED PLATELET ACTIVATION (HIPA) ASSAY AND ACL ACUSTAR ANTIGEN ASSAY Kevin Horner Received Received
  314-WED-PO IMMUNOLOGICAL ASSAYS FOR DIAGNOSIS OF HEPARIN-INDUCED THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS Michael Nagler Received Received
  314-MON-PO SERIAL MEAN PLATELET VOLUMES IN IMMUNE THROMBOCYTOPENIA Mala Varma Received Received
  314-TUE-PO IDARUCIZUMAB SPECIFICALLY REVERSES DABIGATRAN ANTICOAGULATION BUT DOES NOT INDUCE A PROCOAGULANT STATE IN A PORCINE TRAUMA MODEL WITH DABIGATRAN ANTICOAGULATION Oliver Grottke Received Received
  315-WED-PO IMPACT OF OVERDIAGNOSIS OF HIT IN A LARGE COMMUNITY HOSPITAL John Francis Received Received
  316-WED-PO NEW PLATELET FUNCTIONAL METHOD TO IDENTIFY PATHOGENIC ANTIBODIES IN HIT PATIENTS Fabio Pulcinelli Received Received
  317-WED-PO LOW MOLECULAR WEIGHT HEPARIN TREATMENT FOR SUPERFICIAL VEIN THROMBOSIS AND THE RISK OF HEPARIN-INDUCED THROMBOCYTOPENIA Michelangelo Sartori Received Received
  317-MON-PO LEVELS OF CYTOKINES SECRETED BY T LYMPHOCYTE AND THE RELATIONSHIP WITH PROGNOSIS IN CHILDREN IMMUNE THROMBOCYTOPENIA Jingyao Ma Received Received
  318-MON-PO ELEVATED EXPRESSION OF IL-37 IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA Liu Liu Received Received
  318-TUE-PO BLEEDING COMPLICATIONS AFTER INVASIVE DENTAL PROCEDURES IN PATIENTS UNDER VITAMIN K ANTAGONISTS Ana Spinola Received Received
  319-MON-PO ANALYSIS OF HISTOCOMPATIBILITY LOCUS ANTIGEN (HLA)-G AND IMMUNOGLOBULIN-LIKE TRANSCRIPTS (ILTS) ON PATIENTS WITH IMMUNE THROMBOCYTOPENIA Qi Feng Received Received
  319-WED-PO CLINICAL SIGNIFICANCE OF ANTINUCLEAR ANTIBODY TEST AND RISK FACTOR PREDICTORS OF CHILDHOOD CHRONIC IMMUNE THROMBOCYTOPENIA Bunchoo Pongtanakul Received Received
  320-MON-PO AN INCREASED MAJOR LIPID RAFT PROTEIN RAFTLIN ASSOCIATED WITH B CELLS SIGNALING IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA Xian Zhang Received Received
  320-WED-PO CLINICAL SIGNIFICANCE OF IPF OR RP MEASUREMENT IN DISTINGUISHING PRIMARY IMMUNE THROMBOCYTOPENIA FROM APLASTIC THROMBOCYTOPENIC DISORDERS Yoshiaki Tomiyama Received Received
  321-TUE-PO TREATMENT APPROACHES IN SPONTANEOUS RECTUS SHEATH HEMATOMAS IN CLINICAL PRACTICE. A SINGLE-CENTER EXPERIENCE Veronica Pons Received Received
  321-MON-PO NEUTROPHIL ELASTASE IS NOT REQUIRED FOR NEUTROPHIL EXTRACELLULAR TRAP OR DEEP VEIN THROMBUS FORMATION IN MICE Kimberly Martinod Received Received
  322-WED-PO VARIATIONS OF MEAN PLATELET VOLUME OF IMMUNE THROMBOCYTOPENIA Kenji Yokoyama Received Received
  322-MON-PO TISSUE FACTOR-DEPENDENT PLATELET ACTIVATION SUPPORTS NEUTROPHIL RECRUITMENT, ROLLING AND TRANSMIGRATION DURING INFLAMMATION MEZOUAR Soraya Received Received
  323-TUE-PO COMPOSITION-DEPENDENT EFFECTS OF NANOPARTICLES ON COAGULATION Kamran Bakhtiari Received Received
  323-WED-PO THE POLYMORPHISMS OF TUMOR NECROSIS FACTOR-INDUCED PROTEIN 3 GENE MAY CONTRIBUTE TO THE SUSCEPTIBILITY OF CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA IN CHINESE POPULATION Jingyi Yang Received Received
  323-MON-PO EFFECT OF GLUCOSE LEVELS IN INCREASED NEUTROPHIL EXTRACELLULAR TRAP FORMATION (NETS) IN TYPE 2 DIABETES PATIENTS AT DIAGNOSIS AND AFTER 6 AND 12 MONTHS OF METABOLIC CONTROL. Mirta Schattner Received Received
  324-WED-PO ANTI-PLATELET ANTIBODIES PRESENT IN BREAST MILK OF AN IMMUNE THROMBOCYTOPENIC MOTHER CAUSE ELEVATION OF AN APOPTOTIC MARKER IN NORMAL DONORS PLATELETS Hagit Hauschner Received Received
  324-MON-PO IMPACT OF PCSK9 IN A MURINE MOUSE MODEL OF SEPSIS. Dhruva Dwivedi Received Received
  325-TUE-PO CHARACTERISTICS AND ROLE OF EXTRACELLULAR VESICLES IN THE PATHOPHYSIOLOGY OF TRANSFUSION DEPENDENT ?-THALASSEMIA Carina Levin Received Received
  325-MON-PO PLASMA CELL-FREE DNA LEVELS ARE ELEVATED IN PATIENTS WITH ACUTE ISCHEMIC HEART FAILURE PARTIALLY DUE TO NEUTROPHIL EXTRACELLULAR TRAP FORMATION Alexander Brill Received Received
  326-WED-PO ANTI-GPIBALPHA ANTIBODIES INDUCE IMMUNE THROMBOCYTOPENIA IN DISTINCT PATHWAYS: FC-DEPENDENT VS. FC-INDEPENDENT Miao Xu Received Received
  326-MON-PO THE HISTONE-CLEAVING FACTOR SEVEN ACTIVATING PROTEASE DOES NOT PROMOTE DEGRADATION OF NEUTROPHIL EXTRACELLULAR TRAPS Brenda Luken Received Received
  327-WED-PO COMPARISON OF RELAPSE RATES OF IMMUNE THROMBOCYTOPENIA IN PATIENTS WHO RECEIVED INITIAL TREATMENT WITH STEROIDS VERSUS ANTI-RH(D) WITH OR WITHOUT STEROIDS Mala Varma Received Received
  327-MON-PO MECHANISM OF ?- VINIFERIN INHIBITS SUPEROXIDE GENERATION IN HUMAN NEUTROPHIL CHIN-HSUAN LIN Received Received
  328-MON-PO INHIBITORY EFFECT OF NKSE-5A ON SUPEROXIDE ANION GENERATION IN HUMAN NEUTROPHILS Tzu-chi Tseng Received Received
  328-TUE-PO IMPACT OF VARIOUS ANTICOAGULANTS AND STORAGE TIME ONPLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES Simin Jamaly Received Received
  329-TUE-PO PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES IN HEALTHY INDIVIDUALS SUBJECTED TO MILD ISOBAR HYPOXIA AND VENOUS STASIS Trond Brvik Received Received
  329-MON-PO DIABETES PRIMES NEUTROPHILS TO UNDERGO NETOSIS WHICH SEVERELY IMPAIRS WOUND HEALING Siu Ling Wong Received Received
  329-WED-PO ASSOCIATION BETWEEN A PRO-INFLAMMATORY AXIS COMPRISED BY TSP1-TGFB-CTGF WITH THREE MICRO-RNAS, MIR-19A, 122, AND 133A IN THE PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY: A THERAPEUTIC NOVEL MODALITY RAUL DELA CADENA Received Received
  330-MON-PO DETERMINANTS OF THE REGULATORY ACTION OF PLATELETS TOWARDS NEUTROPHIL ACTIVITIES Angèle Gros Received Received
  331-WED-PO INCREASED BIOMARKERS OF METABOLIC SYNDROME IN TOTAL JOINT ARTHOPLASTY PATIENTS Andrew Banos Received Received
  331-MON-PO THE LEUKOCYTE INTEGRIN B2 PRIMES NEUTROPHILS FOR NETOSIS IN SICKLE CELL DISEASE Laila Elsherif Received Received
  331-TUE-PO MICROPARTICLE LEVEL AND ORIGIN DURING PROGRESSION OF NORMAL PREGNANCY: A LONGITUDINAL STUDY IN HEALTHY WOMEN. Elena Campello Received Received
  332-WED-PO END-STAGE RENAL DISEASE ASSOCIATED WITH METABOLIC SYNDROME: A STUDY OF BIOMARKERS RELEVANT TO CARDIOVASCULAR RISK Vinod Bansal Received Received
  332-TUE-PO CIRCULATING MICROPARTICLES IN CORD BLOOD OF NORMAL PREGNANCY AND OF PREGNANCY WITH PREECLAMPSIA. Elena Campello Received Received
  333-WED-PO BARETTIN: A NATURAL MARINE COMPOUND WITH POTENT ANTICOAGULANT AND ANTI-INFLAMMATORY PROPERTIES Bjarne sterud Received Received
  333-TUE-PO A GAIN-OF-FUNCTION VARIANT OF PROTEIN C MANIFESTS ITSELF AS TYPE II PROTEIN C DEFICIENCY IN A HEALTHY SUBJECT qiulan ding Received Received
  333-MON-PO GENERAL DECREASE OF CIRCULATING MICROPARTICLES IS RELATED TO THE PRESENCE OF FVIII INHIBITORS IN HEMOPHILIA A PATIENTS Daniel Chaves Received Received
  334-MON-PO PRO-COAGULANT ACTIONS OF CIRCULATING MICROPARTICLES IN SICKLE CELL ANEMIA AND SEPSIS ASSOCIATED COAGULOPATHY AND THEIR MODULATION BY A TRIBLOCK POLYMER MST 1-88. Jawed Fareed Received Received
  334-TUE-PO EVALUATION OF PROTEIN C LEVELS IN SICKLE CELL DISEASE SUBJECTS SEEN AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL, BENIN CITY, NIGERIA. Obinna Iheanacho Received Received
  335-WED-PO PROCOAGULANT ACTIVITY INCREASES WITH DISEASE SEVERITY IN PATIENTS WITH ASTHMA Marlous Sneeboer Received Received
  335-MON-PO THE ROLE OF MICROVESICELES DERIVED FROM MYELOMA CELLS IN THROMBOGENICITY AND ANGIOGENESIS Anat Aharon Received Received
  336-MON-PO ANTITHROMBIN IS INCORPORATED INTO EXOSOMES AND ITS PRESENCE IN THESE VESICLES IS MODULATED BY LOW MOLECULAR WEIGHT HEPARIN Irene Martínez Martínez Received Received
  336-WED-PO ANTI-POLYPHOSPHATE ANTIBODIES AS ANTI-INFLAMMATORY/ANTICOAGULANT THERAPEUTICS Richard Travers Received Received
  337-TUE-PO THROMBOMODULIN INHIBITS TISSUE FACTOR MEDIATED THROMBIN GENERATION IN BLOOD AND PROTHROMBIN COMPLEX CONCENTRATES Jawed Fareed Received Received
  338-MON-PO PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM HAVE HIGHER CONCENTRATION OF LARGE EXTRACELLULAR VESICLES WITH AUGMENTED POTENTIAL TO INITIATE COAGULATION ACTIVATION Simin Jamaly Received Received
  338-WED-PO EARLY MEASUREMENT OF THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) AND ACTIVATED TAFI (TAFIa) PREDICTS OUTCOME IN PATIENTS WITH SEVERE SEPSIS OR SEPTIC SHOCK FABRIZIO SEMERARO Received Received
  338-TUE-PO HEPARANASE ACTIVATES ANTITHROMBIN THROUGH THE BINDING TO ITS HEPARIN BINDING SITE Irene Martínez Martínez Received Received
  339-MON-PO INFLUENCE OF CALR AND JAK2 MUTATIONS ON PROCOAGULANT POTENTIAL OF PLATELET-DERIVED MICROPARTICLES IN ESSENTIAL THROMBOCYTHEMIA (ET) Sara Gamba Received Received
  339-TUE-PO ANTITHROMBIN BINDS TO AND ENHANCES THE BARRIER FUNCTION OF HUVECS INDEPENDENTLY OF CELL-SURFACE HEPARAN SULFATE PROTEOGLYCANS Franois Saller Received Received
  339-WED-PO INFLAMMATORY CYTOKINE UP REGULATION MAY BE AN EARLY MARKER OF THROMBOSIS IN PATIENTS WITH IMPLANTED LVADS Walter Jeske Received Received
  340-TUE-PO TETRAMETHYLPYRAZINE DECREASES RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) VIA SUPPRESSION OF FOXA2 AND INDUCTION OF NOS IN HEPG2 CELLS Junling Li Received Received
  340-WED-PO ANNEXIN A1 CONCENTRATION IS INCREASED IN PATIENTS WITH PREECLAMPSIA Luiza Perucci Received Received
  341-MON-PO MODULATING THROMBOTIC DIATHESIS IN HEREDITARY THROMBOPHILIA: A ROLE FOR CIRCULATING MICROPARTICLES? Elena Campello Received Received
  342-TUE-PO SIMILAR RESPONSES OF PHOSPHATIDYLSERINE AND PHOSPHATIDYLETHANOLAMINE TOWARDS COFACTOR ACTIVITY OF HUMAN PROTEIN Z, A NATURAL ANTICOAGULANT Tanusree Sengupta Received Received
  342-MON-PO CIRCULATING EXTRACELLULAR VESICLE (EV) AFTER ACUTE HINDLIMB ISCHEMIA Carmen Roncal Received Received
  343-TUE-PO THE EFFECT OF AGE ON GLYCAN MICROHETEROGENEITY OF HUMAN ALPHA-2-MACROGLOBULIN Laura Calvert Received Received
  343-WED-PO DETERMINATION OF HEPARIN LEVEL IN BLOOD PLASMA SENSITIVITY AND SPECIFICITY AS A MARKER FOR IDENTIFICATION OF SYSTEMIC MAST CELL ACTIVATION DISEASE Hans-Joerg Hertfelder Received Received
  344-WED-PO CYTOKINE-MEDIATED TRIGGERING OF THROMBIN GENERATION AND INFLAMMATION IN PATIENTS WITH STEVENS- JOHNSON SYNDROME/TOXIC EPIDERMAL NECROLYSIS. Omer Iqbal Received Received
  344-TUE-PO QUANTITATIVE IMMUNOASSAY FOR THE MEASUREMENT OF ACTIVATED PROTEIN C COMPLEXES WITH ALPHA-2-MACROGLOBULIN (APC:a2M) Francisco España Received Received
  345-TUE-PO IDENTIFICATION OF A NOVEL MUTATION P.K234EFS24 IN THE PROC GENE AND A PHENOTYPE-GENOTYPE CHARACTERISTICS OF THAI PATIENTS DIAGNOSED WITH HEREDITARY PROTEIN C DEFICIENCY AND SYMPTOMATIC THROMBOEMBOLISM Bundarika Suwanawiboon Received Received
  345-WED-PO NONCLINICAL EVALUATION OF CATIONICALLY MODIFIED POLYSACCHARIDE ANTIDOTES FOR UNFRACTIONATED HEPARIN Bartlomiej Kalaska Received Received
  346-WED-PO SCREENING TOOL FOR BLEEDING DISORDERS IN WOMEN WITH HEAVY MENSTRUAL BLEEDING Sophie Wiewel-Verschueren Received Received
  346-MON-PO VALIDATION STUDIES ON COAGULATION LABORATORY ASSAYS USEFUL FOR ASSESSING THE PLASMA LEVELS OF APIXABAN Debra Hoppensteadt Received Received
  347-TUE-PO INVESTIGATION OF PROTEIN S DEFICIENCY INDUCED PURPURA FULMINANS Raja Prince Received Received
  347-MON-PO HOW DO REAL-WORLD APIXABAN CONCENTRATIONS COMPARE TO EXPECTED CONCENTRATIONS? Jignesh Patel Received Received
  348-WED-PO REVERSAL OF DABIGATRAN COULD BE ACHIEVED BY HEMODIALYSIS WITH OR WITHOUT OTHER HEMOSTATIC AGENTS Rachelle Li Received Received
  348-MON-PO THE DAILY PRACTICE OF NOACS; AN OBSERVATIONAL COHORT STUDY arina ten cate-hoek Received Received
  349-WED-PO INCREASED COAGULATION AND FIBRINOLYTIC POTENTIAL OF SOLVENT-DETERGENT PLASMA: AN OBSERVATIONAL STUDY BETWEEN SD-TREATED POOLED PLASMA AND FRESH FROZEN QUARANTINE PLASMA Yvonne Henskens Received Received
  349-MON-PO POTENT ANTITHROMBOTIC EFFECT OF A NOVEL, SMALL-MOLECULE AND DIRECT INHIBITOR OF FACTOR XIA IN PREVENTION AND TREATMENT OF THROMBOSIS IN RABBIT MODEL OF ARTERIAL THROMBOSIS AT DOSES THAT PRESERVE HAEMOSTASIS Pancras Wong Received Received
  350-WED-PO PROSPECTIVE HEMOSTASIS REGISTRY OF PATIENTS IN CARDIAC SURGERY (HEROES-CS): EVALUATION OF THE INTRODUCTION OF A THROMBOELASTOGRAPHY BASED TRANSFUSION PROTOCOL IN CARDIAC SURGERY. Yvonne Henskens Received Received
  350-MON-PO COMPARING FEIBA WITH RECOMBINANT FVIIA FOR REVERSAL OF RIVAROXABAN WITH A MODIFIED ANTI-XA ASSAY IN UNDILUTED PLASMA Jorell Gantioqui Received Received
  350-TUE-PO ASSOCIATION RATE CONSTANTS RATIONALISE THE PHARMACODYNAMICS OF APIXABAN AND RIVAROXABAN GEORGES EL JERDI Received Received
  351-MON-PO DISCOVERY OF ONO-7750512, AN ORALLY BIOAVAILABLE SMALL MOLECULE FACTOR XIA INHIBITOR: THE PHARMACOKINETIC AND PHARMACOLOGICAL PROFILES Sho Koyama Received Received
  353-WED-PO PROTHROMBIN COMPLEX CONCENTRATE CAN INCREASE THROMBIN GENERATION IN THE PRESENCE OF LOW PLATELET NUMBER Colleen Hamid Received Received
  353-MON-PO ENHANCEMENT OF FIBRINOLYSIS BY A FACTOR XA INHIBITOR EDOXABAN AND COMBINATION WITH AN INHIBITOR OF ACTIVATED THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN VITRO Yoshiyuki Morishima Received Received
  354-WED-PO EVALUATION OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE USE AND ITS ROLE IN THE REVERSAL OF NOVEL ORAL ANTICOAGULANTS Sarah Sienko Received Received
  354-MON-PO NOVEL ORAL ANTICOAGULANTS: INCIDENCE AND MANAGEMENT OF MAJOR BLEEDING. RETROSPECTIVE REVIEW AT A SINGLE CENTER. Juan Peris Received Received
  355-MON-PO INITIATING THROMBOPROPHYLAXIS WITH RIVAROXABAN UP TO 26 HOURS AFTER ELECTIVE KNEE ARTHROPLASTY DOES NOT INCREASE THE INCIDENCE OF VENOUS THROMBOEMBOLISM Owais Mian Received Received
  357-MON-PO EVALUATION OF ANTICOAGULANT THERAPY WITH DABIGATRAN BASED ON ECARIN CLOTTING TIME Takeshi Suzuki Received Received
  357-TUE-PO PARADOXICAL ENHANCEMENT OF THE INTRINSIC PATHWAY-INDUCED THROMBIN GENERATION IN HUMAN PLASMA BY MELAGATRAN, A DIRECT THROMBIN INHIBITOR, BUT NOT EDOXABAN, A DIRECT FACTOR XA INHIBITOR Taketoshi Furugohri Received Received
  358-TUE-PO EVALUATION OF ANTICOAGULATION WITH RIVAROXABAN BY ANTI-XA ACTIVITY, THROMBIN GENERATION AND COMPLEX THROMBIN ANTI-THROMBIN LEVELS IN PATIENTS WITH NEW ONSET NON VALVULAR ATRIAL FIBRILLATION. Victor Neira Received Received
  358-MON-PO SWITCH FROM VITAMIN K ANTAGONISTS (VKAS) TO DIRECT ORAL ANTICOAGULANTS (DOACS): A PRATICAL APPROACH Samantha Pasca Received Received
  359-TUE-PO LOW DOSE RIVAROXABAN FOR SECONDARY PROPHYLAXIS AFTER FULL ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM Howard Chan Received Received
  359-MON-PO WARFARIN AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE REAL WORLD OF PATIENTS WITH ATRIAL FIBRILLATION pasquale pignatelli Received Received
  360-MON-PO GLOBAL ANTICOAGULANT SCREENING USING A DILUTE RVV REAGENT Zhenghua Cao Received Received
  360-TUE-PO INTRA-INDIVIDUAL VARIABILITY IN TROUGH AND PEAK DABIGATRAN LEVELS IN REAL-LIFE ATRIAL FIBRILLATION PATIENTS Petra Sinigoj Received Received
  361-TUE-PO DIRECT-ACTING ORAL ANTICOAGULANTS IN THE REAL WORLD: INSIGHTS INTO HEALTH CARE PROVIDERS UNDERSTANDING OF MEDICATION DOSING AND USE Menaka Pai Received Received
  361-MON-PO A CHROMOGENIC FACTOR XA INHIBITOR ASSAY FOR QUANTIFYING RIVAROXABAN LEVELS: OPTIMIZATION AND VALIDATION ON THE ACL TOP 700 Paula Jacobi Received Received
  361-WED-PO IMPROVING EDUCATION AND ADVOCACY FOR YOUNG WOMEN WITH MENORRHAGIA THROUGH USE OF INNOVATIVE TECHNOLOGY Jennifer Dietrich Received Received
  362-TUE-PO DIRECT ORAL ANTICOAGULANTS IN CLINICAL PRACTICE - REAL WORLD AUDIT DATA Sarah Bond Received Received
  363-WED-PO A FIXED DOSE OF PROTHROMBIN COMPLEX CONCENTRATE DOES NOT REDUCE THE INR QUICKER & RELIABLE IN VITAMIN K ANTAGONISTRELATED INTRACRANIAL HAEMORRHAGE Rahat Abdoellakhan Received Received
  363-MON-PO FROM LABORATORY TO CLINICAL PRACTICE: DABIGATRAN EFFECTS ON THROMBIN GENERATION AND COAGULATION IN PATIENT SAMPLES Tuukka Helin Received Received
  364-WED-PO RISKS AND PREDICTORS OF ISCHEMIC/BLEEDING COMPLICATIONS IN CARDIAC PATIENTS UNDERGOING ELECTIVE NON-CARDIAC SURGERY AN ANALYSIS OF THE PRAGUE-14 STUDY Zuzana Motovska Received Received
  364-MON-PO THE ADDITION OF IDARUCIZUMAB TO PLASMA SAMPLES CONTAINING DABIGATRAN ALLOWS THE USE OF ROUTINE COAGULATION ASSAYS FOR THE DIAGNOSIS OF HEMOSTASIS DISORDERS Marc Jacquemin Received Received
  365-WED-PO THE PHARMACOKINETICS AND IMMUNE RESPONSE OF NEW CATIONIC DEXTRAN ANTIDOTES OF HEPARIN Batlomiej Kalaska Received Received
  365-TUE-PO RENAL FUNCTION COURSE IN PATIENTS TREATED WITH NEW ORAL ANTICOAGULANTS. Anna Maria Gori Received Received
  366-WED-PO GENDER AND BLEEDING IN ATRIAL FIBRILLATION: A REAL-WORLD PROSPECTIVE COHORT STUDY Jeroen Jaspers Focks Received Received
  366-TUE-PO THE EFFECTS OF DIRECT ORAL ANTICOAGULANTS APIXABAN AND RIVAROXABAN ON HAEMOSTASIS TESTS: RESULTS FROM A COMPREHENSIVE CROSS-LABORATORY EXERCISE. Roslyn Bonar Received Received
  367-WED-PO LOW-DOSE 4-FACTOR PCC FOR URGENT WARFARIN REVERSAL Wesley Zemrak Received Received
  367-MON-PO A NOVEL PROTHROMBIN TIME (PT) METHOD TO MEASURE ALL NON-VITAMIN K DEPENDENT ORAL ANTICOAGULANTS (NOACS) Tomas Lindahl Received Received
  369-TUE-PO CIRCULATING CONCENTRATION OF RIVAROXABAN OR DABIGATRAN ANTICOAGULANTS IN CLINICALLY SELECTED PATIENTS Jane Needham Received Received
  370-MON-PO REAL-LIFE USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN COMPARISON WITH VITAMIN K ANTAGONISTS FOR NON-VALVULAR ATRIAL FIBRILLATION: DATA FROM A PROSPECTIVE COHORT Michela Giustozzi Received Received
  370-WED-PO INTRAVENTRICULAR FIBRINOLYSIS RESTORES GLYMPHATIC CIRCULATION AFTER SUBARACHNOID HEMORRHAGE. Maxime GAUBERTI Received Received
  371-MON-PO THE MODULATION OF PROTHROMBINASE LIFETIME BY RIVAROXABAN Maria Cristina Bravo Received Received
  371-TUE-PO MANAGEMENT OF BLEEDING AND EMERGENCY SITUATIONS FOR PATIENTS TREATED WITH DABIGATRAN- SINGLE CENTRE EXPERIENCE. Tatiana Prigancova Received Received
  371-WED-PO EVALUATING THE INTER-OBSERVER RELIABILITY OF POTENTIAL PREDICTOR VARIABLES TO DEVELOP A MORE ACCURATE PREDICTION TOOL FOR BLEEDING FOR PATIENTS ON ORAL ANTICOAGULANT Parvaneh Fallah Received Received
  372-TUE-PO BLEEDING AND TREATMENT FAILURE IN PATIENTS TAKING DIRECT ORAL ANTICOAGULANTS REFERRED TO EMERGENCY DEPARTMENT: A COHORT MANAGEMENT STUDY Seena Padayattil Jose Received Received
  372-WED-PO EFFECTS OF HEMOSTATIC GAUZE WITH SELF-PROPELLING THROMBIN PARTICLES ON SURVIVAL AND BLOOD LOSS IN A SWINE MODEL OF LETHAL ARTERIAL HEMORRHAGE Alex St. John Received Received
  373-MON-PO IS IT POSSIBLE TO ASSES RIVAROXABAN ACTIVITY WITHOUT SPECIFIC CALIBRATORS? María de Lourdes Herrera Received Received
  373-TUE-PO PERFORMANCES OF A NEW COMMERCIAL CHROMOGENIC ASSAY FOR THE MEASUREMENT OF APIXABAN CONCENTRATION IN PLASMA Jean-Marc Minon Received Received
  373-WED-PO CLINICAL MANAGEMENT AND OUTCOME OF MAJOR BLEEDING IN PATIENTS ON TREATMENT WITH VITAMIN K ANTAGONISTS: RESULTS FROM THE CLIMBING STUDY. LAURA FRANCO Received Received
  374-MON-PO A NEW ASSAY FOR THE MEASUREMENT OF RIVAROXABAN CONCENTRATIONS IN HUMAN PLASMA Valeri Krougliak Received Received
  374-WED-PO COMPARATIVE STUDIES ON A BRANDED RECOMBINANT FACTOR VIIA AND ITS GENERIC VERSION TO DEMONSTRATE EQUIVALENCE. Paul OMalley Received Received
  375-MON-PO MONITORING VITAMIN K ANTAGONIST TREATMENT : INTERESTS OF GOOD THERAPEUTIC EDUCATION Dalila Atchafa Tadlaoui Received Received
  375-TUE-PO PROTHROMBINASE INDUCED CLOTTING TIME (PICT) FOR MEASURING THE ACTIVITY OF DIRECT FACTOR XA INHIBITORS IN CLINICAL SETTING. Pável Eduardo Olivera Sumire Received Received
  376-WED-PO A MICROFLUIDIC CHAMBER FOR ELONGATING MEGAKARYOCYTES AND PRODUCING FUNCTIONAL PLATELETS Dominique Baruch Received Received
  376-MON-PO HOW PARTICIPATING IN A CLINICAL TRIAL HAS HAD A FAR REACHING EFFECT A CASE STUDY. Claire McGregor Received Received
  377-MON-PO BARRIERS TO INFORM HEMOPHILIC CARRIERS OF THAT POSSIBILITY IN JAPAN Tomie FUJII Received Received
  377-WED-PO NOVEL ROLES OF THE DUAL-SPECIFICITY PHOSPHATASES 1 AND 6 IN MEGAKARYOPOIESIS AND PROPLATELET FORMATION Alexandra Mazharian Received Received
  377-TUE-PO QUALITATIVE FOLLLOW UP OF EMERGENCY DEPARTMENT (ED) PATIENTS DISCHARGED ON RIVAROXABAN FOR LOW RISK VENOUS THROMBOEMBOLISM Kristen Nordenholz Received Received
  378-TUE-PO NET CLINICAL BENEFIT OF DABIGATRAN VERSUS WARFARIN IN PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM: A POOLED ANALYSIS OF RE-COVER AND RE-COVER II Sam Schulman Received Received
  378-WED-PO FUNCTIONALLY ACTIVE TISSUE FACTOR IS EXPRESSED DURING MEGAKARYOCYTE MATURATION AND IS TRANSFERRED TO A SUBSET OF PLATELETS Marina Camera Received Received
  378-MON-PO MECHANICAL THROMBOPROPHYLAXIS SOLVING DILEMMAS Cara Doyle Received Received
  379-TUE-PO IDENTIFICATION OF POSSIBLE DRUG RELATED PROBLEMS IN PATIENTS ON ORAL ANTICOAGULANTS. A SYSTEMATIC REVIEW OF MEDICATION CHARTS BY PHARMACIST. Eva-Marie Jacobsen Received Received
  379-WED-PO FUNCTIONAL ANALYSIS OF NBEAL2 IN HUMAN MEGAKARYOCYTES VIA COLOCALIZATION WITH SUBCELLULAR COMPARTMENTS Richard Lo Received Received
  380-MON-PO THE IMPACT OF FOOTWEAR ON ANKLE ARTHROPATHY IN PATIENTS WITH HEMOPHILIA. Karen Strike Received Received
  380-WED-PO CCL5 RELEASED FROM PLATELETS DRIVES INCREASED MEGAKARYOCYTE MATURATION AND PROPLATELET FORMATION Kellie Machlus Received Received
  382-MON-PO FIRST EXPERIENCE WITH THE HAEMOASSIST, AN ELECTRONIC SUBSTITUTION DIARY THAT WORKS ON THE BASIS OF A PERSONAL DIGITAL ASSISTANT (PDA) Manuela Siebert Received Received
  383-TUE-PO MEAL-INDUCED PLATELET ACTIVATION DIFFERS BETWEEN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES AND IS RELATED TO INSULIN SECRETION Galia Spectre Received Received
  383-WED-PO MEGAKARYOCYTES AND PLATELETS EXPRESS NICOTINIC ACETYLCHOLINE RECEPTORS BUT NICOTINE DOES NOT AFFECT MEGAKARYPOIESIS OR PLATELET FUNCTION Peter Bugert Received Received
  384-TUE-PO INFLUENCE OF PLATELET COUNT IN PLATELET RICH PLASMA FOR ADENOSINE TRIPHOSPHATE RELEASE ASSAY Katrien Devreese Received Received
  385-TUE-PO ACTIVATION OF HUMAN PLATELETS BY STAPHYLOCOCCUS AUREUS SECRETED PROTEASE STAPHOPAIN A Amie Waller Received Received
  385-WED-PO GENE EXPRESSION PROFILE IN MEGAKARYOCYTES FROM TYPE 2 DIABETIC MICE EMPHASIZES INCREASE IN STEFINA EXPRESSION LEVELS Canault Matthias Received Received
  386-WED-PO IDENTIFICATION OF MEGAKARYOCYTIC PROGENITOR CELLS AMONG SUBCUTANEOUS PRE-ADIPOCYTES Keiichi Tozawa Received Received
  386-MON-PO RESPONSE OF LEUCOCYTE COUNT, LEUCOCYTE DIFFERENTIAL COUNT AND THROMBOCYTE COUNT ON FREQUENT BLOOD DONATIONS AMONG MALE SUBJECTS IN UNIVERSITY OF CALABAR TEACHING HOSPITAL DONOR CLINIC, CALABAR, NIGERIA Dorathy Chioma Okpokam Received Received
  387-WED-PO PLATELET FACTOR XIII: THE RESCUE IN THE FACTOR FXIII DEFICIENCY. CLAUDIA MARIA RADU Received Received
  387-TUE-PO EVALUATION OF MULTIPLATE WHOLE BLOOD IMPEDANCE AGGREGOMETRY IN ROUTINE INVESTIGATION OF BLEEDING DISORDERS Joanne Joseph Received Received
  388-MON-PO MILD HAEMOPHILIA A: A MANAGEABLE CONDITION? Daryl Pollock Received Received
  388-WED-PO RAC1 REGULATES PLATELET MICROPARTICLES FORMATION AND RHEUMATOID ARTHRITIS DETERIORATION Xue Chen Received Received
  389-WED-PO ALTERATIONS IN THE EXTRACELLULAR VESICLES PROPERTIES INDICATE HYPERCOAGULABLE STATE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA Inna Tzoran-Rosenthal Received Received
  389-MON-PO SOURCE DATA VERIFICATION PILOT: USING CENTRAL MONITORING IN AN OBSERVATIONAL CRITICAL CARE BIOMARKER STUDY Ellen McDonald Received Received
  390-TUE-PO DETERMINATION OF THRESHOLD AGONIST CONCENTRATIONS FOR WHOLE BLOOD AGGREGATION USING THE MULTIPLATE ANALYZER Sara Israels Received Received
  390-WED-PO EFFECT OF ACETYLSALICYLIC ACID ON THE CONCENTRATION OF MONOCYTE MICROPARTICLES COEXPRESSING TISSUE FACTOR IN PATIENTS WITH DIABETES MELLITUS TYPE 2 Marcelo Luide Goncalves Received Received
  390-MON-PO RAISING AWARENESS OF VENOUS THROMBOEMBOLISM PREVENTION: HOW THE JEWISH GENERAL HOSPITAL IS MEETING THE REQUIREMENTS FOR HOSPITAL ACCREDITATION Jessica Emed Received Received
  391-WED-PO LOW MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH PERSISTENT LUPUS ANTICOAGULANT AND A HISTORY OF THROMBOSIS Lena Hell Received Received
  391-TUE-PO ASSESSMENT OF TIME-RELATED PREANALYTICAL INFLUENCES ON PLATELET FUNCTION: COMPARISON OF THE MULTIPLATE, THE PFA-100 AND THE VERIFY NOW Jilma Petra Received Received
  392-WED-PO MEAL INTAKE INCREASES CIRCULATING PROCOAGULANT MICROPARTICLES IN PATIENTS WITH DIABETES MELLITUS Galia Spectre Received Received
  392-MON-PO A SURVEY OF CLINICAL RESEARCH COORDINATORS TO MANAGE THE CLINICAL RESEARCH PAPERWORK MOUNTAIN Terri Schnurr Received Received
  393-TUE-PO GPVI AND THE CLEC-2/PODOPLANIN AXIS AS POTENTIAL BIOMARKERS OF PLATELET ACTIVATION IN INFLAMMATORY CONDITIONS Samantha Montague Received Received
  393-MON-PO THE JEWISH GENERAL EXPERIENCE IN DEVELOPING PATIENT TEACHING MATERIALS ON WARFARIN AND VENOUS THROMBOEMBOLISM Carla Strulovitch Received Received
  394-MON-PO THE IMPACT OF ?3 CYTOPLASMIC TAIL MIMETIC PEPTIDES ON PLATELET AGGREGATION AND ?IIB?3 ACTIVATION Huong Nguyen Received Received
  394-WED-PO CLINICAL SIGNIFICANCE OF CIRCULATING MICROPARTICLES IN PH- MYELOPROLIFERATIVE NEOPLASMS (MPN) yue han Received Received
  395-WED-PO PLATELET MICROVESICLES IN VASCULAR INFLAMMATION Tanja Vajen Received Received
  395-TUE-PO LOCAL ANAESTHETICS INHIBIT ACTIVATION OF PROTEIN DISULFIDE ISOMERASE (PDI). Anne Bertling Received Received
  395-MON-PO BILE SALT CHENODEOXYCHOLATE SUPPRESSES NORMAL PLATELET FUNCTIONS THROUGH CYCLIC AMP ACTIVATION PATHWAY Pat Metharom Received Received
  396-TUE-PO PROSPECTIVE ANALYSIS OF PLATELET ACTIVATION MARKERS TO PREDICT SEVERE INFECTION AND MORTALITY IN INTENSIVE CARE UNITS. Céline Delierneux Received Received
  396-WED-PO IMPACT OF A FAT-TOLERANCE TEST ON PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES ASSESSED BY NANOPARTICLE TRACKING ANALYSIS Cathrine Ramberg Received Received
  396-MON-PO THE ROLE OF HETEROTRIMERIC G PROTEINS IN REGULATION OF GPIIB-IIIA ACTIVATION AND PLATELET CONTRACTILITY Naphtali Savion Received Received
  397-MON-PO THE GUT MICROBIOTA REGULATES VON WILLEBRAND FACTOR EXPRESSION AND PLATELET PROTHROMBOTIC FUNCTION VIA TOLL-LIKE RECEPTOR-2 Sven Jckel Received Received
  398-WED-PO PERFORMANCE OF THREE FUNCTIONAL ASSAYS FOR THE MEASUREMENT OF DABIGATRAN PLASMA CONCENTRATIONS Geneviève Freyburger Received Received
  398-TUE-PO COMPARATIVE IMPACTS OF ANTIRETROVIRAL HIV THERAPIES ON PLATELET FUNCTION Erica Smyth Received Received
  401-TUE-PO OPIATES MAY ATTENUATE PLATELET ACTIVATION Ankit Macwan Received Received
  401-WED-PO DILUTE RUSSELL VIPER VENOM TIME, A PARTIAL SOLUTION FOR SCREENING AND CONCENTRATION DETERMINATION OF DIRECT ORAL ANTICOAGULANTS An Stroobants Received Received
  401-MON-PO PLATELET-SPECIFIC GARP DEFICIENCY DOES NOT AFFECT THROMBOSIS AND HEMOSTASIS IN MICE Elien Vermeersch Received Received
  402-WED-PO DRUG INTERACTIONS OF NEWER ORAL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN, AND APIXABAN WITH ROUTINELY USED NONANTICOAGULANT/ANTIPLATELET DRUGS Shermin Sayani Received Received
  402-MON-PO CONSTRUCTION OF EXPRESSION SYSTEM FOR BIOLOGICALLY FUNCTIONAL RECOMBINANT RHODOCYTIN TOMOYUKI SASAKI Received Received
  402-TUE-PO IN VIVO AND PROTEASE-ACTIVATED RECEPTOR 1-MEDIATED PLATELET ACTIVATION IN PATIENTS PRESENTING FOR CARDIAC CATHETERIZATION Thomas Gremmel Received Received
  403-MON-PO Localization of Zn2 and Ca2 in Dense-Granules of Human Platelets and the Extent of their Release upon Platelet Activation Sara Henderson Received Received
  403-TUE-PO PLATELET FACTOR-3 (PF-3) AVAILABILITY AND PLATELET COUNT OF PREGNANT WOMEN IN IRRUA, EDO STATE. ROSE ANYANWU Received Received
  404-TUE-PO FLOW CYTOMETRY BASED EVALUATION OF PLATELET-NEUTROPHIL COMPLEX FORMATION IN HUMAN AND MURINE WHOLE BLOOD: A DETAILED ANALYSIS OF EX VIVO SAMPLE PREPARATION, CYTOMETER SETTINGS AND MOLECULAR BASICS Maximilian Mauler Received Received
  404-MON-PO NEUTROPHILS CONTRIBUTE TO THE GENERATION OF PROCOAGULANT PLATELETS BY A MYELOPEROXIDASE INDEPENDENT MECHANISM Leonardo Pasalic Received Received
  404-WED-PO SUCCESSFUL USE OF HEMODIALYSIS IN A DABIGATRAN OVERDOSE Fernando Araújo Received Received
  405-WED-PO CLINICAL IMPACT OF BLEEDING COMPLICATIONS WITH DIRECT ORAL ANTICOAGULANTS FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ORTHOPAEDIC SURGERY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Eleonora Tamborini Permunian Received Received
  406-WED-PO ROLE OF ANTICOAGULANT CLINICS IN THE MANAGEMENT OF PATIENTS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) AT CORK UNIVERSITY HOSPITAL (CUH) Catriona OLeary Received Received
  406-MON-PO IMPROVING THE QUANTIFICATION OF IN VITRO THROMBUS FORMATION Kjersti Claesson Received Received
  407-WED-PO ARE NON-VKA ORAL ANTICOAGULANTS (NOACS) PLASMA CONCENTRATIONS ASSOCIATED WITH THE RISK OF POSTOPERATIVE BLEEDING? PRELIMINARY RESULTS FROM THE REAL LIFE COHORT. Pável Eduardo Olivera Sumire Received Received
  407-MON-PO RS6929846-DEPENDENT REGULATION OF BTN2A1 EXPRESSION IN INNATE AND ADAPTIVE IMMUNE CELLS AFFECTS PLATELET REACTIVITY TO THROMBIN Cécile Oury Received Received
  408-MON-PO MOUSE CLEC-2 CAN SUPPORT PLATELET ADHESION TO MOUSE PODOPLANIN UNDER ARTERIAL FLOW Stephanie Lombard Received Received
  408-TUE-PO PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIERS RELEASE BY COMBINATIONS OF STREPTOCOCCUS SANGUINIS AND PORPHYROMONAS GINGIVALIS Archie McNicol Received Received
  409-TUE-PO INCREASE IN IONIC STRENGTH INHIBITS PLATELET AGGREGATION IRRESPECTIVE OF SOLUTE TYPE IN VITRO GORDON OGWENO Received Received
  409-MON-PO AKT TRANSLOCATION AND PHOSPHORYLATION REGULATES PLATELET AGGREGATION DOWNSTREAM OF G12/13 AND GI PATHWAYS Zhongren Ding Received Received
  410-WED-PO INTERFERENCE STUDY OF DIRECT THROMBIN INHIBITORS AND ANTI-XA INHIBITORS ON HEMOSTASIS ASSAYS ON A COBAS T 411 SYSTEM An Stroobants Received Received
  410-TUE-PO A NEW APPROACH TO MEASURING PLATELET AGGREGATION AND PLATELET-LEUCOCYTE CONJUGATE FORMATION IN A SMALL VOLUME OF FIXED WHOLE BLOOD MOHAMMAD ALGAHTANI Received Received
  410-MON-PO EFFECTS OF CYCLIC NUCLEOTIDES ON PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIER RELEASE INDUCED BY STREPTOCOCCUS SANGUINIS STRAIN 2017-78 Archie McNicol Received Received
  411-WED-PO NEUTRALIZATION OF BLEEDING INDUCED BY NON-VITAMIN K ORAL ANTICOAGULANTS BY PROTHROMBIN COMPLEX CONCENTRATES ALONE AND IN COMBINATION WITH ANTIFIBRINOLYTIC AGENTS Walter Jeske Received Received
  411-MON-PO TRANSGLUTAMINASE ACTIVE COATED PLATELETS FUNCTION IN PLATELET-DEPENDENT FIBRIN FORMATION VIA FXIII AND INTEGRIN ALPHAIIBBETA3 Judith Cosemans Received Received
  412-TUE-PO EFFECTS OF PH AND CONCENTRATION OF SODIUM CITRATE ANTICOAGULANT ON PLATELET AGGREGATION MEASURED BY LIGHT TRANSMISSION AGGREGOMETRY INDUCED BY ADENOSINE DIPHOSPHATE Marco Cattaneo Received Received
  412-MON-PO PIVOTAL ROLE OF SGK1 IN THE REGULATION OF PLATELET SECRETORY PROTEOME, DENSE GRANULE BIOGENESIS AND SECRETION Britta Walker Received Received
  413-TUE-PO Platelet activation in the presence of Neutral Protamine Hagedorn insulin: a new feature of antibodies against protamine/heparin complexes Tamam Bakchoul Received Received
  413-WED-PO EVALUATION OF APPROPRIATENESS OF RIVAROXABAN PRESCRIPTION IN A TERTIARY CARE HOSPITAL IN SINGAPORE Su Ching Tan Received Received
  413-MON-PO IMPACT OF ELEVATED SHEAR STRESS ON INTEGRIN ?LPHAIIB ?ETA3 LIGAND INTERACTION Marianna Gyenes Received Received
  414-MON-PO PLATELET FUNCTION IS REGULATED BY ACETYLATION AND DEACETYLATION MECHANISMS CONTROLLED BY SIRTUINS. Antonio Moscardó Received Received
  414-TUE-PO CHARACTERISING CELL-TYPE INTERACTIONS FOLLOWING PLATELET ACTIVATION IN A NOVEL LOW VOLUME WHOLE BLOOD ASSAY Paul Armstrong Received Received
  414-WED-PO IDARUCIZUMAB ANTAGONIZES DABIGATRAN-INDUCED ALTERATIONS ON PLATELET AND FIBRIN DEPOSITION IN AN IN VITRO THROMBOSIS MODEL WITH CIRCULATING HUMAN BLOOD Eduardo Arellano-Rodrigo Received Received
  415-MON-PO FIBRIN STIMULATES SPREADING AND ACTIVATION OF PLATELETS THROUGH GPVI OSAMA ALSHEHRI Received Received
  415-TUE-PO CHARACTERISATION OF PROCOAGULANT PLATELETS IN WHOLE BLOOD USING A NOVEL CELL DEATH MARKER Leonardo Pasalic Received Received
  416-TUE-PO NATURAL HISTORY OF ACQUIRED GLANZMANN THROMBASTHENIA : A CASE REPORT Mathieu Fiore Received Received
  416-MON-PO KINDLIN-2 IN MEGAKARYOCYTE AND PLATELET FUNCTIONS Canault Matthias Received Received
  416-WED-PO DETECTING RELEVANT RIVAROXABAN OR DABIGATRAN LEVELS IN CLINICAL CARE BY ROUTINE COAGULATION TESTS OR THROMBOELASTOGRAPHY IN PATIENTS WITH ATRIAL FIBRILLATION. Yvonne Henskens Received Received
  417-TUE-PO HOT-WATER EXTRACTS OF THE MUSHROOM, AGARICUS BRASILIENSIS, INHIBITS PLATELET ACTIVATION VIA P2Y1 RECEPTOR. KANEO SATOH Received Received
  417-WED-PO CORRELATION OF CHROMOGENIC RIVAROXABAN ANTI-XA AND DABIGATRAN ANTI-IIA ACTIVITY WITH ROUTINE PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME Jane Needham Received Received
  418-TUE-PO A REDUCED RESPONSE TO TRAP-6 IN PLATELET AGGREGATION STUDIES IS NOT USUALLY DUE TO A PAR-1 RECEPTOR DEFECT. Michael Mitchell Received Received
  418-WED-PO FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE (4F-PCC) REVERSES BLEEDING ASSOCIATED WITH NEW ORAL ANTICOAGULANTS (NOAC) DABIGATRAN, RIVAROXABAN, EDOXABAN AND APIXABAN IN A RABBIT MODEL OF ACUTE BLEEDING Eva Herzog Received Received
  419-MON-PO VASCULAR SMOOTH MUSCLE CELLS STIMULATE PLATELETS VIA CLEC-2: INVOLVEMENT OF INTRACELLULAR AND EXTRACELLULAR LIGANGS OF CLEC-2 Katsue Suzuki-Inoue Received Received
  420-WED-PO BLEEDING ON NOVEL ORAL ANTICOAGULATION - OUR EXPERIENCE IN THE NORTHERN REGION, UNITED KINGDOM:PRESENTING FEATURES AND MANAGEMENT OF BLEEDING IN INDIVIDUALS TREATED WITH A NOVEL ORAL ANTICOAGULANT (NOAC):RESULTS OF AN OBSERVATIONAL COHORT STUDY Shikha Chattree Received Received
  420-TUE-PO GRANULES SECRETION IN PATIENTS WITH GLANZMANNS THROMBASTHENIA Daniele Pillitteri Received Received
  420-MON-PO PLATELET-FIBRIN THROMBI CAN KILL STENOTROPHOMONAS MALTOPHILI Volker R. Stoldt Received Received
  421-TUE-PO THE GFI1B C.503GT MUTATION IN THE FIRST ZINC FINGER DOMAIN PREDICTS A MILDER BLEEDING PHENOTYPE THAN THE GFI1B C.880-881INSC MUTATION david rabbolini Received Received
  422-MON-PO INHIBITION OF SORBITOL DEHYDROGENASE INCREASES PLATELETS ADHESION IN MICE TREATED WITH FIDARESTAT Mariane Flores-Nascimento Received Received
  422-TUE-PO ABNORMAL PROPLATELET FORMATION AND EMPERIPOLESIS IN CULTURED MEGAKARYOCYTES FROM GRAY PLATELET SYNDROME PATIENTS Erica De Candia Received Received
  423-TUE-PO MULTIPLEX PHOSPHOSPECIFIC FLOW CYTOMETRY FOR THE SCREENING OF PLATELET SIGNALLING DISORDERS Marie Levade Received Received
  423-WED-PO USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR NON-VALVULAR ATRIAL FIBRILLATION IN REAL-LIFE: COMPARISON WITH PHASE III TRIALS Maria Cristina Vedovati Received Received
  424-TUE-PO THIOREDOXIN REDUCTASE PROTECTS PLATELETS FROM CELL DEATH Matthew Harper Received Received
  425-MON-PO REVERSAL OF THE ANTITHROMBOTIC PROPERTIES OF QUERCETIN-3-RUTINOSIDE WITH THE B DOMAIN OF PDI IN A MOUSE THROMBOSIS MODEL LIN LIN Received Received
  425-WED-PO ANTICOAGULATION PHARMACOKINETICS DURING DABIGATRAN THERAPY Thomas Orfeo Received Received
  426-TUE-PO VALIDATION OF THE SELF-PBQ (SELF-ADMINISTERED PEDIATRIC BLEEDING QUESTIONNAIRE) AS A SCREENING TOOL FOR A NEW DIAGNOSIS OF VON WILLEBRAND DISEASE Angie Tuttle Received Received
  426-WED-PO EFFICACY OF PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBOPLASTIN TIME AS A GAUGE FOR SPECIFIC FACTOR INHIBITION Catherine Keller Received Received
  428-MON-PO Deletion of PI3K p110&945; results in enhanced platelet priming Thomas Blair Received Received
  429-MON-PO PROFILING OXYLIPINS RELEASED BY GPVI-ACTIVATED PLATELETS AND THE EFFECT OF INHIBITORS OF CYCLOOXYGENASE-1 AND 12-LIPOXYGENASE Robert Turnbull Received Received
  429-TUE-PO SKIN NECROSIS AND PURPURA FULMINANS IN CHILDREN WITH AND WITHOUT THROMBOPHILIA - A TERTIARY CENTERS EXPERIENCE Yariv Fruchtman Received Received
  430-MON-PO Platelet deformation controls cell tethering frequency and translocation velocity under hydrodynamic shear Changjie Zhang Received Received
  430-WED-PO Thrombin-stimulated phosphorylation of Disabled-2 is involved in the regulationof its interaction with CIN85 during human platelet activation Hui Ju Tsai Received Received
  430-TUE-PO INCIDENCE RATE AND RISK FACTORS OF VENOUS THROMBOEMBOLISM IN ASIAN PEDIATRIC ONCOLOGY PATIENTS. Wai Ming Mendy Ong Received Received
  431-TUE-PO CLINICAL FEATURES, RISK FACTORS AND OUTCOME OF PULMONARY EMBOLISM IN CHILDREN ADMITTED TO A SINGLE ACADEMIC CENTER IN SO PAULO BRAZIL: LOTS TO LEARN OR READY TO TEACH? Jorge D. A. Carneiro Received Received
  431-WED-PO INTEGRIN ALPHA IIB BETA 3-MEDIATED C-SRC ACTIVATION: DIFFERENTIAL BINDING TO INACTIVE AND ACTIVE C-SRC Joel Bennett Received Received
  432-TUE-PO AN INTERNATIONAL SURVEY REGARDING MANAGEMENT OF COAGULOPATHY IN CHILDREN UNDERGOING LIVER BIOPSY. Maria Magnusson Received Received
  432-MON-PO MEMBRANE ESTROGEN RECEPTOR (MER) PROTEASE ACTIVATED RECEPTOR (PAR) CROSS TALK MODULATES PLATELET FUNCTION Joseph Aslan Received Received
  433-TUE-PO EVALUATION OF THROMBOPHILIA IN CHILDREN BEFORE RENAL TRANSPLANT AND OUTCOME OF PROPHYLACTIC ANTICOAGULATION POST-TRANSPLANT Jorge D. A. Carneiro Received Received
  433-WED-PO DROSPIRENONE ENHANCES GPIB-IX-V MEDIATED PLATELET ACTIVATION Xiaolin Wu Received Received
  433-MON-PO PLATELET CD34 EXPRESSION IS INCREASED IN FAMILIES WITH DISTINCT GFI1B MUTATIONS: UTILITY AS A SCREENING TEST Marie-Christine Morel-Kopp Received Received
  434-MON-PO A CASE OF MYH9 DISORDERS CAUSED BY A NOVEL MUTATION (P.K74E). Takeshi Kanematsu Received Received
  434-WED-PO A PARADOXICAL HAEMORRHAGIC STATE CAUSED BY DELETION OF THE SRC KINASE INHIBITOR CSK IS PARTIALLY RESCUED BY DELETION OF CD148 Jun Mori Received Received
  434-TUE-PO DETERMINING THE USABILITY OF THE PEDIATRIC THROMBOSIS EDUCATIONAL TOOL (P-TET) IN CHILDREN RECEIVING ANTICOAGULATION THERAPY Madeline Montoya Received Received
  435-TUE-PO RARE LABORATORY PRESENTATION OF TYPE 2B VON WILLEBRANDS DISEASE IN A 6 YEAR OLD BOY. IRENE REGAN Received Received
  435-WED-PO EFFECT OF HOMOCYSTEINE AND FOLIC ACID IN CA2 HOMEOSTASIS AND ROS PRODUCTION IN PLATELETS FROM BILE-DUCT LIGATION RATS. Paola Romecin Received Received
  435-MON-PO CALR MUTATIONS ARE ASSOCIATED WITH LOWER PLATELET AND ENDOTHELIAL ACTIVATION THAN THE JAK2 MUTATION IN ESSENTIAL THROMBOCYTHEMIA Eduardo Arellano-Rodrigo Received Received
  436-MON-PO DIFFERENT MICROTUBULE ABNORMALITIES IN TWO CASES OF MACROTHROMBOCYTOPENIA ASSOCIATED WITH TUBB1 VARIANTS Simon Stritt Received Received
  436-TUE-PO SYNERGISTIC EFFECT OF ELEVATED LIPOPROTEIN (A) LEVELS WITH INHERITED THROMBOPHILIA RISK FACTORS IN CHILDREN WITH ARTERIAL ISCHEMIC STROKE Desiree Coen Herak Received Received
  437-WED-PO SPHINGOSINE KINASE DEFICIENCY MODULATES PLATELET ACTIVATION Benoit DECOUTURE Received Received
  437-MON-PO SOLUBLE GLYCOPROTEIN VI: A POTENTIAL BIOMARKER FOR DISEASE ACTIVITY AND PLATELET REACTIVITY IN ACUTE GOUT. Geraldine McCarthy Received Received
  437-TUE-PO THE ROLE OF FVR2 POLYMORPHISM IN CHILDREN CARRIERS OF FVLEIDEN Zoey Kapsimali Received Received
  438-TUE-PO WHOLE BLOOD THROMBOELASTOMETRY (ROTEM) PROFILES IN CHILDREN WITH CYANOTIC CONGENITAL HEART DISEASES UNDERGOING CARDIAC SURGERY Spiezia Luca Received Received
  438-MON-PO PERSONALIZED REFERENCE INTERVALS FOR PLATELET COUNT REDUCE THE PREVALENCE OF UNEXPLAINED THROMBOCYTOPENIA AND INCREASE THAT OF REACTIVE THROMBOCYTOSIS IN ELDERLY PEOPLE Patrizia Noris Received Received
  439-MON-PO MYH9 DISEASE: IDENTIFICATION OF TWO MUTATIONS ASSOCIATED WITH UNCOMMON CLINICAL PHENOTYPE JOSE RIVERA Received Received
  439-TUE-PO THE INCIDENCE OF DEEP VEIN THROMBOSIS IN CHILDREN WITH PERIPHERALLY INSERTED CENTRAL CATHETERS VERSUS TUNNELED CENTRALLY INSERTED CATHETERS Julie Jaffray Received Received
  440-WED-PO LYSINE ACETYLTRANSFER SUPPORTS PLATELET FUNCTION Joseph Aslan Received Received
  440-MON-PO ACTN1-RELATED THROMBOCYTOPENIAS (ACTN1-RT): PHENOTYPE/GENOTYPE OF A SERIES OF 13 NEW CASES Anne Vincenot Received Received
  441-TUE-PO THROMBOEMBOLIC COMPLICATION IN CHILDHOOD WITH NEPHROTIC SYNDROME: EXPERIENCE IN THREE PEDIATRIC HOSPITAL IN ARGENTINA. Monica Martinez Received Received
  441-MON-PO ROCK1 OR FLI1 MUTATIONS IN PATIENTS WITH MILD THROMBOCYTOPENIA. Canault Matthias Received Received
  442-MON-PO CONGENITAL THROMBOCYTOPENIAS AND IMMUNE THROMBOCYTOPENIC PURPURA : A MISLEADING DIAGNOSIS Maria Coutinho Received Received
  442-TUE-PO ACQUIRED VON WILLEBRAND SYNDROME (AVWS) - AN UNDERDIAGNOSED COMPLICATION IN SEVERELY ILL PEDIATRIC PATIENTS WITH BLEEDING COMPLICATIONS Ivonne Wieland Received Received
  442-WED-PO RELEASE OF EXTRA CELLULAR DNA CONTRIBUTES TO RENAL ISCHEMIA REPERFUSION INJURY THROUGH PLATELET ACTIVATION AND FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS Marcel Jansen Received Received
  443-MON-PO FIVE NEW HETEROZYGOUS MUTATIONS IN THE GPIB AND GPIX ARE ASSOCIATED WITH THE BOLZANO PHENOTYPE BACCINI Véronique Received Received
  443-TUE-PO THE IMPACT OF SERUM BILE ACID LEVELS ON THE MRNA EXPRESSION OF PRO-AND ANTICOAGULANT PROTEINS IN LIVER TISSUE. Maria Magnusson Received Received
  444-WED-PO SPECIFIC REGULATION OF MOUSE PLATELET ADP SECRETION BY SARCO-ENDOPLASMIC RETICULUM CALCIUM ATPASE TYPE 3 ziane elaib Received Received
  444-MON-PO INCREASE THE NUMBER OF GP IIB-IIIA AND P2Y12 RECEPTORS IN ACTIVATED PLATELETS POSSIBLE EVIDENCE FOR PROTEINS SYNTHESIS DE NOVO Olga Sirotkina Received Received
  444-TUE-PO THROMBOMODULIN GEN ANALYSIS IN A CASE OF ATYPICAL HEMOLYTIC-UREMIC SYNDROME Noelia Vilalta Received Received
  445-MON-PO RISK FACTORS AND CO-MORBIDITIES IN ADOLESCENT THROMBOEMBOLISM ARE DIFFERENT THAN THOSE IN YOUNGER CHILDREN Titilope Ishola Received Received
  445-TUE-PO CLINICAL CHARACTERIZATION OF VENOUS THROMBOEMBOLISM IN CHILDHOOD AT A TERTIARY LEVEL HOSPITAL Laura Andreoni Received Received
  446-MON-PO DO PRETERM INFANTS WITH PATENT DUCTUS ARTERIOSUS (PDA) WHO FAIL PRIMARY PHARMACOTHERAPY HAVE LOWER PLATELET COUNTS? : A SYSTEMATIC REVIEW AND META-ANALYSIS Souvik Mitra Received Received
  446-TUE-PO LETS CUT TO THE BONE: RISK FACTORS OF VENOUS THROMBOEMBOLISM IN CHILDREN WITH MUSCULOSKELETAL INFECTIONS Rungrote Natesirinilkul Received Received
  447-TUE-PO FEASIBILITY AND SAFETY OF ENOXAPARIN WHOLE MILLIGRAM DOSING IN PREMATURE AND TERM NEONATES Rebecca Goldsmith Received Received
  447-MON-PO CATHETER DIRECTED THROMBOLYSIS AS SAFE AND EFFECTIVE THERAPY FOR PROXIMAL LOWER LIMB DEEP VEIN THROMBOSIS IN ADOLESCENTS Kathryn Musgrave Received Received
  448-WED-PO MODULATION OF ACTIN CYTOSKELETON ON SHEAR-DEPENDENT FIBRILLOGENESIS OF FIBRONECTIN Huong Nguyen Received Received
  449-WED-PO JANUS KINASE 3 (JAK3) DEPENDENT SIGNALING IS CRITICAL TO CA2-DEPENDENT PLATELET ACTIVATION AND THROMBUS FORMATION Patrick Mnzer Received Received
  450-TUE-PO CANCER CELLS INDUCE THE RELEASE OF MICROPARTICLES FROM HUMAN PLATELETS Gianni Guidetti Received Received
  450-MON-PO EFFECTS OF MATERNAL HYPERTENSION ON NEONATAL HEMOGRAM IN SOUTH-SOUTH NIGERIA Helen Okoye Received Received
  451-MON-PO TREATMENT WITH ROMIPLOSTIM IN CHILDREN. INCIDENCE AND QUALITY OF THE RESPONSE. María del Carmen Gómez del Castillo Received Received
  451-TUE-PO THE EFFECTS OF INTERFERON&945;-2B ON THE DEFECTIVE BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA Tiantian Sun Received Received
  452-TUE-PO SUNITINIB IS TAKEN UP BY PLATELETS AND INHIBITS PLATELET ACTIVATION AND THROMBUS FORMATION IN CANCER PATIENTS Marijke Kuijpers Received Received
  452-WED-PO EFFECT OF PAR-4 TETHERED-LIGAND PEPTIDE ANALOGS ON HUMAN PLATELET ACTIVATION Iraklis Moschonas Received Received
  453-WED-PO PLATELET HSP70 PROMOTES INTEGRIN ALPHAIIBBETA3 ACTIVATION AND PLATELET AGGREGATION Rachel A. Rigg Received Received
  453-TUE-PO ALLELIC VARIANTS WITHIN ANXA5 DIFFERENTIALLY IMPACT ON THE CONTROL OF GENE EXPRESSION Giovanni Tiscia Received Received
  453-MON-PO INVESTIGATING THE ROLE OF POLYPHOSPHATES IN NEONATAL HEMOSTASIS Axel Schlagenhauf Received Received
  454-WED-PO INFLUENCE OF PRO-MMP-9 ON PLATELET AGGREGATION AND ADHESION TO FIBRINOGEN Aneta Wrzyszcz Received Received
  455-WED-PO THE DEFECTIVE CD36 GENE MUTATIONS CAUSE A MOLECULAR EXPRESSION DIVERSITY ON PLATELETS AND MONOCYTES EVEN IN NON-DEFICIENT PHENOTYPE POPULATION Shogo Tamura Received Received
  455-MON-PO USE OF PROTHROMBIN COMPLEX CONCENTRATES (PCC) IN PAEDIATRIC EXTRACORPOREAL LIFE SUPPORT PATIENTS aisha bruce Received Received
  456-MON-PO ANTITHROMBIN PLASMA LEVELS AND FIBTEM DETERMINATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING ASPARAGINASE TREATMENT Spiezia Luca Received Received
  456-TUE-PO THE EFFECT OF ULTRA HIGH LEVELS OF C-REACTIVE PROTEIN (CRP) ON THE COAGULATION SYSTEM Ramin Artang Received Received
  457-MON-PO WARFARIN THERAPY IN CHILDREN: CAN FAMILIES SAFELY AND EFFICIENTLY MONITOR INRS AT HOME? Kathy Harney Received Received
  457-TUE-PO ASSESSMENT OF THE EFFECT OF INTER-ALPHA TRYPSIN INHIBITOR BY THROMBIN GENERATION ASSAY Plantier Jean-Luc Received Received
  457-WED-PO ELASTIN-DERIVED PEPTIDES REGULATE LEUKOCYTE-PLATELET AGGREGATES Pascal MAURICE Received Received
  458-MON-PO PROPHYLACTIC ENOXAPARIN IN YOUNG INFANTS ARE THE CURRENTLY RECOMMENDED DOSES TOO LOW? Kathy Harney Received Received
  458-WED-PO PLATELET DENSE GRANULE SECRETION DEFECTS MAY OBSCURE OUR UNDERSTANDING OF ?-GRANULE SECRETION MECHANISMS: EVIDENCE FROM MUNC13-4-DEFICIENT PLATELETS Matthew Harper Received Received
  458-TUE-PO PROLONGATION OF CLOT LYSIS TIME BY A DIRECT THROMBIN INHIBITOR: INVOLVEMENT OF THROMBIN GENERATION ENHANCEMENT AND THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR Yoshiyuki Morishima Received Received
  459-MON-PO THROMBOEMBOLIC EVENTS IN CHILDREN zafer salcioglu Received Received
  460-MON-PO BIVALIRUDIN USE IN CHILDREN ON ECMO FOLLOWING HEPARIN FAILURE aisha bruce Received Received
  461-WED-PO The Ras/RapGAP Rasa3 negatively regulates Rap1b and integrin &945;IIb&946;3-mediated spreading Anthony Battram Received Received
  461-MON-PO THROMBOEMBOLIC EVENTS IN PEDIATRIC PATIENTS WITH CYANOTIC CONGENITAL HEART DISEASES IN SRINAGARIND HOSPITAL Patcharee Komvilaisak Received Received
  461-TUE-PO A NOVEL APPROACH FOR HEMOPHILIA THERAPY THROUGH ANTIBODY TARGETED TFPI Sumin Lee Received Received
  462-TUE-PO FUNCTIONAL COMPONENTS OF JAPANESE TRADITIONAL SOYBEAN FOOD NATTO?NATTOKINASE, VITAMIN K2 AND POLYAMINE? Hiroyuki Sumi Received Received
  462-WED-PO DEXTRAN SULFATE TRIGGERS PLATELET AGGREGATION VIA PEAR1, INDEPENDENT FROM SYK Christophe Vandenbriele Received Received
  463-TUE-PO FIBRINOLYTIC ACTIVITY PRODUCED BY FERMENTED SWEET CORN WITH BACILLUS SUBTILIS NATTO Hiroyuki Sumi Received Received
  464-WED-PO IDENTIFICATION OF LOW MOLECULAR WEIGHT FACTORS RELEASED FROM PLATELETS THAT INDUCE PROCR IN MONOCYTES Robert Turnbull Received Received
  464-MON-PO EXAMINING THE FEASIBILITY OF RECOMBINANT FACTOR VIIA TO COMPENSATE FOR PHYSIOLOGICAL OR DRUG-INDUCED IMPAIRMENT OF PLATELET FUNCTION: AN IN-VITRO STUDY. Harald Haidl Received Received
  464-TUE-PO INHIBITION OF FIBRINOLYSIS BY HEPARIN, LOW MOLECULAR WEIGHT HEPARIN AND A NOVEL ANTICOAGULANT, ANTITHROMBIN-HEPARIN COVALENT COMPLEX (ATH) Gabriela Chang Received Received
  465-TUE-PO COMPLEMENT C3 AND HYPOFIBRINOLYSIS: A POTENTIAL ROLE FOR PROTEIN GLYCATION Katharina Schuett Received Received
  465-WED-PO CELL SURFACE EXPRESSION OF CHEMERIN RECEPTORS ON HUMAN PLATELETS UPON CELL ACTIVATION Zhifei Shao Received Received
  466-WED-PO GPIB? ACTIVATION MEDIATES PLATELET TISSUE FACTOR (TF) PHOSPHORYLATION, TRANSFER TO LIPID RAFTS (LR) AND ACTIVITY. TFPI AND PROTEIN S, RELEASED BY OTHER AGONISTS, WOULD ASSEMBLE THE INHIBITORY COMPLEX (TF/FVIIA/TFPI/PS) IN LR, DAMPENING FXA ACTIVITY Olga Panes Received Received
  466-MON-PO DENSER CLOTS PREDISPOSE TO POST THROMBOTIC SYNDROME Annemieke Bouman Received Received
  467-MON-PO PRACTICE VARIATION IN THE TREATMENT OF DVT AND PREVENTION OF POST THROMBOTIC SYNDROME BETWEEN INTERNISTS AND VASCULAR SURGEONS: A CANADIAN SURVEY OF PHYSICIAN PRACTICES. Rick Ikesaka Received Received
  467-TUE-PO EFFECTS OF AN ACIDIC ENVIRONMENT ON COAGULATION DYNAMICS Matthew Gissel Received Received
  468-TUE-PO EXERCISE-INDUCED CORE BODY TEMPERATURE ELEVATIONS SHIFT HEMOSTASIS TO A PROTHROMBOTIC STATE Waander L. van Heerde Received Received
  468-WED-PO EVALUATION OF ISTH-BLEEDING ASSESSMENT TOOL IN INDIVIDUALS WITH SUSPECTED INHERITED PLATELET FUNCTION DISORDER REFERRED TO TERTIARY HEALTH CARE FACILITY IN PAKISTAN. ANILA RASHID Received Received
  469-TUE-PO IN VITRO INTERACTIONS OF SUGAMMADEX WITH VARIOUS ANTICOAGULANTS Annelieke Kruithof Received Received
  469-WED-PO EFFECT OF CARDIOPULMONARY BYPASS PUMP ON THE PLATELET FUNCTION USING PLATELET FUNCTION ANALYZER (PFA-100) PRE AND POSTOPERATIVE CARDIAC SURGERY OPERATION. AL Bakr Rashed Bakr R Received Received
  470-WED-PO DECREASED PLATELET REACTIVITY IN WOMEN WITH HEAVY MENSTRUAL BLEEDING: A NOVEL APPROACH IN THE GYNAECOLOGY CLINIC TO DIAGNOSE THROMBOPATHY USING A NOVEL PLATELET FUNCTION TEST. Heleen Eising Received Received
  470-MON-PO TOLL-LIKE 9 GENE EXPRESSION IN THE POST THROMBOTIC SYNDROME, RESIDUAL THROMBOSIS AND RECURRENT DEEP VENOUS THROMBOSIS: A CASE-CONTROL STUDY Whitney Cheung Received Received
  471-MON-PO PATIENTS PREFERENCES REGARDING ELASTIC COMPRESSION STOCKING THERAPY FOR THE PREVENTION OF POST THROMBOTIC SYNDROME Annemieke Bouman Received Received
  471-WED-PO DIAGNOSTIC ACCURACY OF FLOW CYTOMETRY ANALYSIS OF PLATELET LEUKOCYTE AGGREGATES IN ACUTE CORONARY SYNDROME PATIENTS VERSUS NORMAL VOLUNTEERS najib dally Received Received
  472-MON-PO COMPARISON OF SELF-RATED AND PROFESSIONAL-RATED SCORES OF THE VILLALTA SCALE FOR EVALUATION OF THE POST-THROMBOTIC SYNDROME IN PATIENTS WITH PROXIMAL DEEP VEIN THROMBOSIS Trond Isaksen Received Received
  472-TUE-PO EARLY ANTICOAGULATION AND PREGNANCY OUTCOMES IN PATIENTS REFERRED TO A SERVICE OF THROMBOSIS AND THROMBOPHILIA IN PREGNANCY VENINA BARROS Received Received
  472-WED-PO A STEP FORWARD IN THE EVALUATION OF PLATELET FUNCTION TESTING: ROUTINE, SIMULTANEOUS MEASUREMENT OF PLATELET AGGREGATION, SEROTONIN (5-HT) CONTENT AND SECRETION BY HPLC-ELECTROCHEMICAL DETECTION IN HEMOSTASIS LABORATORIES. Diego Mezzano Received Received
  473-MON-PO IS POST THROMBOTIC SYNDROME PERCEIVED TO BE A CLINICALLY RELEVANT OUTCOME?: A SURVEY OF PHYSICIAN PRIORITIES Rick Ikesaka Received Received
  473-WED-PO OUTCOMES OF 65 PREGNANCIES IN 34 WOMEN WITH 5 DIFFERENT FORMS OF INHERITED PLATELET FUNCTION DISORDERS ENROLLED IN A RETROSPECTIVE AND MULTICENTRIC STUDY, ON BEHALF OF EHA-SWG ON THROMBOCYTOPENIAS AND PLATELET FUNCTION DISORDERS Patrizia Noris Received Received
  474-TUE-PO NEW THROMBOPHILIC RISK FACTORS IN PATIENTS WITH VASCULAR PLACENTAL COMPLICATIONS (VPC) AND PREGNANCY OR HORMONAL THERAPY - RELATED THROMBOSIS AND MANAGEMENT IN THE CLINICAL PRACTICE . RESULTS FROM THE INTERNATIONAL TEAM PROJECT. Amparo santamaria Received Received
  474-WED-PO THE VALUE OF IMPEDANCE AGGREGOMETRY IN ACUTE LEUKEMIA PATIENTS Andra Costache Received Received
  475-WED-PO A NATIONAL REGISTRY OF PATIENTS WITH INHERITED PLATELET DISORDERS: BLEEDING SCORE IS ASSOCIATED WITH TIME OF FOLLOW-UP Shoshana Revel-Vilk Received Received
  476-TUE-PO MATERNAL DEATH AND VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS ADMITTED IN A MATERNITY OF HIGH RISK: RESULTS PRE AND POST APPLICATION OF A RISK SCORE. Roberta Santos Received Received
  476-MON-PO FIBRINOGEN CHARACTERISTICS HELP PREDICT CHRONIC THROMBOTIC VENOUS DISEASE AFTER ACUTE DEEP VEIN THROMBOSIS Timothy Morris Received Received
  476-WED-PO PLASMA MARKERS OF FIBRINOLYSIS, THROMBIN GENERATION AND PLATELET ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS Hung Chang Received Received
  477-TUE-PO A COMMON GENETIC BACKGROUND SHARED BY WOMEN WITH HISTORY OF ADVERSE PREGNANCY OUTCOMES AND CARDIOVASCULAR DISEASE: A WINDOW TO FUTURE CARDIOVASCULAR RISK. Ilaria Romagnuolo Received Received
  477-WED-PO COMPARISON OF A NOVEL AUTOMATED MICROCHIP FLOW-CHAMBER SYSTEM AND CONVENTIONAL PLATELET FUNCTION TESTS IN PATIENTS WITH ISCHEMIC CEREBROVASCULAR DISEASES Masako Yamazaki Received Received
  478-MON-PO THE ROLE OF INFLAMMATION IN POST-THROMBOTIC SYNDROME AFTER PREGNANCY-RELATED VENOUS THROMBOSIS Hilde Skuterud Wik Received Received
  478-WED-PO GENETIC AND NON-GENETIC DETERMINANTS OF MPV DIFFER IN MALES AND FEMALES RESULTS FROM THE GUTENBERG HEALTH STUDY Marina Panova-Noeva Received Received
  479-WED-PO EVALUATION OF PLATELETS COUNT AND ACTIVATION DURING MENSTRUAL CYCLE IN YOUNG WOMEN IN ORAL CONTRACEPTIVE USE Luci Maria SantAna Dusse Received Received
  479-TUE-PO THE IMPACT OF MODE OF DELIVERY AND POSTPARTUM THROMBOPROPHYLAXIS ON ROTATIONAL THROMBOELASTOMETRY (ROTEM) IN PREGNANT WOMEN WITH A HIGH RISK OF POSTPARTUM VENOUS THROMBOEMBOLISM. Boriana Guimicheva Received Received
  479-MON-PO MOM, WHY SHOULD I WEAR THESE SOCKS? TAKING THE FIRST STEP IN THE JOURNEY TO UNDERSTANDING THE ROLE OF COMPRESSION GARMENTS IN THE TREATMENT OF PEDIATRIC POST-THROMBOTIC SYNDROME Madeline Montoya Received Received
  480-WED-PO REVISITING THE HEMOSTATIC DISORDER OF UREMIA : PATIENTS ON PERITONEAL DIALYSIS (CRF-PD) HAVE NORMAL PLATELET AGGREGATION AND SECRETION BUT INCREASED PLATELET TISSUE FACTOR ACTIVITY (TF-PCA), PROBABLY THE CAUSE OF INTRAVASCULAR CLOTTING ACTIVATION. Olga Panes Received Received
  480-TUE-PO RETROSPECTIVE STUDY OF PATIENTS WHO WERE TREATED WITH FONDAPARINUX PRE-, PERI- AND/OR POSTPARTUM FOR PROPHYLAXIS OR TREATMENT OF VENOUS THROMBOEMBOLISM (FONDAPPP) Carl-Erik Dempfle Received Received
  480-MON-PO INADEQUATE ANTICOAGULATION IS THE ONLY RISK FACTOR FOR DEVELOPMENT OF POST THROMBOTIC SYNDROME IN UNPROVOKED DEEP VEIN THROMBOSIS PRAVAS MISHRA Received Received
  481-MON-PO PATIENT COMPRESSION HOSIERY CONCORDANCE GARY BENSON Received Received
  481-TUE-PO ROTATIONAL THROMBOELASTOMETRY IN PREGNANCY AND ITS ROLE IN ASSESSMENT OF HAEMOSTASIS IN WOMEN WITH FACTOR XI DEFICIENCY Joanna Davies Received Received
  482-TUE-PO THROMBIN GENERATION IN WOMEN UNDERGOING IVF TREATMENT IS PROLONGED, BUT NOT ENHANCED COMPARED TO CONTROLS. Roza Chaireti Received Received
  482-MON-PO THE UTILITY OF THROMBELASTOGRAPHY AND MULTIPLATE AS SCREENING TOOLS FOR RARE INHERITED BLEEDING DISORDERS NOT ASSOCIATED WITH A COAGULATION FACTOR DEFICIENCY Eva Leinoe Received Received
  483-MON-PO BLEEDING SCORE AND CLOTTING SCREENING TESTS PERFORMED BEFORE ELECTIVE SURGERY TO DIAGNOSE UNKNOWN HEMORRHAGIC DISEASES. Gabriella Gamba Received Received
  484-TUE-PO EFFECTS OF SILDENAFIL CITRATE ON COAGULATION PROCESS DURING PREGNANCY: A PROMISING THERAPEUTIC APPROACH IN COMBINATION WITH LOW MOLECULAR WEIGHT HEPARIN FOR RECURRENT PREGNANCY LOSS Rayana Luna Received Received
  485-WED-PO SUCCESSFUL USE OF LOCAL PLATELET PELLET FOR CHILDREN WITH SEVERE EPISTAXIS davut albayrak Received Received
  485-TUE-PO A RISK SCORE FOR PREDICTION OF RECURRENCE IN PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM (DAMOVES) Ana Isabel Franco Received Received
  485-MON-PO A NEW SWISS FAMILY WITH CONSTITUTIONAL HYPOFIBRINOGENEMIA AND LIVER DISEASE Alessandro Casini Received Received
  486-TUE-PO ANALYSIS OF PROTHROMBIN MUTANTS IN NA BINDING DOMAIN AS A POTENTIAL CANDIDATE CONVEYING ANTITHROMBIN RESISTANCE Moe Murata Received Received
  486-WED-PO ELEVATED SOLUBLE PLATELET GLYCOPROTEIN VI LEVELS IN PATIENTS AFTER LIVING DONOR LIVER TRANSPLANTATION Takeshi Matsumoto Received Received
  486-MON-PO SAFE USE OF FXI CONCENTRATE IN A SINGLE CENTRE EXPERIENCE OVER 19 YEARS Gavin Ling Received Received
  487-WED-PO NICOTINIC ACETYLCHOLINE RECEPTOR FUNCTION IN PLATELETS FROM ALZHEIMER DISEASE PATIENTS Peter Bugert Received Received
  487-TUE-PO ORAL ANTICOAGULANT THERAPY FOR THE PREVENTION OF RECURRENT THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA Eduardo Arellano-Rodrigo Received Received
  488-TUE-PO ACSF2 EXPRESSION AND RISK OF RECURRENCE AFTER A FIRST UNPROVOKED DEEP VENOUS THROMBOSIS EVENT. RESULTS FROM THE RETRO STUDY Ramón Lecumberri Received Received
  489-MON-PO ALTERNATIVE STRATEGY TO TREAT HEMOPHILIA TROUGH PROTEIN S INACTIVATION: INSIGHT FROM A MOUSE MODEL Luca Bologna Received Received
  490-WED-PO INCREASED MITOCHONDRIAL ELECTRON TRANSPORT ASSOCIATED WITH APOPTOSIS IN HYPER-REACTIVE PLATELETS OF PATIENTS WITH ACUTE PULMONARY EMBOLISM Samin Rezania Received Received
  490-MON-PO GENOTYPE AND PHENOTYPE REPORT ON PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY IN SOUTH OF IRAN Mehran Karimi Received Received
  490-TUE-PO INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH INTRACRANIAL VENOUS THROMBOSIS: SINGLE CENTER EXPERIENCE IN TURKEY TURKAN PATIROGLU Received Received
  491-WED-PO ANTENATAL GENETIC ANALYSIS OF A JAPANESE TYPE I CD36-DEFICIENT WOMAN IN THE PREGNANCY Naomi Sanda Received Received
  491-TUE-PO THROMBOPROPHYLAXIS SKIPPED DOSES IN HOSPITALIZED PATIENTS.CAN WE RECOGNIZE WHICH ARE THE CAUSES OR FACTORS? alicia beatriz vilaseca Received Received
  492-WED-PO A RELIABLE AND SIMPLE DIAGNOSTIC APPROACH TO DETECT PLATELET SECRETION DEFECTS IN SUBJECTS WITH MUCOCUTANEOUS BLEEDING Stan Heptinstall Received Received
  493-MON-PO CHARACTERIZING MECHANISMS OF FACTOR VIII BINDING TO THE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 Patricia Young Received Received
  493-WED-PO PLATELET CD40L CONTROLS BLEEDING DURING P2Y12 BLOCKERS TREATMENT. Canault Matthias Received Received
  493-TUE-PO IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOEMBOLISM (VTE) ON THE ASSOCIATIONS BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF VTE. Trygve Ellingsen Received Received
  494-TUE-PO IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOSIS ON RISK OF STROKE AND VTE IN ATRIAL FIBRILLATION Ina Rye-Holmboe Received Received
  494-WED-PO CLINICAL AND GENETIC PREDICTORS OF POOR PLATELET RESPONSE TO CLOPIDOGREL IN PATIENTS WHO UNDERWENT PERCUTANEOUS CORONARY INTERVENTION A. Anil Timur Received Received
  495-WED-PO NO INCREASE IN PLATELET AGGREGATION IN HEALTHY WOMEN STARTING COMBINED ORAL CONTRACEPTIVES Julie Brogaard Larsen Received Received
  495-TUE-PO IMPACT OF THE FIBRINOGEN GAMMA GENE RS2066865 VARIANT ON THE RISK OF VENOUS THROMBOSIS IN CANCER PATIENTS Olga Dziewiecka Received Received
  496-TUE-PO CHARACTERISTICS OF HOSPITAL-ASSOCIATED THROMBOSIS ATTRIBUTED TO THROMBOPROPHYLAXIS FAILURE Emma Gee Received Received
  497-TUE-PO ANTI-VIMENTIN ANTIBODIES INCREASE THROMBUS FORMATION AT VENOUS SHEAR RATES IN VITRO AND IN VIVO: IMPLICATION FOR VENOUS THROMBOEMBOLISM IN AUTOIMMUNE DISEASES Miguel Cruz Received Received
  497-MON-PO ACQUIRED GPVI DEFICIENCY IN TWO UNRELATED PATIENTS WITH MILD THROMBOCYTOPENIA JOSE RIVERA Received Received
  497-WED-PO STUDY OF PLATELET FUNCTION IN HEMOPHILIA A IN THE REGION OF MURCIA Antonia Melero Amor Received Received
  498-MON-PO IDENTIFICATION OF THE PATHOPHYSIOLOGICAL MECHANISM OF THE VKCFD2 CAUSING MUTATION P.ARG98TRP IN HUMAN VKORC1 GENE Katrin Czogalla Received Received
  499-TUE-PO FORGOTTEN NO MOREA CASE OF A 54 YEAR OLD FEMALE WITH LEMIERRES SYNDROME Edward Gacrama Received Received
  499-MON-PO SCOTT SYNDROME PLATELETS SHOW ALTERATIONS IN PROTEIN EXPRESSION LEVELS, CALCIUM-DEPENDENT PHOSPHORYLATION AND CLEAVAGE AS REVEALED BY PROTEOMICS Johan Heemskerk Received Received
  499-WED-PO CEREBRAL VENOUS THROMBOSIS OCCURRING DURING OXYMETHOLONE THERAPY IN A PATIENT WITH FANCONI APLASTIC ANEMIA erol erduran Received Received
  500-MON-PO A FAILURE TO DIAGNOSE DYSFIBRINOGENAEMIA: DATA FROM MULTICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES. Ian Jennings Received Received
  500-TUE-PO PREAVELANCE OF RISK FACTORS PREDISPOSING TO THROMBOSIS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION Jerzy Dropinski Received Received
  501-TUE-PO NO DIFFERENCES IN THROMBIN GENERATION BETWEEN PATIENTS WITH AND WITHOUT PORTAL VEIN THROMBOSIS IN END-STAGE LIVER DISEASE Dana Tomescu Received Received
  501-WED-PO THROMBOSIS IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: ENDOGENOUS AND EXOGENOUS RISK FACTORS O.V. Shpitonkova Received Received
  502-WED-PO EVALUATION OF AGE-DEPENDENT DOSING RECOMMENDATIONS FOR THE ADMINISTRATION OF TINZAPARIN IN THE TREATMENT OF PAEDIATRIC THROMBOSIS Tina Biss Received Received
  503-MON-PO DECREASED FIBRINOLYTIC RESISTANCE IN FXI-DEFICIENCY IS INDEPENDENT OF CLOTTING IMPAIRMENT Francesca Incampo Received Received
  503-WED-PO USING A FUNCTIONAL PLATELET ACTIVITY ANALYSIS IN CHILDREN WITH UNEXPLAINED BLEEDING. FIRST RESULTS FROM RUSSIA Pavel Zharkov Received Received
  503-TUE-PO A-FIBRINOGEN THR312ALA POLYMORPHISM IS AN INDEPENDENT GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN THE POPULATION OF NORTH-WESTERN RUSSIA Sergey Kapustin Received Received
  504-WED-PO FOUR YOUNG CHILDREN WITH THROMBOTIC COMPLICATIONS AS A RESULT OF ANTITHROMBIN HEPARIN-BINDING DEFECTS. Michael Mitchell Received Received
  504-TUE-PO VENOUS THROMBOEMBOLISM (VTE) IN HOSPITALISED NON-SURGICAL CANCER PATIENTS AND ITS BURDEN ON HEALTHCARE IN AN ASIAN TERTIARY HOSPITAL Lai Heng Lee Received Received
  505-WED-PO RISK OF THROMBOSIS IN A COHORT OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS Sule Unal Received Received
  506-WED-PO COMPARISON OF THE IMPACT OF SERPINC1, PROC AND PROS1 MUTATIONS ON THROMBOTIC PHENOTYPES IN CHILDREN AND ADULTS: AN OBSERVATIONAL MULTICENTER COHORT STUDY Verena Limperger Received Received
  506-TUE-PO ANTICOAGULANTS FOR PREVENTION OF THROMBOTIC COMPLICATIONS IN PATIENTS ON PARENTERAL NUTRITION: A SYSTEMATIC REVIEW. Stefano Barco Received Received
  507-TUE-PO LONG-TERM PARENTERAL NUTRITION-ASSOCIATED THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS IN 236 SINGLE-CENTER OUTPATIENTS. Stefano Barco Received Received
  507-WED-PO ACQUIRED VON WILLEBRAND DISEASE IN A PATIENT WITH UNDERLYING BECKWITH-WIEDEMANN SYNDROME Fatma Gumruk Received Received
  508-MON-PO PLACENTAL INSUFFICIENCY RESOLUTION WITH FULL ANTICOAGULATION IN PATIENTS WITH PRIOR BAD OBSTETRIC OUTCOME AND DYSLIPIDAEMIA DURING PREGNANCY. roberta santos Received Received
  508-WED-PO NOVEL HOMOZYGOUS MUTATION IN MCFD2 AND HETEROZYGOUS SMALL DELETION IN LMAN1 GENES CAUSING COMBINED FACTOR V AND VIII DEFICIENCY Mualla Cetin Received Received
  509-TUE-PO UROKINASE PLASMINOGEN ACTIVATOR PROTECTS CARDIAC MYOCYTES FROM OXIDATIVE DAMAGE AND APOPTOSIS VIA OGG1 Philipp Hohensinner Received Received
  509-MON-PO D-DIMER MEASUREMENT HAS NO DIAGNOSTIC VALUE DURING PREGNANCY A LONGITUDINAL STUDY OF 4314 SAMPLES FROM 791 HEALTHY WOMEN Katrine Hedengran Received Received
  510-TUE-PO FACTOR VII ACTIVATING PROTEASE (FSAP) EXPRESSION IS NEGATIVELY REGULATED BY TRANSFORMING GROWTH FACTOR-BETA (TGF-?) IN THE LIVER. Sebastian Seidl Received Received
  510-MON-PO MEN WITH FACTOR V LEIDEN HAVE INCREASED SPERM COUNTS Thijs van Mens Received Received
  511-MON-PO INCIDENCE OF VENOUS THROMBOSIS IN PREGNANCIES AFTER SPONTANEOUS AND ART CONCEPTION - AN ITALIAN COHORT STUDY - MICHELA VILLANI Received Received
  511-TUE-PO PHOSPHATIDYLINOSITOL-3,4,5-TRISPHOSPHATE STIMULATES CA2 ELEVATION AND AKT PHOSPHORYLATION TO CONSTITUTE A MAJOR MECHANISM OF THROMBOXANE A2 FORMATION IN HUMAN PLATELETS. KALWANT AUTHI Received Received
  511-WED-PO THE INFLUENCE OF CHILDHOOD IMMUNIZATIONS ON WARFARIN EFFECT siddons suzanne Received Received
  512-TUE-PO A SYSTEMS BIOLOGY MODEL FOR THE COAGULATION NETWORK DESCRIBES BIOMARKER CHANGES OBSERVED IN A CLINICAL STUDY WITH FVIIA VARIANT Fei Hua Received Received
  512-MON-PO POST-PARTUM PROPHYLAXIS IN PRACTICE. Emmanuelle Le Moigne Received Received
  513-MON-PO THE M2 HAPLOTYPE WITHIN THE ANNEXIN A5 GENE AND ANTIPHOSPHOLIPID ANTIBODIES IN UNSELECTED PREGNANT WOMEN- A PROSPECTIVE HOSPITAL- BASED STUDY- MICHELA VILLANI Received Received
  513-WED-PO HEMOSTASIS PROFILE IN CALVES RECEIVING THE CARMAT BIOPROSTHETIC ARTIFICIAL HEART David SMADJA Received Received
  515-MON-PO EFFECT OF PROPHYLAXIS WITH LMWH ON IMPLANTATION IN WOMEN UNDERGOING ASSISTED REPRODUCTIVE PROCEDURES (IVF OR ICSI): A PROSPECTIVE RANDOMIZED STUDY daniela tormene Received Received
  515-TUE-PO EVALUATION OF THE THERAPEUTIC EFFECT OF NOVEL STROKE DRUG SMTP-7 ON EMBOLIC STROKE IN MONKEYS Eriko Suzuki Received Received
  516-TUE-PO THE ASSOCIATION OF FACTOR VIII AND VON WILLEBRAND FACTOR LEVELS AND THE OUTCOME OF THROMBOLYSIS IN ISCHEMIC STROKE PATIENTS Noemi Klara Toth Received Received
  516-MON-PO PREDICTION OF VENOUS THROMBOEMBOLIC RELATED FETAL LOSSES BY A NEW GENETIC RISK SCORE Jose A. Paramo Received Received
  517-TUE-PO ADAMTS13 DESTABILIZES THROMBI IN A MOUSE MODEL OF THROMBOTIC FOCAL CEREBRAL ISCHEMIA Frederik Denorme Received Received
  518-TUE-PO REMOTE PLATELET FUNCTION TESTING USING MEASUREMENTS OF P-SELECTIN IN PATIENTS WITH ACUTE STROKE OR TIA ALREADY RECEIVING TREATMENT WITH ANTIPLATELET AGENTS Stan Heptinstall Received Received
  518-WED-PO TWO FAMILIES FROM ARGENTINA WITH FX DEFICIENCY DUE TO TWO DIFFERENT MUTATIONS (P.CYS241GLY AND P.GLN138ARG ). Hugo A. Guglielmone Received Received
  519-TUE-PO INHIBITION OF TAFI AND PAI-1 IS PROTECTIVE IN A MOUSE MODEL OF CEREBRAL ISCHEMIA/REPERFUSION INJURY Frederik Denorme Received Received
  521-MON-PO ALL CAUSE MORTALITY AND USE OF ANTITHROMBOTICS WITHIN 90 DAYS OF DISCHARGE IN ACUTELY ILL MEDICAL PATIENTS Charles Mahan Received Received
  521-TUE-PO GENETIC ABLATION OF EXTRA DOMAIN A OF CELLULAR FIBRONECTIN PROTECTS HYPERCHOLESTEROLEMIC MICE FROM ACUTE STROKE BY REDUCING THROMBO-INFLAMMATION Nirav Dhanesha Received Received
  522-MON-PO RISK OF VENOUS THROMBOSIS AND COAGULATION PROFILE IN DUTCH NATIVES AND IMMIGRANTS IN THE NETHERLANDS: RESULTS FROM THE MEGA STUDY Suely Rezende Received Received
  522-WED-PO EFFECTS OF FACTOR XIII DEFICIENCY ON THROMBOELASTOGRAPHY. BASAL THROMBELASTOGRAPH AND LYSIS BY ADDITION OF STREPTOKINASE ARE MORE AFFECTED THAN SOLUBILITY TESTS Marta E Martinuzzo Received Received
  522-TUE-PO EFFECTS OF THE MAIN ACTIVE COMPONENT COMBINATION BETWEEN ASTRAGALUS AND PANAX NOTOGINSENG ON INFLAMMATION AND APOPTOSIS OF NERVE CELL AFTER CEREBRAL ISCHEMIA-REPERFUSION Chang-Qing Deng Received Received
  523-WED-PO HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY: A REPORT OF ELEVEN VENEZUELAN CASES MARION ECHENAGUCIA Received Received
  523-MON-PO IMPACT OF TORNADOES ON HOSPITAL ADMISSIONS FOR VENOUS THROMBOEMBOLISM AND CARDIOVASCULAR EVENTS Ana Casanegra Received Received
  524-MON-PO JOINT EFFECTS OF F5 GENE VARIANTS AND TALL STATURE ON VTE RISK Tine Lnneberg Received Received
  524-WED-PO DIAGNOSIS OF FXIII DEFICIENCY: DATA FROM MULTICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES. Ian Jennings Received Received
  524-TUE-PO THROMBOELASTOMETRY (ROTEM) PROFILES IN PATIENTS UNDERGOING THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE. Elena Campello Received Received
  525-MON-PO JOINT EFFECT OF OBESITY AND RISK ALLELES IN THE KNG1 GENE ON RISK OF VENOUS THROMBOEMBOLISM. Tine Lnneberg Received Received
  525-TUE-PO SEVERE OBESITY IS A RISK FACTOR FOR CEREBRAL VENOUS THROMBOSIS: A CASE-CONTROL STUDY Jonathan Coutinho Received Received
  525-WED-PO THE CLINICAL FINDINGS OF CHILDREN WITH FACTOR X DEFICIENCY AT A SINGLE CENTER IN THE MIDDLE EAST OF TURKEY Funda Tayfun Received Received
  526-MON-PO JOINT EFFECT OF CANCER AND THE GP6 RS1613662 SINGLE NUCLEOTIDE POLYMORPHISM ON VTE RISK Olga Dziewiecka Received Received
  527-WED-PO INHERITED FXI DEFICIENCY IS NOT A RARE DISEASE IN THE NORTHERN REGION OF TURKEY albayrak davut Received Received
  527-TUE-PO THE ALTERATION OF IRON TRANSMEMBRANE PROTEINS EXPRESSION IN THE RAT HIPPOCAMPUS FOLLOWING FOCAL CEREBRAL ISCHEMIA Jun Liao Received Received
  527-MON-PO SEX HORMONE-BINDING GLOBULIN AND HEMOSTATIC VARIABLES IN WOMEN USING COMBINED OR PROGESTIN-ONLY PILLS. Justine Hugon-Rodin Received Received
  528-MON-PO INVOLVEMENT OF HEREDITARY THROMBOPHILIA IN CEREBRAL VENOUS THROMBOSIS OCCURRING IN YOUNG PATIENTS Héla Baccouche Received Received
  528-TUE-PO NONCLINICAL AND CLINICAL DEVELOPMENT OF TMS-007, A MEMBER OF THE ANTI-INFLAMMATORY SMALL-MOLECULE THROMBOLYTIC SMTPS Keiji Hasumi Received Received
  529-TUE-PO ANTITHROMBIN LEVELS IN ADULT STROKE PATIENTS AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL Omolade Awodu Received Received
  529-MON-PO CHRONIC LIVER DISEASE IS A SIGNIFICANT RISK FACTOR FOR VENOUS THROMBOEMBOLISM AMONG MEDICAL PATIENTS IN SINGAPORE GENERAL HOSPITAL Lai Heng Lee Received Received
  530-WED-PO CLINICAL PRESENTATION AND MANAGEMENT OF RARE FACTOR DEFICIENCIES:CASE STUDY Bulent Antmen Received Received
  530-MON-PO THE EFFECT OF HEMODIAFILTRATION AND HEMODIALYSIS ON COAGULATION PARAMETERS IN PATIENTS WITH END-STAGE RENAL DISEASE Krisztina Pénzes-Daku Received Received
  531-MON-PO MIR-15A, MIR-96, MIR-144, MIR-150, MIR-155, MI210, MIR-212, MIR-223, MIR-424 AND MIR-451 ARE DIFFERENTLY EXPRESSED IN PLATELETS FROM DVT PATIENTS Mariane Flores-Nascimento Received Received
  532-TUE-PO THROMBOLYSIS USING N-ACETYLCYSTEINE IN ACUTE ISCHEMIC STROKE Maxime Gauberti Received Received
  533-TUE-PO MULTIPLE MENINGIOMAS DOES NOT INCREASE THE RISK OF INTRACRANIAL HEMORRHAGE AFTER INTRAVENOUS THROMBOLYSIS FOR ACUTE ISCHEMIC STROKE Navdeep Lail Received Received
  534-MON-PO INCREASED CIRCULATING DNA, CALPROTECTIN AND MYELOPEROXIDASE, AS NEUTROPHIL EXTRACELLULAR TRAP MARKERS, ARE RISK FACTORS FOR DEEP VEIN THROMBOSIS Pilar Medina Received Received
  534-WED-PO CONGENITAL FXI DEFICIENCY: PRELIMINARY RESULTS OF PHENOTYPIC (CLINICAL AND LABORATORY) AND GENOTYPIC CHARACTERIZATION OF A CASE SERIES FROM A SINGLE CENTER. Cristina Santoro Received Received
  535-WED-PO FACTOR VII DEFICIENCY AND PROPHYLAXIS DUE TO INTERVENTIONS Violeta Dejanova-Ilijevska Received Received
  536-TUE-PO ALTERED FIBRIN CLOT STRUCTURE/FUNCTION IN PATIENTS WITH CEREBRAL SINUS VENOUS THROMBOSIS AND THE RISK OF RECURRENCE. Jakub Siudut Received Received
  536-MON-PO IDENTIFICATION AND VALIDATION OF PLASMA microRNAS INVOLVED IN VENOUS AND ARTERIAL THROMBOSIS. Silvia Navarro Received Received
  536-WED-PO COURSE OF PREGNANCY, LABOUR AND PERIOPERATIVE MANAGEMENT OF TWO PATIENTS WITH BERNARD-SOULIER SYNDROME CASE REPORTS AND LITERATURE REVIEW Anna Sikorska Received Received
  537-WED-PO INHERITED FXIII DEFICIENCY IN THE NORTHERN REGION OF TURKEY albayrak davut Received Received
  537-MON-PO THE INCIDENCE OF CATHETER-RELATED THROMBOSIS IN PATIENTS ON LONG-TERM PARENTERAL NUTRITION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Stefano Barco Received Received
  538-MON-PO VENA CAVA THROMBOSIS IN ADULTHOOD VS PEDIATRICS PATIENTS: DIFFERENT PHENOTYPES AND RISK FACTORS FOR THE SAME ENTITY. Georgina Stefanía Daher Reyes Received Received
  538-WED-PO VON WILLEBRAND DISEASE: BE OR NOT TO BE, THAT IS THE QUESTION ANA AZEVEDO Received Received
  539-TUE-PO INDIVIDUAL ABSOLUTE AND RELATIVE RISK (RR) OF PULMONARY EMBOLISM (PE) IN PREGNANCY AND PUERPERIUM IN PRESENCE OF HEREDITARY THROMBOPHILIC RISK FACTORS Rainer B. Zotz Received Received
  539-MON-PO A CLINICAL AUDIT OF HERITABLE THROMBOPHILIA TEST PROFILE IN A TERTIARY HEALTH CARE FACILITY, PAKISTAN. ANILA RASHID Received Received
  540-MON-PO THROMBOPHILIC PROFILE IN EXTRAHEPATIC PORTAL VEIN OBSTRUCTION- EXPERIENCE FROM A TERTIARY CENTRE IN INDIA Pratibha Dhiman Received Received
  541-MON-PO ISTHS CLARION CALL: TO RAISE THE AWARENESS OF THROMBOSIS WORLDWIDE - A GLOBAL DISEASE BURDEN Thiruchelvam Ayadurai Received Received
  542-TUE-PO THROMBIN GENERATION TEST AT R2 POLYMORPHISM OF FACTOR V Jana Prochazkova Received Received
  542-MON-PO RISK FACTORS OF THROMBOSIS AND SICKLE CELL ANEMIA Awa oumar Toure Received Received
  542-WED-PO ORM1: A NOVEL REGULATOR OF THROMBIN GENERATION AND POTENTIAL CARDIOVASCULAR RISK FACTOR Mohammed Alsahli Received Received
  543-WED-PO Role of coagulation factor XI in promoting distal platelet activation and consumption in whole blood under shear flow Jevgenia Zilberman-Rudenko Received Received
  543-TUE-PO FACTOR V LEIDEN IN THE ABSENCE OF APC RESISTANCE IN A PATIENT AFTER LIVER TRANSPLANTATION Jerzy Windyga Received Received
  543-MON-PO GENETIC VARIABILITY OF KNG1 AND F11 GENES USING NEXT GENERATION SEQUENCING. Laura Martin Received Received
  544-TUE-PO VENOUS THROMBOEMBOLISM ASSOCIATED WITH FIRST PREGNANCY IN 80 WOMEN WITH HEREDITARY ANTITHROMBIN DEFICIENCY. Horellou Marie Helene Received Received
  545-MON-PO EVALUATION OF PROTEIN S SPECIFIC ACTIVITY PERMITS ACCURATE DIAGNOSIS OF PROTEIN S TOKUSHIMA, A MISSENSE MUTATION WITH TYPE II PROTEIN S DEFICIENCY Hiroko Tsuda Received Received
  545-WED-PO SELECTIVE NEUTRALIZATION OF THE SERPIN PROTEASE NEXIN-1 BY A SPECIFIC MONOCLONAL ANTIBODY Marie-Christine BOUTON Received Received
  546-TUE-PO ANTIPHOSPHOLIPID ANTIBODIES AS EMBOLIC RISK MARKER OF INFECTIVE ENDOCARDITIS. Jean Devignes Received Received
  547-MON-PO THE POSSIBLE ROLE OF C.1824CT PROTHROMBIN GENE VARIANT IN PATHOGENESIS OF THROMBOPHILIA Valentina Djordjevic Received Received
  547-TUE-PO HEREDITARY AND ACQUIRED THROMBOPHILIAS IN WOMEN Ivo Elezovic Received Received
  548-WED-PO THE IMMEDIATE AND LATE EFFECTS OF THYROID HORMONE (TRIIODOTHYRONINE) ON MURINE COAGULATION GENE TRANSCRIPTION Salloum-Asfar Salam Received Received
  548-TUE-PO CHARACTERIZATION OF A NEW HEREDITARY PROTHROMBIN VARIANT ASSOCIATED WITH INCREASED RISK OF VENOUS THROMBOEMBOLISM Cristiana Bulato Received Received
  549-WED-PO INDIRECT REGULATION OF HEMOSTATIC PROTEINS BY MIR24 AND MIR34A THROUGH HEPATIC NUCLEAR FACTOR 4 ALPHA (HNF4A) Salloum-Asfar Salam Received Received
  549-TUE-PO ARTERIOVENOUS THROMBOSIS IN END STAGE RENAL DISEASE PATIENTS MUNIRA BORHANY Received Received
  550-MON-PO MOLECULAR CHARACTERIZATION OF NEW ANTITHROMBIN MUTATIONS Zsuzsanna Bereczky Received Received
  550-WED-PO INVESTIGATION OF MODE OF ACTION OF SUGAMMADEX EFFECTS ON COAGULATION Annelieke C. Kruithof Received Received
  550-TUE-PO EFFECT OF A CARBOXY-TERMINAL PEPTIDE ON FACTOR VIIA ACTIVITY Dougald Monroe Received Received
  551-MON-PO A REASON TO INCLUDE HOMOCYSTEINE IN THE HYPERCOAGULABLE WORKUP Mala Varma Received Received
  552-TUE-PO TISSUE FACTOR / FVIIa TRANSACTIVATES THE IGF-1R IN PROSTATE CANCER CELLS VIA INHIBITION OF CAVEOLIN-1 Mikael berg Received Received
  552-MON-PO PATHOLOGICAL DETERMINANTS OF HUMAN CORONARY THROMBUS FORMATION: DISTINCT PROCOAGULANT ACTIVITY AND LACTATE PRODUCTION OF M1/M2 POLARIZED MACROPHAGES. Atsushi Yamashita Received Received
  553-TUE-PO THE LRP1 RECEPTOR PROMOTES THE IN VIVO CLEARANCE OF ACTIVATED FACTOR VII (FVIIA) IN COMPLEX WITH ANTITHROMBIN Judicael Fazavana Received Received
  553-MON-PO SINGLE PHOSPHORYLATION OF THE CYTOPLASMIC DOMAIN OF TISSUE FACTOR AT SERINE 253 IS SUFFICIENT FOR THE BINDING OF TISSUE FACTOR TO FILAMIN-A Mary Collier Received Received
  554-MON-PO Alternatively spliced Tissue Factor has no function in hemostasis Betul Unlu Received Received
  554-TUE-PO HIGH PLASMA CONCENTRATION OF ACTIVATED FACTOR VII-ANTITHROMBIN COMPLEX IS ASSOCIATED WITH AN ENHANCED THROMBIN GENERATION Marcello Baroni Received Received
  555-MON-PO K63-LINKED POLYUBIQUITINATION OF LYSINE 255 WITHIN TF PROMOTES SELECTIVE TF-DEPHOSPHORYLATION, TRIGGERS TF-ENDOCYTOSIS AND TERMINATES TF ACTIVITY Camille Ettelaie Received Received
  556-TUE-PO THE ROLE OF FACTOR VII MUTATIONS IN ENDOPLASMIC RETICULUM STRESS Elisabeth Drum Received Received
  556-MON-PO CHARACTERISATION OF TF UBIQUITINATION: INVOLVEMENT OF MDM2 AND THE UBE2D FAMILY OF E2 ENZYMES Camille Ettelaie Received Received
  557-TUE-PO FVII DEFICIENCY: UNVEILING THE CELLULAR AND MOLECULAR MECHANISMS UNDERLYING THREE MODEL ALTERATIONS (MISSENSE, DELETION, EXTENSION) OF THE FVII CATALYTIC DOMAIN Maria Eugenia Chollet Dugarte Received Received
  557-MON-PO HIGH LEVEL OF TISSUE FACTOR INDUCES CELL APOPTOSIS IN ENDOTHELIAL CELLS, MEDIATED THROUGH ACTIVATION OF P38 AND P53 Camille Ettelaie Received Received
  558-TUE-PO MICRORNAS MODULATE HUMAN TISSUE FACTOR PATHWAY INHIBITOR-a (TFPIa) EXPRESSION IN RESPONSE TO ANDROGENS IN ENDOTHELIAL CELLS ANA BELÉN ARROYO-RODRÍGUEZ Received Received
  558-WED-PO OBSTRUCTIVE SLEEP APNOEA DOES NOT ENHANCE HYPERCOAGULABILITY AS MEASURED BY THROMBIN GENERATION IN THE MORBIDLY OBESE Paradzai Chitongo Received Received
  558-MON-PO THE POTENTIAL OF CANCER CELL LINES TO RELEASE TISSUE FACTOR-CONTAINING MICROVESICLES CORRELATES WITH TISSUE FACTOR AND PAR2 MRNA LEVELS BUT NOT TISSUE FACTOR PROTEIN OR SURFACE ACTIVITY Camille Ettelaie Received Received
  559-TUE-PO SINGLE CENTRE EXPERIENCE OF FACTOR VII DEFICIENCY Bella Madan Received Received
  559-WED-PO VEREMA - AN AFFINITY PROTEOMICS STUDY TO IDENTIFY AND TRANSLATE PLASMA BIOMARKERS FOR VENOUS THROMBOEMBOLISM Maria Bruzelius Received Received
  559-MON-PO TISSUE FACTOR IS INDUCED BY INTERLEUKIN-33 IN HUMAN ENDOTHELIAL CELLS: A NEW LINK BETWEEN COAGULATION AND INFLAMMATION Stefan Stojkovic Received Received
  560-TUE-PO THROMBIN GENERATION IN PATIENTS WITH MILD FACTOR VII DEFICIENCY MEASURED IN THE PRESENCE OF THROMBOPLASTINS OF DIFFERENT ORIGIN Roza Chaireti Received Received
  560-MON-PO SOLUBLE TISSUE FACTOR IMPROVES DETECTION OF THROMBIN GENERATION RESPONSES TO WIDE RANGE OF FACTOR VIIA DOSES Mikhail Ovanesov Received Received
  560-WED-PO ANALYSIS OF PROTHROMBIN MISSENSE MUTANTS AT 596ARG BY SINGLE NUCLEOTIDE SUBSTITUTION FOR ANTICOAGULANT SYSTEM TAKAGI YUKI Received Received
  561-WED-PO RED CELL DISTRIBUTION WIDTH AND FUTURE RISK OF VENOUS THROMBOSIS, MYOCARDIAL INFARCTION, STROKE AND CANCER A CAUSE SPECIFIC ANALYSIS. Trygve Ellingsen Received Received
  561-TUE-PO MUTATIONS IN THE F7 GENE IN SWEDISH PATIENTS WITH DISCREPANT FACTOR VII ACTIVITY IN THE PRESENCE OF THROMBOPLASTINS OF DIFFERENT ORIGIN Roza Chaireti Received Received
  562-TUE-PO FVII DEFICIENCY AND THROMBOSIS, COINCIDENCE OR NEW MECHANISM OFTHROMBOPHILIA Y.LARFI, I.BACHIRI, W.ZAZOUA , N.FENNI, M.GIANCILY-BLAIZOT J.F.SCHVED Yacine Larfi Received Received
  563-WED-PO DEHYDRATION AS A POSSIBLE CAUSE OF SEASONAL VARIATIONS IN THE INCIDENCE OF VENOUS THROMBOEMBOLISM elias saad Received Received
  563-MON-PO TISSUE FACTOR/FACTOR VIIA SIGNALING PROMOTES CYTOKINE-INDUCED BETA CELL DEATH AND IMPAIRS GLUCOSE STIMULATED INSULIN SECRETION FROM HUMAN PANCREATIC ISLETS. Desirée Edén Received Received
  564-TUE-PO ANTI-IDIOTYPIC DARPINS RESTORE ADAMTS13 ACTIVITY IN BABOONS CHALLENGED WITH HUMAN MONOCLONAL ANTIBODIES: FIRST STEP TOWARDS AN ANIMAL MODEL FOR HUMAN ACQUIRED TTP Monica Schaller Received Received
  564-WED-PO AN AFFINITY PROTEOMICS STUDY FOR PLASMA BIOMARKER CANDIDATES OF CARDIOVASCULAR DISEASE IN VENOUS THROMBOEMBOLISM Maria Jesus Iglesias Received Received
  564-MON-PO TISSUE FACTOR ACTIVATION IN PREGNANCY COMPLICATIONS Martin Prochazka Received Received
  565-TUE-PO THE LABORATORY PROFILE THAT PREDICTS FAVORABLE OUTCOME AFTER ECULIZUMAB THERAPY IN PATIENTS WITH CLINICAL FEATURES COMPATIBLE WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME Hira Mian Received Received
  565-MON-PO ACTIVATED PLATELETS REGULATE MONOCYTE TFPI GENE EXPRESSION THROUGH THE NUCLEAR TRANSCRIPTION FACTOR PPARG Robert Turnbull Received Received
  566-WED-PO ASSESSMENT OF RISK FACTORS IN ESTABLISHED CASES OF DEEP VEIN THROMBOSIS (DVT) AND GREAT SAPHENOUS VEIN THROMBOSIS (GSVT) IN INDIAN PATIENTS CHITHRA BARVADHEESH Received Received
  566-MON-PO TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR ASSESSMENT IN EARLY AND LATE SEVERE PREECLAMPSIA Lara Carvalho Godoi Received Received
  566-TUE-PO THE CLINICAL ANALYSIS OF 58 THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS Cuicui Lyu Received Received
  567-WED-PO JOINT EFFECT HOMOZYGOUS CARRIERS OF A RISK ALLELE IN THE FIBRINOGEN GAMMA CHAIN AND OVERWEIGHT ON RISK OF VENOUS THROMBOEMBOLISM. Tine Lnneberg Received Received
  568-WED-PO IMPACT OF THE ABO RS8176719 SINGLE NUCLEOTIDE POLYMORPHISM ON CANCER-RELATED VENOUS THROMBOEMBOLISM Olga Dziewiecka Received Received
  568-TUE-PO CLINICAL AND BIOCHEMICAL STUDIES OF TWO PATIENTS WITH ACUTE THROMBOTIC THROMBOCYTOPENIC PURPURA TREATED WITH N-ACETYLCYSTEINE Junmei Chen Received Received
  570-MON-PO QUANTIFICATION OF CELL FREE DNA IN RED BLOOD CELL CONCENTRATES PRODUCED VIA BUFFY COAT (B1) OR WHOLE BLOOD (B2) METHODS Andrew Shih Received Received
  570-WED-PO NEUTROPHILS AND FACTOR XII , UNLIKE PLATELETS, ARE NOT CRUCIAL FOR DEVELOPMENT OF EXPERIMENTAL SPONTANEOUS VENOUS THROMBOSIS Marco Heestermans Received Received
  571-MON-PO RESPONSIVENESS OF PLATELETS DURING STORAGE STUDIED WITH FLOW CYTOMETRY FORMATION OF PLATELET SUBPOPULATIONS AND LAMP-1 AS NEW MARKERS FOR THE PLATELET STORAGE LESION Anna Sdergren Received Received
  571-TUE-PO OBESITY AS A RISK FACTOR FOR THE DEVELOPMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN ADAMTS13 DEFICIENT MICE Elien Roose Received Received
  572-WED-PO DIFFERENTIAL EXPRESSION OF MIRNAS IN PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS COLLECTED FROM PATIENTS WITH UNPROVOKED VENOUS THTOMBOEMBOLISM AND HEALTHY CONTROL INDIVIDUALS Irina Starikova Received Received
  572-TUE-PO A MULTICENTER, RANDOMIZED STUDY OF CYCLOSPORINE OR CORTICOSTEROIDS AS AN ADJUNCT TO PLASMA EXCHANGE IN INITIAL THERAPY OF THROMBOTIC THROMBOCYTOPENIC PURPURA Spero Cataland Received Received
  572-MON-PO PRESERVED ULTRASTRUCTURE AND BIOCHEMICAL CHARACTERISTICS OF PLATELET COMPONENTS PREPARED WITH AMOTOSALEN AND UVA FOR PATHOGEN INACTIVATION Beatrice Hechler Received Received
  574-MON-PO RELATIVE EFFECTS OF FRESH FROZEN PLASMA, FIBRINOGEN CONCENTRATE, AND FACTOR XIII IN MASSIVE TRANSFUSION REGIMENS: A LABORATORY STUDY David Schmidt Received Received
  576-MON-PO PROTHROMBIN ACTIVATION IN PACKED RED BLOOD CELL UNITS OVER THEIR STORAGE LIFETIME Thomas Orfeo Received Received
  576-TUE-PO INCORPORATION OF RIGHT VENTRICULAR DYSFUNCTION INTO THE SIMPLIFIED PULMONARY EMBOLISM SEVERITY INDEX AS A PREDICTOR OF COMPLICATED CLINICAL COURSE IN LOW-RISK PATIENTS PRESENTING WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM David Jimenez Received Received
  577-TUE-PO RADIATION AND BREAST CANCER RISK IN WOMEN DIAGNOSED WITH PULMONARY EMBOLISM: CT PULMONARY ANGIOGRAPHY VERSUS VENTILATION-PERFUSION SCANNING Vicky Tagalakis Received Received
  578-MON-PO NEURO-IMAGING DOES NOT CORRELATE WITH DISEASE SEVERITY IN ACUTE THROMBOTIC THROMBOCYTOPENIA PURPURA (TTP), BUT MAY PREDICT LONG TERM SEQUELAE. Indrani Karpha Received Received
  578-WED-PO SECONDARY THROMBOPROPHYLAXIS WITH RIVAROXABAN IN MAJOR INHERITED THROMBOPHILIAS Karen Schreiber Received Received
  578-TUE-PO RISK-ASSESSMENT MODEL OF RECURRENCE WITHIN 3 MONTHS AFTER A FIRST EPISODE OF ACUTE VENOUS THROMBOEMBOLISM: WORCESTER VENOUS THROMBOEMBOLISM STUDY Wei Huang Received Received
  579-WED-PO MONITORING DRUG ACTIVITY OF DABIGATRAN AND RIVAROXABAN BY THROMBIN GENERATION USING THE CALIBRATED AUTOMATED THROMBINOSCOPE. Andrés Moret Received Received
  579-MON-PO PHASE II STUDY OF DANAZOL WITH PLASMA EXCHANGE AND CORTICOSTEROIDS FOR THE TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA Vamsee Torri Received Received
  579-TUE-PO PERFORMANCE OF PULMONARY EMBOLISM RULE-OUT CRITERIA (PERC) COMBINED WITH LOW GESTALT CLINICAL PROBABILITY IN EUROPEAN CHEST PAIN POPULATION Emilie Friou Received Received
  580-TUE-PO AN ELECTRONIC TOOL AND RECORD FOR DEEP VEIN THROMBOSIS (DVT) ASSESSMENT, DIAGNOSIS, TREATMENT AND FOLLOW UP. jo eggleston Received Received
  580-WED-PO DIFFERENT PATTERNS OF THROMBOPHILIA MARKERS IN PREGNANCY COMPLICATIONS Gabriella Gamba Received Received
  581-MON-PO CHARACTERIZATION OF SINGLE SORTED ANTI-ADAMTS13 SPECIFIC B CELLS FROM THE SPLEEN OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) PATIENTS Magdalena Skowronska Received Received
  581-TUE-PO VALIDATION OF THE USE OF AGE ADJUSTED D DIMER CUT OFF VALUES TO REDUCE THE COMPRESSION VENOUS ULTRASOUND RATES IN AN ACUTE AMBULATORY DVT SERVICE Jane Strong Received Received
  582-TUE-PO THE USE OF AN AGE-ADJUSTED CUT-OFF FOR D-DIMER IN SCREENING PATIENTS FOR SUSPECTED DVT IN THE COMMUNITY CAN SAFELY DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY. Andrew Hughes Received Received
  582-WED-PO TOWARDS IDENTIFICATION OF GENETIC RISK FACTORS IN TWO DUTCH FAMILIES WITH UNEXPLAINED HEREDITARY VENOUS THROMBOEMBOLISM Marisa Cunha Received Received
  582-MON-PO THE NATURAL MUTATION ASP173GLY IN THE CATALYTIC SITE OF THE ADAMTS-13 GENE CAUSES A SEVERE UPSHAW-SCHLMAN SYNDROME: CLINICAL COURSE, BIOCHEMISTRY AND MOLECULAR DYNAMICS INVESTIGATION Stefano Lancellotti Received Received
  583-WED-PO RECURRENT VENOUS THROMBOEMBOLISM DURING PREGNANCY IN WOMEN WITH QUANTITATIVE ANTITHROMBIN DEFICIENCY WITH OR WITHOUT ANTITHROMBOTIC PROPHYLAXIS Serena Maria Passamonti Received Received
  583-TUE-PO DIAGNOSTIC PREDICTION MODEL VERSUS GESTALT IN THE DIAGNOSIS OF PULMONARY EMBOLISM IN PRIMARY CARE Janneke Hendriksen Received Received
  584-TUE-PO CLINICAL PREDICTION RULES PLUS D-DIMER TESTING DO NOT ENABLE A SAFE EXCLUSION OF DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM IN ELDERLY PATIENTS RESIDING IN NURSING HOMES OF HOMES FOR THE ELDERLY. Geert-Jan Geersing Received Received
  584-WED-PO MOLECULAR ANALYSIS OF PROTEIN S DEFICIENCY IN THAILAND Ponlapat Rojnuckarin Received Received
  585-WED-PO INHERITED THROMBOPHILIA AS A HIGH RISK FACTOR OF RECURRENT PREGNANCY LOSS IN GEORGIAN POPULATION Nino Pirtskhelani Received Received
  586-WED-PO DO ENDOTHELIUM-RELATED GENES AND INHERITED THROMBOPHILIA INTERACT IN INCREASING PREGNANCY LOSS RISK? Ilaria Romagnuolo Received Received
  588-TUE-PO REVIEW OF EMERGENCY DEPARTMENT INVESTIGATED DVT ROSEMARY LAVERY Received Received
  588-WED-PO OBSTETRIC HISTORY, COURSE OF PREGNANCY AND LABOUR OF PATIENTS WITH MTHFR MUTATION CASE REPORT AND LITERATURE REVIEW Justyna Magdalena Teliga-Czajkowska Received Received
  589-TUE-PO PREVALENCE OF VENOUS THROMBOEMBOLISM & RELATED MORBIDITY AND MORTALITY AMONG HOSPITALIZED PATIENTS IN SAUDI ARABIA (SAVTE STUDY) essam aboelnazar Received Received
  590-TUE-PO BELOW KNEE DEEP VEIN THROMBOSIS (BKDVT): A BENIGN ENTITY OR NOT? Prahlad Ho Received Received
  590-MON-PO A CASE OF THROMBOTIC MICROANGIOPATHY WITH CFH GENE ALTERATIONS THAT ARE NOT ASSOCIATED WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME yesim oymak Received Received
  591-MON-PO SEVERE FIRST MANIFESTATION OF TTP IN A 96-YEAR-OLD FEMALE Inge Scharrer Received Received
  591-TUE-PO ETIOLOGY OF PORTAL VENOUS THROMBOSIS AND BUDD-CHIARI SYNDROME IN ADULTS ANIL TOMBAK Received Received
  591-WED-PO EXPLOITING THE BIOLOGY OF TISSUE FACTOR PATHWAY INHIBITOR: PROSPECT FOR FUTURE THERAPEUTIC TARGETS. Samuel Abegunde Received Received
  592-TUE-PO INCIDENCE OF CATHETER-RELATED VENOUS THROMBOEMBOLISM EVENTS IN ACUTE LEUKEMIA PATIENTS; A RETROSPECTIVE STUDY OF THE SAFETY OF PERIPHERALLY-INSERTED CENTRAL CATHETER. Mohammad Refaei Received Received
  593-TUE-PO EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN THE FRAMINGHAM HEART STUDY Marja Puurunen Received Received
  594-WED-PO COMPREHENSIVE ASSESSMENT OF THE SAFETY AND EFFICACY OF FACTOR VIIA-CTP SUPPORTING PHASE 2A STUDY Lior Binder Received Received
  594-TUE-PO IMPACT OF INCIDENT STROKE ON FUTURE RISK OF VENOUS THROMBOEMBOLISM Ludvig Balteskard Rinde Received Received
  594-MON-PO THE NEW CLINICAL PREDICTION SCORE FOR DIAGNOSIS OF LOWER LIMB DEEP VEIN THROMBOSIS IN UNSELECTED POPULATION OF OUTPATIENTS AND INPATIENTS Nuttawut Sermsathanasawadi Received Received
  595-WED-PO FACTOR VIIA-CTP, A LONG-ACTING COAGULATION FACTOR PROPOSING A NOVEL SUBCUTANEOUS (SC) ROUTE OF ADMINISTRATION FOR PROPHYLACTIC TREATMENT EFFICACY AND SAFETY IN PREPARATION FOR FIRST IN HUMAN STUDY. Lior Binder Received Received
  595-MON-PO OVER-REPRESENTATION OF SEVERE SUBCLAVIAN VEIN OCCLUSION IN THE AFFECTED ARM, COMPARED WITH THE CONTRALATERAL ARM, IN PATIENTS WITH UNPROVOKED UNILATERAL UPPER EXTREMITY DEEP VEIN THROMBOSIS Shuoyan Ning Received Received
  595-TUE-PO EVALUATING THE ACCURACY OF INTERNATIONAL CLASSIFICATION OF DISEASES 10TH REVISION CODES FOR VENOUS THROMBOEMBOLISM (VTE) AND MAJOR BLEEDING (MB) IN EMERGENCY ROOM (ER) DISCHARGES Fatimah Al-Ani Received Received
  596-MON-PO Performance of the Age-Adjusted D-dimer Threshold for Suspected Pulmonary Embolism in Clinically Relevant Subgroups: an Individual Patient Data Meta-Analysis of 7,000 Patients Nick van Es Received Received
  597-TUE-PO CEREBRAL VENOUS THROMBOSIS: A LONGITUDINAL FOLLOW UP Maria T DeSancho Received Received
  597-MON-PO A SIMPLE DECISION RULE INCLUDING THE D-DIMER TEST TO REDUCE THE NEED FOR CT-SCANNING IN PATIENTS WITH SUSPECTED PULMONARY EMBOLISM Josien van Es Received Received
  598-MON-PO ACCURACY OF X-RAY WITH PERFUSION SCAN IN YOUNG PATIENTS WITH SUSPECTED PULMONARY EMBOLISM Josien van Es Received Received
  599-MON-PO DEVELOPMENT OF ELISA SYSTEM FOR DETECTION OF PROTEIN S K196E MUTATION, A GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM keiko maruyama Received Received
  600-TUE-PO LONG-TERM HEALTH-RELATED QUALITY OF LIFE AFTER DEEP VEIN THROMBOSIS IS IMPAIRED COMPARED TO CONTROLS. Kristin Utne Received Received
  600-MON-PO MODIFIED COMPUTER-ASSISTED STRAIN GAUGE PLETHYSMOGRAPHY AS A SIMPLE SCREENING TEST FOR PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: A COHORT STUDY. Andrew Hughes Received Received
  601-MON-PO MODIFIED STRAIN GAUGE PLETHYSMOGRAPHY CAN DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS: A RETROSPECTIVE MULTICENTRE COHORT STUDY. Andrew Hughes Received Received
  601-WED-PO DOSE-RELATED PULMONARY COMPLICATION RATES AFTER FRESH FROZEN PLASMA ADMINISTRATION FOR WARFARIN REVERSAL Ariela Marshall Received Received
  602-MON-PO ULTRASOUD DIAGNOSTIC CRITERIA AND CLOT DIAMETERS OF ISOLATED DISTAL DEEP VENOUS THROMBOSIS Michelangelo Sartori Received Received
  602-TUE-PO RECENT DISCHARGE CONFERS RISK FOR VENOUS THROMBOEMBOLISM Hiren Shah Received Received
  603-MON-PO OUTCOME OF SCREENING FOR OCCULT MALIGNANCY IN PATIENTS PRESENTING WITH UNPROVOKED VENOUS THROMBOEMBOLISM AT A LARGE TERTIARY HOSPITAL IN CENTRAL LONDON Anne Mwirigi Received Received
  604-WED-PO PHOSPHATIDYLINOSITOL-3-KINASE IS IMPAIRED FOLLOWING AMOTOSALEN AND ULTRAVIOLET A LIGHT TREATMENT OF PLATELETS IN CONCENTRATES FOR TRANSFUSION Hendrik Feys Received Received
  605-TUE-PO PREDICTION OF THE BLEEDING RISK DURING ANTICOAGULATION TREATMENT FOR PULMONARY THROMBOEMBOLISM Zhenguo Zhai Received Received
  605-MON-PO VENOUS THROMBOEMBOLISM IN NORTHEAST MELBOURNE, AUSTRALIA: EVALUATION OF EPIDEMIOLOGY, RISK FACTORS AND TREATMENT STRATEGIES IN THE WARFARIN ERA. Prahlad Ho Received Received
  606-TUE-PO RECURRENCES AFTER STOPPING ANTICOAGULANT THERAPY IN THAI PATIENTS WITH NON CANCER-RELATED VENOUS THROMBOEMBOLISM Pitiphong Kijrattanakul Received Received
  606-MON-PO LOW INCIDENCE OF DEEP VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN AN ASIAN POPULATION Seok Wei, Stephrene Chan Received Received
  606-WED-PO PLATELETS ARE DISPENSABLE DURING THE INITIAL STEPS OF IMMUNOLOGICAL TRANSFUSION RELATED ACUTE LUNG INJURY (TRALI) Beatrice Hechler Received Received
  608-WED-PO RAPID ASSESSMENT OF PLATELET FUNCTION UNDER FLOW FOLLOWING TRAUMA & RECAPITULATION OF TRAUMA-INDUCED COAGULOPATHY IN WHOLE BLOOD MICROFLUIDIC ASSAYS Ruizhi Li Received Received
  609-TUE-PO SHOULD WE USE VENOUS THROMBOEMBOLISM PROPHYLAXIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING CHEMOTHERAPY? Adam Wiszniewski Received Received
  609-MON-PO TIME TRENDS IN INCIDENCE RATES OF VENOUS THROMBOEMBOLISM IN A LARGE COHORT RECRUITED FROM THE GENERAL POPULATION Nadia Arshad Received Received
  609-WED-PO MONITORING PLATELET TRANSFUSION IN THROMBOCYTOPENIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES MEASURED BY THROMBOELASTOMETRY: A PILOT STUDY. Floor Moenen Received Received
  610-TUE-PO LOW-RISK PULMONARY EMBOLISM AND LENGTH OF HOSPITAL-STAY: THE LORPELHS STUDY marco donadini Received Received
  610-MON-PO POOR SELF-RATED HEALTH IS ASSOCIATED WITH FUTURE RISK OF VENOUS THROMBOEMBOLISM IN WOMEN. THE TROMSO STUDY. Sigrid Braekkan Received Received
  611-TUE-PO ANTITHROMBOTIC TREATMENT AND OUTCOMES OF NON-MALIGNANT NON-CIRRHOTIC SPLANCHNIC VEIN THROMBOSIS: A SUB-ANALYSIS FROM THE ISTH REGISTRY Nicoletta Riva Received Received
  611-MON-PO ORAL AND INHALED CORTICOSTEROID USE IS ASSOCIATED WITH RECURRENT PULMONARY EMBOLISM Marlous Sneeboer Received Received
  612-WED-PO ASPHYXIA BY DROWNING INDUCES MASSIVE BLEEDING DUE TO HYPERFIBRINOLYTIC DISSEMINATED INTRAVASCULAR COAGULATION Michael Schwameis Received Received
  612-MON-PO CASE FATALITY AND RECURRENCE RATES AFTER FIRST VENOUS THROMBOEMBOLISM IN A LARGE POPULATION-BASED COHORT Nadia Arshad Received Received
  613-WED-PO THE STABILITY OF FVIII:C, VON WILLEBRAND FACTOR AND FIBRINOGEN IN FFP AND CRYOPRECIPITATE IN THAI BLOOD DONORS Theera RUCHUTRAKOOL Received Received
  614-MON-PO NATURAL HISTORY AND ANTITHROMBOTIC TREATMENT OF INCIDENTALLY DETECTED SPLANCHNIC VEIN THROMBOSIS: FINDINGS FROM THE ISTH REGISTRY Nicoletta Riva Received Received
  614-TUE-PO INFLUENCE OF VKA-POTENTIATING DRUGS ON OVER-ANTICOAGULATION IN ATRIAL FIBRILLATION Stijn van Vugt Received Received
  614-WED-PO INFUSION OF CRYOPRESERVED POOLED PLATELETS IN PATIENTS WITH ACUTE LEUKEMIA: PRELIMINARY RESULTS OF A CLINICAL TRIAL (NCT02032134) mariasanta Napolitano Received Received
  615-WED-PO MASSIVE HAEMORRHAGE MANAGEMENT: FROM CHAOS TO ORDER. LEGNANO HOSPITALS EXPERIENCE. Chiara Novelli Received Received
  615-MON-PO DEEP VEIN THROMBOSIS IN SEPTIC PATIENTS IN THE INTENSIVE CARE UNIT Vaia Florou Received Received
  615-TUE-PO AGREEMENT OF POINT-OF-CARE INR TEST WITH STANDARD VENOUS SAMPLING ASSAY AT HIGHER EXTREME RANGES Yi Feng Lai Received Received
  616-WED-PO INTERVENTIONS TO REDUCE BLOOD LOSS FROM LABORATORY TESTING IN CRITICALLY ILL PATIENTS AND IMPACT ON TRANSFUSION: A SYSTEMATIC REVIEW Deborah Siegal Received Received
  616-TUE-PO IN ANTICOAGULATION TREATMENT WITH VITAMIN K ANTAGONISTS (AVKS): WHICH IS THE BEST MONITORING TEST? alicia vilaseca Received Received
  617-WED-PO COMPARISON OF THE EFFECT OF FRESH FROZEN PLASMA PRE- AND POST-TRANSFUSION IN ITU PATIENTS ON STANDARD AND GLOBAL COAGULATION ASSAYS Emma Fosbury Received Received
  617-TUE-PO COMPARISON OF RISK FACTORS FOR WARFARIN-ASSOCIATED BLEEDING Muzaffer Demir Received Received
  618-TUE-PO EXPANDING TELEMEDICINE TO MEDICAL HOMES FOR COMPREHENSIVE CARE DELIVERY FOR PERSONS WITH HEMOSTATIC DISORDERS: A PILOT STUDY OF THE AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK (ATHN)/NATIONAL HEMOPHILIA PROGRAM COORDINATING CENTER (NHPCC). Roshni Kulkarni Received Received
  619-MON-PO A CANADIAN CONSENSUS ON VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS PREVENTION IN THORACIC SURGERY, A NATIONAL DELPHI CONSENSUS SURVEY Yaron Shargall Received Received
  619-WED-PO DERIVATION OF A NEW SCORE TO PREDICT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION AFTER ACUTE PULMONARY EMBOLISM Erik Klok Received Received
  620-WED-PO THE PREVALENCE OF DEEP VEIN THROMBOSIS IN HOSPITALIZED PATIENTS WITH SUSPECTED PULMONARY EMBOLISM RULED OUT BY MULTISLICE CT ANGIOGRAPHY Fernando Vazquez Received Received
  620-MON-PO ADHERENCE TO INTERNATIONAL GUIDELINES IN TREATMENTOF THROMBOEMBOLIC EVENTS IN CANCER PATIENTS: AHOSPITAL-BASED COHORT STUDY IN PARIS, FRANCE Isabelle MAHE Received Received
  621-TUE-PO ASSESSMENT OF THE TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS BY SPECIALISTS IN HAEMOSTASIS IN ARGENTINA. THE TERRA REGISTRY. JOSE CERESETTO Received Received
  622-TUE-PO RESULTS FROM THE PROSPECTIVE FARMAMICO STUDY: INR VARIATIONS IN WARFARIN-TREATED PATIENTS UNDERGOING ANALGESIC AND ANTI-INFLAMMATORY THERAPIES Laura Russo Received Received
  624-MON-PO LONG-TERM USE OF LOW-MOLECULAR-WEIGHT HEPARINS (LMWH) FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (CAT): FACTORS ASSOCIATED WITH NON-COMPLIANCE WITH TREATMENT RECOMMENDATIONS (NCTR) IN CLINICAL PRACTICE. Vidal Benatar Received Received
  624-TUE-PO WHAT BLEEDINGS PREDICT HAS-BLED AND HEMORR2HAGES SCALES IN PATIENTS ON LONG-TERM WARFARIN THERAPY? Olga Moreva Received Received
  624-WED-PO Performance of a Diagnostic Strategy Using a Clinical Decision Rule and D-dimer Testing to Exclude Upper Extremity Deep Vein Thrombosis (UEDVT) in Clinically Important Subgroups Nick van Es Received Received
  625-TUE-PO VITAMIN K ANTAGONISTS FAVORABLY MODULATE FIBRIN CLOT PROPERTIES IN PATIENTS WITH ATRIAL FIBRILLATION AS EARLY AS AFTER 3 DAYS OF TREATMENT: RELATION TO COAGULATION FACTORS AND THROMBIN GENERATION Michal Zabczyk Received Received
  626-TUE-PO PREVALENCE OF ANEMIA IN PATIENTS UNDER TREATMENT WITH VITAMIN K ANTAGONISTS Maria Faria Received Received
  626-MON-PO ACUTE PULMONARY EMBOLISM: EXTERNAL VALIDATION OF THE 2014 RISK STRATIFICATION MODEL OF THE EUROPEAN SOCIETY OF CARDIOLOGY Cecilia Becattini Received Received
  627-WED-PO RELATIONSHIP OF PATIENT AFFECT TO CLINICIAN-DERIVED PRETEST PROBABILITY ASSESSMENT FOR PULMONARY EMBOLISM Jeff Kline Received Received
  627-MON-PO RISK FACTORS FOR RECURRENCE AND THROMBOEMBOLIC EVENTS AFTER ISOLATED SUPERFICIAL VEIN THROMBOSIS OF LOWER LIMBS Michelangelo Sartori Received Received
  627-TUE-PO GENETIC VARIATIONS IN EXON 28 OF VON WILLEBRANDS FACTOR GENE IN NIGERIAN POPULATION Eyiuche Ezigbo Received Received
  628-MON-PO EFFICACY AND SAFETY OF TREATMENT WITH ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA Hun Gyu Hwnag Received Received
  628-WED-PO CURRENT PRACTICES IN LUNG SCINTIGRAPHY FOR PULMONARY EMBOLISM (PE) DIAGNOSIS: AN INTERNATIONAL SURVEY IN AUSTRALIA, CANADA AND FRANCE Pierre-Yves Le Roux Received Received
  629-MON-PO PREVALENCE OF VKORC-1 POLYMORPHISMS ACROSS CAUCASIANS AND AMERINDIANS Maria Paula Vera Morandini Received Received
  629-WED-PO COMPARISON OF RISK FACTORS AND OUTCOMES ASSOCIATED WITH COMMUNITY (CAT) VERSUS HOSPITAL ACQUIRED THROMBOSIS (HAT). Huw Rowswell Received Received
  630-WED-PO ASSOCIATION BETWEEN VENOUS THROMBOEMBOLISM (VTE) MINOR RISK FACTORS AND THE RISK OF RECURRENCE AFTER A FIRST UNPROVOKED EPISODE Luana Farren-Dai Received Received
  630-TUE-PO VON WILLEBRAND DISEASE AND MENORRHAGIA: MULTIPLE TREATMENT OPTIONS FOR DIFFERENT PATIENTS KAAN KAVAKLI Received Received
  631-WED-PO DO PATIENTS WHO EXPERIENCED VENOUS THROMBOEMBOLISM DESPITE THROMBOPROPHYLAXIS DURING A MEDICAL IMMOBILIZATION HAVE A WORSE OUTCOME ? Laurent BERTOLETTI Received Received
  631-MON-PO SUSCEPTIBILITY OF VKORC1 AND ITS PARALOG VKORC1L1 TOWARDS DIFFERENT 4-HYDROXYCOUMARINS Kerstin Liphardt Received Received
  632-WED-PO DISCREPANCIES IN SEVERE RI SCREENING IN THE ELDERLY WITH COCKCROFT-GAULT AND MDRD FORMULAS: 20 OF PATIENTS ARE MISEVALUATED. Nicolas Janus Received Received
  632-TUE-PO PERCENTAGE OF PLATELET AGGREGATES AND MACROPLATELETS: A POTENTIAL USEFUL LABORATORY PARAMETER FOR PREDICTING BLEEDING IN VON WILLEBRAND DISEASE TYPE 2B (VWD2B) WITH THE P.VAL1361MET MUTATION Hugo A. Guglielmone Received Received
  633-TUE-PO DEVELOPMENT OF APLASTIC ANEMIA IN A PATIENT WITH ACQUIRED VON WILLEBRANDS SYNDROME AND AUTOIMMUNE PREPONDERANCE Arief Gunawan Received Received
  633-WED-PO ASSOCIATION BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF VENOUS THROMBOEMBOLISM Paolo Bucciarelli Received Received
  633-MON-PO CLINICAL AUDIT OF ANTICOAGULATION REVERSAL AND OUTCOME IN WARFARIN-ASSOCIATED INTRACRANIAL HAEMORRHAGE Danielle Blunt Received Received
  634-MON-PO EFFECT OF INR PRECISION AND ACCURACY ON THERAPEUTIC QUALITY CONTROL IN PATIENTS RECEIVING VITAMIN K-ANTAGONISTS Anton Van den Besselaar Received Received
  634-TUE-PO RELATIONSHIP BETWEEN BLEEDING TENDENCY AND THE AFFECTED DOMAIN WITH MUTATIONS RESPONSIBLE OF VWD2M PHENOTYPE Adriana Woods Received Received
  635-TUE-PO CHARACTERIZATION OF VON WILLEBRAND DISEASE SUBTYPES IN 303 PATIENTS - A SINGLE CENTRE STUDY OVER THE PAST 10 YEARS Anil Pathare Received Received
  636-WED-PO IMPACT OF WEIGHT CHANGE ON RISK OF VENOUS THROMBOEMBOLISM: THE TROMSO STUDY Lars Horvei Received Received
  636-TUE-PO VWD2B PHENOTYPE: ITS PREVALENCE WITHIN FAMILIES AND BLEEDING TENDENCY IN AFFECTED MEMBERS Adriana Woods Received Received
  637-MON-PO ANTAGONIZATION OF WARFARIN IN CELLS: WARFARIN BINDING ON HUMAN VKORC1 IS REVERSIBLE Katrin Czogalla Received Received
  638-WED-PO CASE-FATALITY AFTER PULMONARY EMBOLISM AND STROKE IN SUBJECTS WITH ATRIAL FIBRILLATION Ina Rye-Holmboe Received Received
  638-TUE-PO TWO UNUSUAL CASES OF TYPE 2N VON WILLEBRAND DISEASE. PATRICIA BIGNELL Received Received
  639-MON-PO RISK FACTORS FOR GASTRO-INTESTINAL BLEEDING IN ATRIAL FIBRILLATION PATIENTS ON VKA TREATMENT: PROSPECTIVE ANALYSIS OF TWO COHORTS OF PATIENTS Daniela Poli Received Received
  640-MON-PO PREDICTORS OF ICH RECURRENCE ON VKA: SEVERITY OF THE FIRST EPISODE AND HASBLED SCORE FAIL TO IDENTIFY HIGH RISK PATIENTS FROM THE CHIRONE STUDY Daniela Poli Received Received
  640-TUE-PO POOR RESPONSE TO 1-DESAMINO-8-D ARGININE VASOPRESSIN (DDAVP) TEST IN A PATIENT WITH VON WILLEBRAND DISEASE TYPE 2M (VWD2M) WITH P.GLU1549LYS MUTATION Hugo A. Guglielmone Received Received
  641-TUE-PO ALLELE-SPECIFIC SILENCING OF THE VON WILLEBRAND FACTOR GENE TO AMELIORATE THE VON WILLEBRAND DISEASE PHENOTYPE Annika de Jong Received Received
  642-WED-PO INHOSPITAL MORTALITY AMONG CLINICAL AND SURGICAL INPATIENTS RECENTLY DIAGNOSED WITH VENOUS THROMBOEMBOLIC DISEASE Fernando Vazquez Received Received
  642-TUE-PO EVALUATION OF A NEW AUTOMATED RISTOCETIN COFACTOR ASSAY ON THE STA-R EVOLUTION ANALYZER Jasper Remijn Received Received
  643-TUE-PO HOW WELL CAN LABORATORIES DIAGNOSE TYPE 2N VWD? DATA FROM A UK NEQAS (BLOOD COAGULATION) EXERCISE. Ian Jennings Received Received
  643-WED-PO Low Prevalence of Symptomatic Venous Thromboembolism After Hip and Knee Arthroplasty Without Medical Thromboprophylaxis Among Thai Patients at Siriraj Hospital Chompunut Wongprasert Received Received
  644-WED-PO THE PREVALENCE AND DIAGNOSTIC CHARACTERISTICS OF PATIENTS WITH ANTIPHOSHOLIPID ANTIBODIES IN CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION William Auger Received Received
  645-MON-PO Ruling out von Willebrand Disease in preoperative patients with bleeding symptoms Minka Vries Received Received
  646-WED-PO DABIGATRAN OR WARFARIN IN THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN ANTIPHOSPHOLIPID SYNDROME Sam Schulman Received Received
  646-TUE-PO CLINICAL AND LABORATORY DETECTION OF TRANSIENT NEUTRALIZING ANTIBODIES IN SEVERE VON WILLEBRAND DISEASE ON LONG TERM PROPHYLAXIS Analía Sánchez-Luceros Received Received
  647-WED-PO MULTICENTER PROSPECTIVE STUDY OF TREATMENT AND RISK FACTORS FOR UNUSUAL SITE THROMBOSIS: TRUST REGISTRY Kim Ma Received Received
  647-TUE-PO VON WILLEBRAND DISEASE: THE PHENOTYPIC CHARACTERIZATION IN THAILAND Theera RUCHUTRAKOOL Received Received
  649-WED-PO RIVAROXABAN VERSUS VITAMIN K ANTAGONIST IN PROVOKED DEEP VENOUS THROMBOSIS - WHICH TREATMENT IS BETTER FOR THE PATIENT ? Emma Groarke Received Received
  649-MON-PO NEW INSIGHTS INTO TYPE 3 VON WILLEBRAND DISEASE: THE TYPE 3 VON WILLEBRAND DISEASE INTERNATIONAL REGISTRIES AND INHIBITOR PROSPECTIVE STUDY (3WINTERS-IPS) PROJECT UPDATE LUCA MARAVIGNA Received Received
  649-TUE-PO IDENTIFICATION OF NOVEL VWF GENE MUTATIONS IN THE TURKISH TYPE 2 VWD PATIENT POPULATION Ergul berber Received Received
  650-WED-PO WARFARIN DOSING AND TIME TO THERAPUTIC INTERNATIONAL NORMALIZED RATIO IN PATIENTS WITH HYPERCOAGULABILITY SYNDROMES Pushpinderdeep Kahlon Received Received
  650-TUE-PO CANCERS IN PATIENTS WITH VON WILLEBRAND DISEASE: A SURVEY FROM THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES Giancarlo Castaman Received Received
  651-MON-PO OVERDOSING OF REPLACEMENT THERAPY IN PERIOPERATIVE VON WILLEBRAND PATIENTS: A LOT TO WIN Hilde Veerman Received Received
  651-WED-PO SAFETY OF STOPPING ANTICOAGULANT TREATMENT FOR CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM AFTER REACHING COMPLETE REMISSION FROM CANCER Tom van der Hulle Received Received
  651-TUE-PO MODIFICATIONS OF HEMOSTATIC THERAPY FOR PATIENTS WITH VON WILLEBRAND DISEASE BASED ON COMORBIDITY Nadezhda Zozulya Received Received
  652-TUE-PO ACQUIRED VON WILLEBRAND SYNDROME (AVWS) WITH A TYPE 2B PHENOTYPE SECONDARY TO AN IGA AUTOANTIBODY WITH ANTI-VON WILLEBRAND FACTOR ACTIVITY. Analía Sánchez-Luceros Received Received
  652-WED-PO PROLONGED USE OF LMWH DURING PREGNANCY AND BONE SAFETY Pivi Galambosi Received Received
  653-TUE-PO ACCUIRED VON WILLEBRAND SYNDROME IN PATIENTS TREATED WITH LEFT VENTRICULAR ASSIST DEVICES Kenki Saito Received Received
  653-MON-PO THE USE OF NEXT-GENERATION SEQUENCING TO SCREEN FOR DISORDERS OF COAGULATION USING A 24 GENE PANEL. PATRICIA BIGNELL Received Received
  654-TUE-PO DENTAL INVASIVE PROCEDURES IN VON WILLEBRAND DISEASE (VWD) OUTPATIENTS TREATED WITH HIGH PURITY VWF/FVIII COMPLEX CONCENTRATE: EXPERIENCE OF A SINGLE CENTER. Valeria De Padua Received Received
  654-MON-PO COURSE OF VON WILLEBRAND FACTOR (VWF) DURING PREGNANCY IN WOMEN WITH VON WILLEBRAND DISEASE (VWD) Carsten Detering Received Received
  655-MON-PO IDENTIFICATION OF LARGE VWF GENE DELETIONS AND DUPLICATIONS BY MLPA IN THE SOUTH MORAVIAN (CZECH REPUBLIC) VWD COHORT IN THE BRNO-VWD STUDY Inge Vangenechten Received Received
  656-TUE-PO LONG TERM EXERCISE SIGNIFICANTLY DECREASES VON WILLEBRAND FACTOR ANTIGEN LEVELS IN ABDOMINALLY OBESE ADULTS Cynthia Pruss Received Received
  656-MON-PO BASELINE FACTOR VIII PLASMA LEVELS AND AGE AT FIRST BLEEDING IN PATIENTS WITH SEVERE FORMS OF VON WILLEBRAND DISEASE Simona Maria Siboni Received Received
  657-MON-PO TYPE 1 VWD DOES NOT LEAD TO INCREASED GINGIVAL BLEEDING Wolfgang Miesbach Received Received
  657-TUE-PO DEVELOPMENT OF A VWF PROPEPTIDE ASSAY Muriel Meiring Received Received
  658-MON-PO JOINT SURGERY IN MODERATE AND SEVERE VON WILLEBRAND DISEASE: A CROSS-SECTIONAL STUDY. Roger Schutgens Received Received
  658-TUE-PO CROSS-SPECIES INHIBITION OF HUMAN AND MURINE VON WILLEBRAND FACTOR BY A SINGLE DOMAIN VHH-ANTIBODY Ibrahim HABIB Received Received
  658-WED-PO GLOBAL ADHERENCE TO AMERICAN COLLEGE OF CHEST PHYSICIANS GUIDELINES FOR THROMBOPROPHYLAXIS AFTER MAJOR ORTHOPEDIC SURGERY. HAVE WE IMPROVED? A SYSTEMATIC REVIEW OF THE LITERATURE MIGUEL ANDRES FARFAN AYALA Received Received
  659-TUE-PO HIGH ACTIVITY OF VON WILLEBRAND FACTOR AND LEVELS OF VWF-CLEAVING PROTEASE (ADAMTS-13) IN TERM AND PRETERM NEONATES Tzipora Strauss Received Received
  660-TUE-PO ANGIOGENIC CHARACTERISTICS OF BLOOD OUTGROWTH ENDOTHELIAL CELLS FROM PATIENTS WITH VON WILLEBRAND DISEASE Dafna Groeneveld Received Received
  661-MON-PO TOTAL THROMBUS-FORMATION ANALYSIS SYSTEM (T-TAS) FOR THE MONITORING OF VON WILLEBRAND FACTOR-FVIII CONCENTRATE TREATMENT IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 3. Anna gren Received Received
  662-TUE-PO VON WILLEBRAND FACTOR TO MONITOR PERCUTANEOUS AORTIC VALVE INTERVENTIONS Antoine Rauch Received Received
  662-WED-PO BIOMARKERS FOR PREDICTION OF REOCCURRENCE OF VENOUS THROMBOEMBOLISM Abimbola Jarvis Received Received
  663-TUE-PO PLATELET AND ENDOTHELIAL FUNCTION EVALUATION IN PEDIATRIC CHRONIC KIDNEY DISEASE (CKD) Luci Maria SantAna Dusse Received Received
  663-MON-PO PREDICTORS OF COMPLETE RESPONSE TO DDAVP IN PATIENTS WITH VON WILLEBRAND DISEASE eugenia biguzzi Received Received
  663-WED-PO MEDICATION ADHERENCE OF NOVEL ORAL ANTICOAGULANT VERSUS WARFARIN Yi Feng Lai Received Received
  664-TUE-PO FUNCTIONAL STUDY OF TWO NEW MUTATIONS IN THE C4 DOMAIN OF VON WILLEBRAND FACTOR Cecile Denis Received Received
  665-TUE-PO POSTOPERATIVE CHANGES IN VON WILLEBRAND FACTOR (VWF) AFTER ORTHOPAEDIC SURGERY IN HAEMOSTATICALLY HEALTHY PATIENTS Carsten Detering Received Received
  666-TUE-PO GENERATION OF REFERENCE INTERVALS FOR TWO AUTOMATED, NEW-GENERATION VON WILLEBRAND FACTOR ACTIVITY ASSAYS ON A LARGE DONOR POPULATION. Katarzyna Mayger Received Received
  667-TUE-PO EXPOSURE OF VON WILLEBRAND FACTOR (VWF) TO VORTEX SHEAR SIGNIFICANTLY ENHANCES ITS PROTEOLYSIS BY PLASMIN Teresa Brophy Received Received
  668-TUE-PO BELGIAN MULTICENTER STUDY INTO VON WILLEBRAND DISEASE (B-WILL STUDY): FIRST RESULTS Inge Vangenechten Received Received
  669-TUE-PO THE VON WILLEBRAND FACTOR A2 DOMAIN DISULFIDE BOND EXISTS IN OXIDIZED AND REDUCED STATES IN THE CIRCULATION AND REGULATES FUNCTION Philip Hogg Received Received
  669-MON-PO CO-OCCURRENCE OF V.WILLEBRAND DISEASE AND BERNARD SOULIER-SYNDROME Carl-Erik Dempfle Received Received
  669-WED-PO ACCURACY OF A WARFARIN MAINTENANCE DOSE PREDICTOR AFTER COMPLETION OF THE 10 MG INITIATION NOMOGRAM Parvaneh Fallah Received Received
  670-MON-PO IDENTIFICATION AND CHARACTERIZATION OF ABERRANT SPLICING FROM A NOVEL BRANCH SITE MUTATION IN VON WILLEBRAND FACTOR Lindsey Hawke Received Received
  670-WED-PO A NATIONAL ANTICOAGULANT MANAGEMENT SERVICE PROVIDED BY COMMUNITY PHARMACIES IN NEW ZEALAND ACHIEVES A HIGH LEVEL OF ANTICOAGULANT CONTROL Paul Harper Received Received
  671-TUE-PO REFERENCE VALUE OF VON WILLEBRAND FACTOR ACTIVITY BY IMMUNO-TURBIDIMETRY METHOD DHARMA RAHAJUNINGSIH Received Received
  671-WED-PO RECURRENT THROMBOTIC EVENTS AFTER DISCONTINUATION OF VITAMIN K ANTAGONIST TREATMENT FOR SPLANCHNIC VEIN THROMBOSIS: A MULTICENTER RETROSPECTIVE COHORT STUDY Nicoletta Riva Received Received
  671-MON-PO FUNCTIONAL LINK BETWEEN VON WILLEBRAND FACTOR (VWF) AND TISSUE FACTOR (TF) IN FLOW-DEPENDENT THROMBUS FORMATION: AUGMENTATION OF INTRA-THROMBUS FIBRIN GENERATION BY CATHEPSIN G ON VWF-TF COMPLEX Mitsuhiko Sugimoto Received Received
  672-TUE-PO ANALYSIS OF PLASMA VON WILLEBRAND FACTOR AND COMPLEMENT FACTOR H POLYMORPHISMS IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION Mariko Yamashita Received Received
  673-WED-PO SIMILAR PERFORMANCE OF HASBLED, CHADS2 AND CHA2DS2VASC SCORES IN BLEEDING RISK PREDICTION: DO WE NEED A BLEEDING SCORE? Daniela Poli Received Received
  673-MON-PO MIR-24 REGULATES VON WILLEBRAND FACTOR IN DIABETES YAOZU XIANG Received Received
  674-MON-PO THE FIRST CASE OF AN INTRON RETENTION RESULTING FROM A SILENT MUTATION IN THE VWF WHICH EXERTS A STRUCTURAL IMPACT ON THE 5 SPLICE SITE Hamideh Yadegari Received Received
  674-TUE-PO ANALYSIS OF OXALIPLATIN-BASED CHEMOTHERAPY INDUCED LIVER INJURY IN PATIENTS WITH ADVANCED COLORECTAL CANCER WITH SPECIAL REFERENCES TO VON WILLEBRAND FACTOR Naoto Nishigori Received Received
  674-WED-PO LOW INCIDENCE OF BLEEDING EVENTS IN A REAL WORLD, VITAMIN K ANTAGONIST-TREATED PATIENT POPULATION: RESULTS FROM THE START-REGISTER Emilia Antonucci Received Received
  675-WED-PO THE START-REGISTER (SURVEY ON ANTICOAGULATED PATIENTS REGISTER): FOCUS ON PATIENTS TREATED FOR NON-VALVULAR ATRIAL FIBRILLATION Emilia Antonucci Received Received
  675-MON-PO ASSESSMENT OF VON WILLEBRAND FACTOR PANEL AND PLATELET FUNCTION IN PATIENTS WITH MODERATE TO SEVERE RENAL INSUFFICIENCY UNDERGOING RENAL BIOPSY Bundarika Suwanawiboon Received Received
  675-TUE-PO DESMOPRESSIN TREATMENT IMPROVES PLATELET FUNCTION UNDER FLOW IN PATIENTS WITH POSTOPERATIVE BLEEDING Paola Van der Meijden Received Received
  677-WED-PO POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH VENOUS THROMBOEMBOLISM TAKING VITAMIN K ANTAGONISTS: A ROLE OF THE QUALITY OF ANTICOAGULATION Michal Zabczyk Received Received
  677-MON-PO MINIMUM LEVELS OF VON WILLEBRAND FACTOR AND PLATELETS TO CREATE OCCLUSIVE HIGH SHEAR THROMBOSIS Lauren Casa Received Received
  678-MON-PO AGING AND ABO BLOOD TYPE REGULATE VON WILLEBRAND FACTOR AND FACTOR VIII LEVELS THROUGH DISTINCT PATTERNS OF BOTH SECRETION AND CLEARANCE Silvia Albanez Received Received
  679-TUE-PO EVALUATION OF AGE AND GLYCAN-RELATED CHANGES ON VON WILLEBRAND FACTOR (VWF) CLEARANCE IN A VWF DEFICIENT MOUSE MODEL Silvia Albanez Received Received
  680-TUE-PO ANNEXIN A2 SNP REGULATES PLASMA VON WILLEBRAND FACTOR LEVELS AND IS ENRICHED IN PATIENTS WITH VON WILLEBRAND DISEASE Waander L. van Heerde Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
07:19
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image

INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTA..

ISTH 2015 Congress

 

20-25 June 2015 Toronto
HELP LINE
Manage Orders
FAQs

THE SUBMISSION DEADLINE HAS BEEN EXTENDED UNTIL WEDNESDAY 15TH JULY AT 23:00 GMT+1.

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 20/06/2015 TO 25/06/2016
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.ISTH2015.2015 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 15/06/2015
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster







PosterSessionOnline
Logo Draft
 
Logo Cert